Chimeric cytokine receptors comprising TGF β binding domains

Abstract

Provided herein are chimeric cytokine receptors bearing a binding domain capable of binding a TGF- ligand or a TGF- receptor antibody. When present on chimeric antigen receptor (CAR)-bearing immune cells (CAR-T-cells), such receptors allow for increased CAR-T cell expansion, activity and persistence, constitutively and/or through engagement of a TGF- ligand or a TGF- receptor antibody. Also provided are methods of making and using the chimeric cytokine receptors described herein.

Claims

1. A chimeric cytokine receptor comprising: a) a binding domain comprising an extracellular portion of a TGF- receptor, or a TGF- antigen binding domain; b) a transmembrane domain; c) an intracellular Janus Kinase (JAK)-binding domain; and d) an intracellular recruiting domain, wherein the transmembrane domain and the intracellular JAK-binding domain is a fragment of a variant of the full-length thrombopoietin receptor/myeloproliferative leukemia protein receptor (TPOR/MPLR) as shown in SEQ ID NO: 26, wherein the fragment is selected from the group consisting of SEQ ID NO: 30-71, 73-79, 160, and 217-234, and wherein the intracellular recruiting domain is not from TPOR/MPLR.

2. The chimeric cytokine receptor of claim 1, wherein the intracellular recruiting domain is a STAT-recruiting domain.

3. The chimeric cytokine receptor of claim 2, wherein the STAT-recruiting domain is from a receptor selected from BLNK, IL2RG, EGFR, EpoR, GHR, IFNAR1, IFNAR2, IFNAR1/2, IFNLR1, IL10R1, IL12Rb1, IL12Rb2, IL2Rb, IL2small, IL7R, IL7Ra, IL9R, IL15R, and IL21R.

4. The chimeric cytokine receptor of claim 3, wherein the recruiting domain comprises the STAT-recruiting domain from one or more receptors of IL7Ra, IL12Rb2, EGFR, IL21R, or IL2Rb.

5. The chimeric cytokine receptor of claim 2, wherein the STAT-recruiting domain comprises any one of the amino acid sequences of SEQ ID NO: 80-SEQ ID NO: 122 and SEQ ID NO: 161.

6. The chimeric cytokine receptor of claim 2, wherein the STAT-recruiting domain comprises SEQ ID NO: 80, SEQ ID NO: 112, SEQ ID NO: 111, SEQ ID NO: 101, SEQ ID NO: 120, SEQ ID NO: 99, or SEQ ID NO: 161.

7. The chimeric cytokine receptor of claim 1, wherein the chimeric cytokine receptor is a dimerized chimeric cytokine receptor comprising monomers that each comprise a) to d).

8. The chimeric cytokine receptor of claim 1, wherein the binding domain comprising an extracellular portion of a TGF- receptor comprises an extracellular portion of a wild type TGF- receptor sequence or one or more mutations to the extracellular portion of a wild type TGF- receptor sequence.

9. The chimeric cytokine receptor of claim 8, wherein the binding domain comprising an extracellular portion of a TGF- receptor comprises the extracellular portion of TGFBR2.

10. The chimeric cytokine receptor of claim 8, wherein the binding domain comprising an extracellular portion of a TGF- receptor comprises the amino acid sequence of any one of SEQ ID NO: 2 to SEQ ID NO: 20 and SEQ ID NO: 159.

11. The chimeric cytokine receptor of claim 1, wherein the transmembrane domain and intracellular JAK-binding domain comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 37-40, 53-56, 44-45, 64 and 70.

12. The chimeric cytokine receptor of claim 1, wherein the chimeric cytokine receptor is inducible.

13. The chimeric cytokine receptor of claim 12, wherein the chimeric cytokine receptor can be induced by a TGF- ligand or an anti-TGFR antibody.

14. The chimeric cytokine receptor of claim 13, wherein the TGF-B ligand is any one of TGF-1, TGF-2, or TGF-3.

15. The chimeric cytokine receptor of claim 1, wherein the chimeric cytokine receptor is constitutively active.

16. The chimeric cytokine receptor of claim 15, wherein the chimeric cytokine receptor is constitutively active and can be further induced or exhibits further improved activities in the presence of TGF- or an anti-TGFR antibody.

17. The chimeric cytokine receptor of claim 1, wherein the chimeric cytokine receptor is capable of inhibiting TGFR2-mediated signal transduction and/or enhancing STAT-mediated signal transduction when expressed in a cell.

18. The chimeric cytokine receptor of claim 17, wherein the cell is an immune cell.

19. A polynucleotide encoding the chimeric cytokine receptor of claim 1.

20. An expression vector comprising the polynucleotide of claim 19.

21. The expression vector of claim 20, further comprising a polynucleotide encoding a chimeric antigen receptor (CAR).

22. The expression vector of claim 21, wherein the CAR binds to any one or more of the targets selected from BCMA, EGFRVIII, Flt-3, WT-1, CD20, CD23, CD30, CD38, CD70, CD33, CD133, MHC-WT1, TSPAN10, MHC-PRAME, Liv1, ADAM10, CHRNA2, LeY, NKG2D, CS1, CD44v6, ROR1, CD19, Claudin-18.2, Claudin-18A2, Claudin18 isoform 2, Delta-like protein 3 (DLL3), Drosophila Delta homolog 3, Delta3, Mucin 17, Muc3, Fibroblast Activation Protein alpha (FAP alpha), Lymphocyte antigen 6 complex locus protein God (Ly6G6D), c6orf23, G6D, MEGT1, NG25, E3 ubiquitin-protein ligase RNF43, RING finger protein 43, ErbB2, carcinoembryonic antigen (CEA), epithelial cell adhesion molecule (EpCAM), epidermal growth factor receptor (EGFR), CD40, disialoganglioside GD2, GD3, C-type lectin-like molecule-1 (CLL-1), ductal-epithelial mucin, gp36, TAG-72, a glycosphingolipid, glioma-associated antigen, -human chorionic gonadotropin, alphafetoprotein (AFP), lectin- reactive AFP, thyroglobulin, RAGE-1, MN-CA IX, human telomerase reverse transcriptase, RU1, RU2, intestinal carboxyl esterase, mut hsp70-2, M-CSF, prostase, prostase specific antigen (PSA), PAP, NY-ESO-1, LAGA-1a, p53, prostein, PSMA, survivin, telomerase, prostate-carcinoma tumor antigen-1 (PCTA-1), MAGE, ELF2M, neutrophil elastase, ephrin B2, CD22, insulin growth factor (IGF1)-1, IGF-II, IGFI receptor, mesothelin, a major histocompatibility complex (MHC) molecule presenting a tumor-specific peptide epitope, 5T4, O1, Nkp30, tumor stromal antigen, the extra domain A (EDA) of fibronectin, the extra domain B (EDB) of fibronectin, the AI domain of tenascin-C (TnC AI), fibroblast associated protein (fap), LRP6, melanoma-associated Chondroitin Sulfate Proteoglycan (MCSP), MARTI, MUC1, LMP2, Idiotype, NY-ESO-1, Ras mutant, gp100, proteinase 3, bcr-abl, tyrosinase, hTERT, EphA2, ML-TAP, ERG, NA17, PAX3, ALK, Androgen receptor, CD3, CD4, CD8, CD24, CD25, CD34, CD79, CD116, CD117, CD135, CD123, CD138, CTLA-4, B7-1, B7-2, endoglin, a major histocompatibility complex (MHC) molecule, MUC16, PSCA, Trop2, CD171, CA9, STEAP1, and VEGFR2.

23. An engineered immune cell comprising the vector of claim 20.

24. A method of preparing an engineered immune cell, the method comprising introducing the polynucleotide of claim 19 into an immune cell.

25. The method of claim 24, wherein the immune cell is selected from the group consisting of: T-cell, dendritic cell, killer dendritic cell, mast cell, NK-cell, macrophage, monocyte, B-cell and an immune cell derived from a stem cell.

26. An engineered immune cell expressing the chimeric cytokine receptor of claim 1.

27. The engineered immune cell of claim 26, further expressing at least one CAR.

28. The engineered immune cell of claim 27, wherein the CAR binds to any one or more of the targets selected from BCMA, EGFRVIII, Flt-3, WT-1, CD20, CD23, CD30, CD38, CD70, CD33, CD133, MHC-WT1, TSPAN10, MHC-PRAME, Liv1, ADAM10, CHRNA2, LeY, NKG2D, CS1, CD44v6, ROR1, CD19, Claudin-18.2, Claudin-18A2, Claudin18 isoform 2, Delta-like protein 3 (DLL3), Drosophila Delta homolog 3, Delta3, Mucin 17, Muc3, Fibroblast Activation Protein alpha (FAP alpha), Lymphocyte antigen 6 complex locus protein God (Ly6G6D), c6orf23, G6D, MEGT1, NG25, E3 ubiquitin-protein ligase RNF43, RING finger protein 43, ErbB2, carcinoembryonic antigen (CEA), epithelial cell adhesion molecule (EpCAM), epidermal growth factor receptor (EGFR), CD40, disialoganglioside GD2, GD3, C-type lectin-like molecule-1 (CLL-1), ductal-epithelial mucin, gp36, TAG-72, a glycosphingolipid, glioma- associated antigen, -human chorionic gonadotropin, alphafetoprotein (AFP), lectin-reactive AFP, thyroglobulin, RAGE-1, MN-CA IX, human telomerase reverse transcriptase, RU1, RU2, intestinal carboxyl esterase, mut hsp70-2, M-CSF, prostase, prostase specific antigen (PSA), PAP, NY-ESO-1, LAGA-1a, p53, prostein, PSMA, survivin, telomerase, prostate-carcinoma tumor antigen-1 (PCTA-1), MAGE, ELF2M, neutrophil elastase, ephrin B2, CD22, insulin growth factor (IGF1)-1, IGF-II, IGFI receptor, mesothelin, a major histocompatibility complex (MHC) molecule presenting a tumor-specific peptide epitope, 5T4, O1, Nkp30, tumor stromal antigen, the extra domain A (EDA) of fibronectin, the extra domain B (EDB) of fibronectin, the AI domain of tenascin-C (TnC AI), fibroblast associated protein (fap), LRP6, melanoma-associated Chondroitin Sulfate Proteoglycan (MCSP), MARTI, MUC1, LMP2, Idiotype, NY-ESO-1, Ras mutant, gp100, proteinase 3, bcr-abl, tyrosinase, hTERT, EphA2, ML-TAP, ERG, NA17, PAX3, ALK, Androgen receptor, CD3, CD4, CD8, CD24, CD25, CD34, CD79, CD116, CD117, CD135, CD123, CD138, CTLA-4, B7-1, B7-2, endoglin, a major histocompatibility complex (MHC) molecule, MUC16, PSCA, Trop2, CD171, CA9, STEAP1, and VEGFR2.

29. The engineered immune cell of claim 27, wherein the immune cell is an allogeneic immune cell or an autologous immune cell.

30. The engineered immune cell of claim 27, wherein the immune cell is selected from the group consisting of: T-cell, dendritic cell, killer dendritic cell, mast cell, NK-cell, macrophage, monocyte, B-cell and an immune cell derived from a stem cell.

31. The engineered immune cell of claim 27, wherein the immune cell exhibits reduced TGFR-mediated signal transduction and/or enhanced STAT-mediated signal transduction as compared to an immune cell without expressing the chimeric cytokine receptor.

32. The engineered immune cell of claim 31, wherein the immune cell exhibits reduced TGFR mediated signal transduction and/or enhanced STAT-mediated signal transduction when engaged with TGF- or an anti-TGFR antibody.

33. A pharmaceutical composition comprising the immune cells of claim 27.

34. A kit comprising the pharmaceutical composition of claim 33.

35. A method of treating a cancer, an autoimmune disorder, or an infection in a subject, comprising administering to the subject a therapeutically effective amount of the engineered immune cells of claim 27.

36. The method of claim 35, wherein the cancer comprises a solid tumor or a liquid tumor.

37. The method of claim 36, wherein the tumor is TGF- positive tumor.

38. The method of claim 35, wherein the subject is treated with an anti-TGFR-antibody.

39. A method of modulating an activity of the engineered immune cell of claim 32, comprising contacting the immune cell with a TGF- ligand or with an anti-TGFR antibody.

40. A chimeric cytokine receptor comprising the amino acid sequence selected from SEQ ID NOs: 124-151 and SEQ ID NOs: 163-216.

Description

BRIEF DESCRIPTION OF THE DRAWINGS

(1) FIG. 1 shows a schematic of the inducible chimeric cytokine receptor of the disclosure.

(2) FIG. 2A shows a schematic of the lentiviral vector used to co-express the dominant negative truncations of the TGFR1 or TGFR2 cytokine receptor with the 2.sup.nd generation EGFRvIII CAR.

(3) FIG. 2B shows the inhibition of the TGF- signaling by expression of either the TGFR1 DN or TGFR2 DN.

(4) FIG. 3 shows a general schematic of the lentiviral vector used to co-express the TGFR2 cytokine receptor with the 2.sup.nd generation EGFRvIII CAR.

(5) FIG. 4A shows a schematic of the prototypic lentiviral vector used, bearing the IL7R(316-459) and the IL12Rb2(775-825) recruiting domains to mimic IL7 and IL12 signaling in CAR-T-cells.

(6) FIG. 4B shows TGF- signaling activity determined by a luciferase reporter assay.

(7) FIG. 4C shows the activation of the chimeric cytokine receptors of FIG. 4A in the presence of TGF-.

(8) FIG. 5A shows a schematic of the prototypic lentiviral vector used, having truncations in the binding domain.

(9) FIG. 5B shows TGF- signaling activity determined by a luciferase reporter assay.

(10) FIG. 5C shows the activation of the chimeric cytokine receptors of FIG. 5A in the presence of TGF-.

(11) FIG. 6A shows a schematic of the modification introduced into the TGFR2 cassette.

(12) FIG. 6B shows that the TGFR2N25 chimeric cytokine receptors still retained the ability to inhibit TGF- signaling.

(13) FIG. 6C shows the activation of the chimeric cytokine receptors of FIG. 6A, evaluated by the STAT reporter activity.

(14) FIG. 7 shows a schematic of the constitutively active chimeric cytokine receptor.

(15) FIG. 8A shows a schematic of the modification introduced into the TGFR2 cassette.

(16) FIG. 8B shows the inhibition of TGF- signaling by the expression of the chimeric cytokine receptors of FIG. 8A.

(17) FIG. 8C shows the activation of cytokine signaling via the chimeric cytokine receptors of FIG. 8A, measured by the STAT5 reporter activity.

(18) FIGS. 9A-9B show the amino acid sequences for the wild type TPOR and the various transmembrane deletion or insertion variants. FIGS. 9A-B disclose SEQ ID NOS 235-246, 235, and 247-254, respectively, in order of appearance.

(19) FIG. 10A shows the amino acid sequences for the wild type TPOR and additional transmembrane variants. FIG. 10B shows the inhibition of endogenous TGF- signaling as determined by luciferase assay by the overexpression of TGF--driven chimeric cytokine receptors shown in FIG. 10A, in the presence of different concentrations of TGF-. FIG. 10C shows the activation of chimeric cytokine receptors in the presence of TGF- at various concentrations. FIG. 10A discloses SEQ ID NOS 235 and 255-271, respectively, in order of appearance.

(20) FIG. 11A shows schematics of chimeric cytokine receptor (CCR) CAR expression construct where the expression of the CCR and the EGFRvIII CAR are linked by a P2A peptide. FIGS. 11B-11C are bar graphs depicting the yield of CAR+ T cells expressing various CCRs. FIGS. 11D-11E show results of STAT5 phosphorylation in CAR T cells expressing various CCR or controls. FIGS. 11F-11G depict CAR T cells phenotype at Day 14 of production. FIG. 11H shows results of total TGF-R2 extracellular staining on CAR T cells. FIG. 11I depicts results of inhibition of TGF-R2 signaling in CAR T cells expressing different CCRs in the presence of different concentrations of TGF-.

(21) FIG. 12A exhibits results of cytotoxicity assay of CAR T cells expressing various CCRs against U87-EGFRvIII cells in the absence of exogenous TGF. FIGS. 12B-12C show results of cytotoxicity assay of CAR T cells expressing various CCRs at different concentrations of TGF.

(22) FIG. 13A shows STAT5 phosphorylation and FIG. 13B depicts the T cell phenotype of CAR T cells expressing CCRs with the S505N/W515K with or without the K553R/K573R substitutions in the TOPR/MPLR and JAK binding domain. All TGFbR2 chimeric cytokine receptor constructs tested in this experiment contain the S505N/W515K substitutions. The constructs labeled RR further contain the additional K553R/K573R substitutions.

(23) FIGS. 14A-14B show results of long-term cell killing assay of CAR T cells expressing various CCRs in the absence (FIG. 14A) or presence (FIG. 14B) of 5 ng/ml TGF.

(24) FIGS. 15A-15C show results of activation of STAT5 signaling (FIG. 15A), inhibition of TGF signaling (FIG. 15B), and long-term cell killing assay (FIG. 15C) of CAR T cells expressing various CCRs, some of which have reduced affinity for TGF (e.g., D32A, E119A and/or I53A substitutions in the ECD of TGFR2).

(25) FIGS. 16A-16B compare the effects of TGFR2 chimeric cytokine receptors with or without the degradation-resistant K533R/K573R substitutions on STAT5 signaling (FIG. 16A) and long-term cell killing (FIG. 16B).

DETAILED DESCRIPTION

(26) Provided herein are chimeric cytokine receptors comprising TGF- binding domains. Provided herein are inducible chimeric cytokine receptors, active when engaged with TGF- ligands (e.g. TGF-1, TGF-2, and/or TGF-3) or activation with an anti-TGF--receptor antibody. Also provided herein are constitutively active chimeric cytokine receptors comprising TGF- binding domains. Also provided herein are chimeric antigen receptor (CAR)-bearing immune cells (CAR-I-cells, e.g. CAR-T-cells), expressing the chimeric cytokine receptors of the disclosure. In some embodiments, the constitutively active chimeric cytokine receptors exhibit improved properties or activities when engaged with a TGF- ligand or activation with an anti-TGF--receptor antibody, as compared with constitutively active chimeric cytokine receptors without a TGF- binding domain. Also provided herein are methods of making and using the chimeric cytokine receptors.

(27) I. TGF--Bearing Chimeric Cytokine Receptors

(28) The chimeric cytokine receptors of the disclosure activate signaling upon binding of a TGF- ligand (for example, TGF-1, TGF-2, and/or TGF-3), or an anti-TGF--receptor antibody. These receptors activate signaling when monomers of the receptor cluster and/or dimerize. The chimeric cytokine receptors of the disclosure are dual-function chimeric cytokine receptors which can simultaneously neutralize the immune-suppressive effects of a TGF- ligand, and mimic the transmission of an immune-potentiating cytokine signal.

(29) In some embodiments, a monomer of the chimeric cytokine receptor of the disclosure comprises: (a) a binding domain capable of binding a TGF- ligand or an anti-TGF--receptor antibody; (b) a transmembrane domain; (c) a Janus Kinase (JAK)-binding domain; and; (d) a STAT-recruiting domain (e.g. from the cytoplasmic domain of a receptor; e.g. from a cytokine receptor). Each domain can be linked either directly or via one or more peptide linkers. In some embodiments, a monomer of the chimeric cytokine receptor of the disclosure comprises: (a) a binding domain capable of binding a TGF- ligand or an anti-TGF--receptor antibody; (b) a transmembrane domain; (c) a Janus Kinase (JAK)-binding domain; and; (d) a recruiting domain (e.g. from the cytoplasmic domain of a receptor; e.g. from a cytokine receptor). The recruiting domain can be a STAT-recruiting domain, an AP1recruiting domain, a Myc/Max recruiting domain; or a NFkB-recruiting domain. In some embodiments, the chimeric cytokine receptors are clustered and activated when they bind to TGF- ligands, and/or are clustered and activated with an anti-TGF--receptor antibody. The chimeric cytokine receptors activate signaling upon for example binding a TGF- ligand, and/or a TGF--receptor antibody. In some embodiments, the TGF- receptor antibody is, without limitation, PF-03446962 or LY3022859. In some embodiments, the chimeric cytokine receptors are constitutively clustered or dimerized.

(30) As used herein, TGF- ligand, refers to TGF-1, TGF-2, and TGF-3, and isoforms and derivatives thereof. It should be understood that TGF- ligand and TGF- are used interchangeably herein.

(31) A. Binding Domains

(32) The chimeric cytokine receptors of the disclosure comprise a binding domain capable of binding a TGF- ligand or an anti-TGF--receptor antibody. As referred to herein, a binding domain is the domain of the chimeric cytokine receptor that extends into the extracellular space. The binding domain binds and sequesters TGF- away from the endogenous TGF- receptor, thereby preventing or reducing TGF--induced immune-suppression. The binding domains of the disclosure bind with TGF- ligands and anti-TGF--receptor antibodies, leading to binding-induced signal transduction.

(33) In some embodiments, the binding domain comprises an extracellular portion of a TGF- receptor, for example the extracellular portion of TGFR1 or TGFR2.

(34) In some embodiments, the binding domain comprises an extracellular portion of a wild type TGF receptor. In some embodiments, the TGF- receptor comprises one or more mutations that enhance or alter the affinity to the binding to the TGF ligands.

(35) In some embodiments, the binding domain comprises the extracellular portion of a wild type TGFR1 or TGFR2; in some embodiments, the binding domain comprises the extracellular portion of a wild type TGFR1 or TGFR2 and comprises the amino acid sequence of SEQ ID NOS: 2 or 3, respectively.

(36) In some embodiments, the binding domain comprises mutations to the extracellular portion of a wild type TGF- receptor. In some embodiments, the binding domain comprises mutations to the extracellular portion of a wild type TGF- receptor, and comprises the amino acid sequences of any one of SEQ ID NO: 4 to SEQ ID NO: 20. In some embodiments, the chimeric cytokine receptor comprises a binding domain that is at least 80%, 85%, 90%, 95%, 98%, or 99%, or 100% identical to any one of the amino acid sequences of SEQ ID NOs: 4-20. In some embodiments, the binding domain does not comprise a signal sequence.

(37) Table 1 shows exemplary binding domain amino acid sequences of the disclosure. It is noted that the expression and extracellular location of the exemplary binding domain sequences, such as TGF- receptor amino acid sequences, can be achieved with the use of a signal sequence. In an exemplary embodiment, a CD8 signal sequence (CD8SS) MALPVTALLLPLALLLHAARP (SEQ ID NO: 1) is utilized. In some embodiments, the binding domain comprises the extracellular domain of wild type TGFR2 comprising the amino acid sequence of SEQ ID NO:159. In some embodiments, the signal sequence is the endogenous signal sequence of human TGF-R2.

(38) TABLE-US-00001 TABLE1 ExemplaryBindingDomainSequences SEQ BindingDomain Aminoacidsequence IDNO: TGFR1(1-126) MEAAVAAPRPRLLLLVLAAAAAAAAALLPGAT 2 ALQCFCHLCTKDNFTCVTDGLCFVSVTETTDKVI HNSMCIAEIDLIPRDRPFVCAPSSKTGSVTTTYCC NQDHCNKIELPTTVKSSPGLGPVEL TGFR2(1-166) MGRGLLRGLWPLHIVLWTRIASTIPPHVQKSVNN 3 UnderlinedTGFR2 DMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSC signalsequence MSNCSITSICEKPQEVCVAVWRKNDENITLETVC HDPKLPYHDFILEDAASPKCIMKEKKKPGETFFM CSCSSDECNDNIIFSEEYNTSNPDLLLVIFQ TGFR2N25 QLCKFCDVRFSTCDNQKSCMSNCSITSICEKPQE 4 VCVAVWRKNDENITLETVCHDPKLPYHDFILED AASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFS EEYNTSNPDLLLVIFQ TGFR2N25FSE-N8 QLCKFCDVRFSTCDNQKSCMSNCSITSICEKPQE 5 VCVAVWRKNDENITLETVCHDPKLPYHDFILED AASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFS ELLLVIFQ TGFR2N25FSE-N6 QLCKFCDVRFSTCDNQKSCMSNCSITSICEKPQE 6 VCVAVWRKNDENITLETVCHDPKLPYHDFILED AASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFS EPDLLLVIFQ TGFR2N25FSE-N5 QLCKFCDVRFSTCDNQKSCMSNCSITSICEKPQE 7 VCVAVWRKNDENITLETVCHDPKLPYHDFILED AASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFS EEPDLLLVIFQ TGFR2N25FSE-N4 QLCKFCDVRFSTCDNQKSCMSNCSITSICEKPQE 8 VCVAVWRKNDENITLETVCHDPKLPYHDFILED AASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFS EEYPDLLLVIFQ TGFR2N25FSE-N3 QLCKFCDVRFSTCDNQKSCMSNCSITSICEKPQE 9 VCVAVWRKNDENITLETVCHDPKLPYHDFILED AASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFS EEYNPDLLLVIFQ TGFR2N25.Glyc33 QLCKFCDNRTSTCDNQKSCMSNCSITSICEKPQE 10 VCVAVWRKNDENITLETVCHDPKLPYHDFILED AASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFS EEYNTSNPDLLLVIFQ TGFR2N25.Glyc40 QLCKFCDVRFSTCDNQTSCMSNCSITSICEKPQEV 11 CVAVWRKNDENITLETVCHDPKLPYHDFILEDA ASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSE EYNTSNPDLLLVIFQ TGFR2N25.Glyc56 QLCKFCDVRFSTCDNQKSCMSNCSITSICENPTEV 12 CVAVWRKNDENITLETVCHDPKLPYHDFILEDA ASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSE EYNTSNPDLLLVIFQ TGFR2N25.Glyc58 QLCKFCDVRFSTCDNQKSCMSNCSITSICEKPNET 13 CVAVWRKNDENITLETVCHDPKLPYHDFILEDA ASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSE EYNTSNPDLLLVIFQ TGFR2N25.V33K QLCKFCDKRFSTCDNQKSCMSNCSITSICEKPQE 14 VCVAVWRKNDENITLETVCHDPKLPYHDFILED AASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFS EEYNTSNPDLLLVIFQ TGFR2N25.E70K QLCKFCDVRFSTCDNQKSCMSNCSITSICEKPQE 15 VCVAVWRKNDKNITLETVCHDPKLPYHDFILED AASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFS EEYNTSNPDLLLVIFQ TGFR2N25.Glyc87 QLCKFCDVRFSTCDNQKSCMSNCSITSICEKPQE 16 VCVAVWRKNDENITLETVCHDPKLPYHNFTLED AASPKCIMKEKKKPGETFFMCSCSSDECNDNIIF TGFR2N25.Glyc89 QLCKFCDVRFSTCDNQKSCMSNCSITSICEKPQE 17 VCVAVWRKNDENITLETVCHDPKLPYHDFNLTD AASPKCIMKEKKKPGETFFMCSCSSDECNDNIIF TGFR2N25.Glyc102 QLCKFCDVRFSTCDNQKSCMSNCSITSICEKPQE 18 VCVAVWRKNDENITLETVCHDPKLPYHDFILED AASPKCIMKNKTKPGETFFMCSCSSDECNDNIIF TGFR2N25.Glyc123 QLCKFCDVRFSTCDNQKSCMSNCSITSICEKPQE 19 VCVAVWRKNDENITLETVCHDPKLPYHDFILED AASPKCIMKEKKKPGETFFMCSCSSDECNDNITF TGFR2N25.I89E QLCKFCDVRFSTCDNQKSCMSNCSITSICEKPQE 20 VCVAVWRKNDENITLETVCHDPKLPYHDFELED AASPKCIMKEKKKPGETFFMCSCSSDECNDNIIF TGFR2(withoutthe IPPHVQKSVNNDMIVTDNNGAVKFPQLCKFCDV 159 signalsequence) RFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRK NDENITLETVCHDPKLPYHDFILEDAASPKCIMKE KKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDL LLVIFQ

(39) In some embodiments, the chimeric cytokine receptor is a dominant negative (DN) wherein the binding domain of the TGF- receptor is expressed, but the chimeric cytokine receptor does not comprise an intracellular signaling domainthe chimeric cytokine receptor can bind TGF- but does not transmit a positive signal (DN chimeric cytokine receptor). In some embodiments, the TGF- receptor is TGFR1 (dominant-negative TGFR1, or TGFR1 DN) and comprises the amino acid sequence of SEQ ID NO: 2. In some embodiments, the TGF- receptor is TGFR2 (dominant-negative TGFR2, or TGFR2 DN) and comprises the amino acid sequence of SEQ ID NO: 3. TGF- receptor dominant negative sequences may be expressed with the aid of a signal sequence, e.g. a CD8SS signal sequence of SEQ ID NO: 1. Example schematics of a DN chimeric cytokine receptor are shown in FIG. 2A.

(40) In other embodiments, the binding domain comprises a TGF- antigen binding domain. Such antigen binding domains include, but are not limited to, a single chain variable fragment (scFv) that can bind the TGF- ligands, and single domain antibodies (nanobodies). These scFvs and single domain antibodies may include commercially available scFvs and single domain antibodies, and those derived from, for example, camelid and shark antibodies.

(41) In other embodiments, the binding domain comprises a TGF- antigen binding domain, wherein the antigen binding domain comprises a Fab fragment.

(42) B. Transmembrane Domains

(43) The chimeric cytokine receptors of the disclosure comprise transmembrane domains. Such transmembrane domains are coupled to the extracellular binding domain on the N-terminus, and to additional intracellular/cytoplasmic domains on the C-terminus. In some embodiments, the coupling is achieved optionally through a linker.

(44) As used herein, the transmembrane domains are capable of insertion into the membrane of a cell in which it is expressed. In some embodiments, the transmembrane domains of the disclosure span a cellular membrane, and comprise an extracellular portion, and/or an intracellular portion.

(45) In some embodiments, the transmembrane domains of the disclosure are engineered and do not resemble any naturally occurring transmembrane domain, e.g. they are non-naturally occurring.

(46) In other embodiments, the transmembrane domains of the disclosure are derived from naturally occurring receptors.

(47) In some embodiments, the transmembrane and/or JAK domains of the disclosure are derived from, for example, one or more of the following receptors: erythropoietin receptor (EpoR), Interleukin 6 signal transducer (GP130 or IL6ST), prolactin receptor (PrlR), growth hormone receptor (GHR), granulocyte colony-stimulating factor receptor (GCSFR), and thrombopoietin receptor/myeloproliferative leukemia protein receptor (TPOR/MPLR). When derived from naturally occurring receptors, the entire receptor, or the entire transmembrane sequence of the receptor may not be necessary to effectuate constitutive activation and constitutive JAK binding/activation on the intracellular portion. Accordingly fragments of naturally occurring receptors may be utilized. Furthermore, certain mutations may be introduced into the transmembrane domains derived from naturally occurring receptors, to further tune the downstream JAK-dependent signaling. In some embodiments, the chimeric cytokine receptor of the disclosure comprises a portion or a fragment of a naturally occurring receptor, e.g., the transmembrane and/or JAK binding/activation domain of the naturally occurring receptor, optionally comprising one or more mutations therein (e.g., one or more deletions, insertions and/or substitutions).

(48) In some embodiments, the transmembrane and/or JAK domains of the disclosure is derived from the naturally occurring EpoR receptor.

(49) In some embodiments, the transmembrane and/or JAK domains of the disclosure is derived from the naturally occurring GP130 receptor.

(50) In some embodiments, the transmembrane and/or JAK domains of the disclosure is derived from the naturally occurring PrlR receptor.

(51) In some embodiments, the transmembrane and/or JAK domains of the disclosure is derived from the naturally occurring GHR receptor.

(52) In some embodiments, the transmembrane and/or JAK domains of the disclosure is derived from the naturally occurring GCSF receptor.

(53) In some embodiments, the transmembrane and/or JAK domains of the disclosure is derived from the naturally occurring TPOR receptor. When the TPOR transmembrane domain assumes a permissive homodimeric conformation, such as in response to a ligand or forced activation resulting from the introduction of engineered modifications, it is capable of activating downstream cytokine signaling in a JAK2-dependent fashion. The introduction of various modifications to the TPOR transmembrane domain can result in the following: the immune-potentiating cytokine signal may either be (a) quiescent until induced to activate in the presence of extracellular TGF-, or (b) constitutively active regardless of TGF- availability.

(54) Table 2 provides exemplary full length sequences of naturally occurring receptors provided in the disclosure, from which the transmembrane and/or JAK domains are derived.

(55) TABLE-US-00002 TABLE2 ExemplaryNaturallyOccurringReceptors SEQ ID NaturallyOccurringReceptorName NO: >AAI12154.1Erythropoietinreceptor[Homosapiens] 21 MDHLGASLWPQVGSLCLLLAGAAWAPPPNLPDPKFESKAALLAARGPEELLCFTE RLEDLVCFWEEAASAGVGPGNYSFSYQLEDEPWKLCRLHQAPTARGAVRFWCSLP TADTSSFVPLELRVTAASGAPRYHRVIHINEVVLLDAPVGLVARLADESGHVVLR WLPPPETPMTSHIRYEVDVSAGNGAGSVQRVEILEGRTECVLSNLRGRTRYTFAV RARMAEPSFGGFWSAWSEPVSLLTPSDLDPLILTLSLILVVILVLLTVLALLSHR RALKQKIWPGIPSPESEFEGLFTTHKGNFQLWLYQNDGCLWWSPCTPFTEDPPAS LEVLSERCWGTMQAVEPGTDDEGPLLEPVGSEHAQDTYLVLDKWLLPRNPPSEDL PGPGGSVDIVAMDEGSEASSCSSALASKPSPEGASAASFEYTILDPSSQLLRPWT LCPELPPTPPHLKYLYLVVSDSGISTDYSSGDSQGAQGGLSDGPYSNPYENSLIP AAEPLPPSYVACS >AAI17403.1Interleukin6signaltransducer 22 (GP130,oncostatinMreceptor)[Homosapiens] MLTLQTWLVQALFIFLTTESTGELLDPCGYISPESPVVQLHSNFTAVCVLKEKCM DYFHVNANYIVWKTNHFTIPKEQYTIINRTASSVTFTDIASLNIQLTCNILTFGQ LEQNVYGITIISGLPPEKPKNLSCIVNEGKKMRCEWDRGRETHLETNFTLKSEWA THKFADCKAKRDTPTSCTVDYSTVYFVNIEVWVEAENALGKVTSDHINFDPVYKV KPNPPHNLSVINSEELSSILKLTWTNPSIKSVIILKYNIQYRTKDASTWSQIPPE DTASTRSSFTVQDLKPFTEYVFRIRCMKEDGKGYWSDWSEEASGITYEDRPSKAP SFWYKIDPSHTQGYRTVQLVWKTLPPFEANGKILDYEVTLTRWKSHLQNYTVNAT KLTVNLTNDRYVATLTVRNLVGKSDAAVLTIPACDFQATHPVMDLKAFPKDNMLW VEWTTPRESVKKYILEWCVLSDKAPCITDWQQEDGTVHRTYLRGNLAESKCYLIT VTPVYADGPGSPESIKAYLKQAPPSKGPTVRTKKVGKNEAVLEWDQLPVDVQNGF IRNYTIFYRTIIGNETAVNVDSSHTEYTLSSLTSDTLYMVRMAAYTDEGGKDGPE FTFTTPKFAQGEIEAIVVPVCLAFLLTTLLGVLFCFNKRDLIKKHIWPNVPDPSK SHIAQWSPHTPPRHNFNSKDQMYSDGNFTDVSVVEIEANDKKPFPEDLKSLDLFK KEKINTEGHSSGIGGSSCMSSSRPSISSSDENESSQNTSSTVQYSTVVHSGYRHQ VPSVQVFSRSESTQPLLDSEERPEDLQLVDHVDGGDGILPRQQYFKQNCSQHESS PDISHFERSKQVSSVNEEDFVRLKQQISDHISQSCGSGQMKMFQEVSAADAFGPG TEGQVERFETVGMEAATDEGMPKSYLPQTVRQGGYMPQ >XP_011512371.1prolactinreceptorisoformX2[Homo 23 sapiens] MKENVASATVFTLLLFLNTCLLNGQLPPGKPEIFKCRSPNKETFTCWWRPGTDGG LPTNYSLTYHREGETLMHECPDYITGGPNSCHFGKQYTSMWRTYIMMVNATNQMG SSFSDELYVDVTYIV0PDPPLELAVEVK0PEDRKPYLWIKWSPPTLIDLKTGWFT LLYEIRLKPEKAAEWEIHFAGQQTEFKILSLHPGQKYLVQVRCKPDHGYWSAWSP ATFIQIPSDFTMNDTTVWISVAVLSAVICLIIVWAVALKGYSMVTCIFPPVPGPK IKGFDAHLLEKGKSEELLSALGCQDFPPTSDYEDLLVEYLEVDDSEDQHLMSVHS KEHPSQGMKPTYLDPDTDSGRGSCDSPSLLSEKCEEPQANPSTFYDPEVIEKPEN PETTHTWDPQCISMEGKIPYFHAGGSKCSTWPLPQPSQHNPRSSYHNITDVCELA VGPAGAPATLLNEAGKDALKSSQTIKSREEGKATQQREVESFHSETDQDTPWLLP QEKTPFGSAKPLDYVEIHKVNKDGALSLLPKQRENSGKPKKPGTPENNKEYAKVS GVMDNNILVLVPDPHAKNVACFEESAKEAPPSLEQNQAEKALANFTATSSKCRLQ LGGLDYLDPACFTHSFH >NP_000154.1growthhormonereceptorisoform1 24 precursor[Homosapiens] MDLWQLLLTLALAGSSDAFSGSEATAAILSRAPWSLQSVNPGLKTNSSKEPKFTK CRSPERETFSCHWTDEVHHGTKNLGPIQLFYTRRNTQEWTQEWKECPDYVSAGEN SCYFNSSFTSIWIPYCIKLTSNGGTVDEKCFSVDEIVQPDPPIALNWTLLNVSLT GIHADIQVRWEAPRNADIQKGWMVLEYELQYKEVNETKWKMMDPILTTSVPVYSL KVDKEYEVRVRSKQRNSGNYGEFSEVLYVTLPQMSQFTCEEDFYFPWLLIIIFGI FGLTVMLFVFLFSKQQRIKMLILPPVPVPKIKGIDPDLLKEGKLEEVNTILAIHD SYKPEFHSDDSWVEFIELDIDEPDEKTEESDTDRLLSSDHEKSHSNLGVKDGDSG RTSCCEPDILETDFNANDIHEGTSEVAQPQRLKGEADLLCLDQKNQNNSPYHDAC PATQQPSVIQAEKNKPQPLPTEGAESTHQAAHIQLSNPSSLSNIDFYAQVSDITP AGSVVLSPGQKNKAGMSQCDMHPEMVSLCQENFLMDNAYFCEADAKKCIPVAPHI KVESHIQPSLNQEDIYITTESLTTAAGRPGTGEHVPGSEMPVPDYTSIHIVQSPQ GLILNATALPLPDKEFLSSCGYVSTDQLNKIMP >XP_016855859.1granulocytecolony-stimulatingfactor 25 receptorisoformX1[Homosapiens] MARLGNCSLTWAALIILLLPGSLEECGHISVSAPIVHLGDPITASCIIKQNCSHL DPEPQILWRLGAELQPGGRQQRLSDGTQESIITLPHLNHTQAFLSCCLNWGNSLQ ILDQVELRAGYPPAIPHNLSCLMNLTTSSLICQWEPGPETHLPTSFTLKSFKSRG NCQTQGDSILDCVPKDGQSHCCIPRKHLLLYQNMGIWVQAENALGTSMSPQLCLD PMDVVKLEPPMLRTMDPSPEAAPPQAGCLQLCWEPWQPGLHINQKCELRHKPQRG EASWALVGPLPLEALQYELCGLLPATAYTLQIRCIRWPLPGHWSDWSPSLELRTT ERAPTVRLDTWVVRQRQLDPRTVQLFWKPVPLEEDSGRIQGYVVSWRPSGQAGAI LPLCNTTELSCTFHLPSEAQEVALVAYNSAGTSRPTPVVFSESRGPALTRLHAMA RDPHSLWVGWEPPNPWPQGYVIEWGLGPPSASNSNKTWRMEQNGRATGFLLKENI RPFQLYEIIVTPLYQDTMGPSQHVYAYSQEMAPSHAPELHLKHIGKTWAQLEWVP EPPELGKSPLTHYTIFWTNAQNQSFSAILNASSRGFVLHGLEPASLYHIHLMAAS QAGATNSTVLTLMTLTPEGSELHIILGLFGLLLLLTCLCGTAWLCCSPNRKNPLW PSVPDPAHSSLGSWVPTIMEELPGPRQGQWLGQTSEMSRALTPHPCVQDAFQLPG LGTPPITKLTVLEEDEKKPVPWESHNSSETCGLPTLVQTYVLQGDPRAVSTQPQS QSGTSDQVLYGQLLGSPTSPGPGHYLRCDSTQPLLAGLTPSPKSYENLWFQASPLGTLVTPAP SQEDDCVFGPLLNFPLLQGIRVHGMEALGSF >NP_005364.1thrombopoietinreceptorprecursor 26 [Homosapiens] MPSWALFMVTSCLLLAPQNLAQVSSQDVSLLASDSEPLKCFSRTFEDLTCFWDEEE AAPSGTYQLLYAYPREKPRACPLSSQSMPHFGTRYVCQFPDQEEVRLFFPLHLWVK NVFLNQTRTQRVLFVDSVGLPAPPSIIKAMGGSQPGELQISWEEPAPEISDFLRYELR YGPRDPKNSTGPTVIQLIATETCCPALQRPHSASALDQSPCAQPTMPWQDGPKQTSP SREASALTAEGGSCLISGLQPGNSYWLQLRSEPDGISLGGSWGSWSLPVTVDLPGDA VALGLQCFTLDLKNVTCQWQQQDHASSQGFFYHSRARCCPRDRYPIWENCEEEEK TNPGLQTPQFSRCHFKSRNDSIIHILVEVTTAPGTVHSYLGSPFWIHQAVRLPTPNLH WREISSGHLELEWQHPSSWAAQETCYQLRYTGEGHQDWKVLEPPLGARGGTLELR PRSRYRLQLRARLNGPTYQGPWSSWSDPTRVETATETAWISLVTALHLVLGLSAVL GLLLLRWQFPAHYRRLRHALWPSLPDLHRVLGQYLRDTAALSPPKATVSDTCEEVE PSLLEILPKSSERTPLPLCSSQAQMDYRRLQPSCLGTMPLSVCPPMAESGSCCTTHIA NHSYLPLSYWQQP

(56) In some embodiments, the transmembrane domain of the disclosure is derived from a truncated, or otherwise modified version of the naturally occurring TPOR/MPLR receptor shown in Table 2.

(57) FIGS. 9A-9B and 10A show the amino acid sequences for the wild type TPOR and the various transmembrane deletion (FIGS. 9A, 10A) or insertion (FIG. 9B) variants.

(58) Table 3 shows exemplary transmembrane amino acid sequences, coupled to intracellular JAK2 binding domain sequences.

(59) In some embodiments, the transmembrane domain of the chimeric cytokine receptor comprises the amino acid sequence of SEQ ID NO: 27. In some embodiments, the transmembrane domain of the chimeric cytokine receptor comprises the amino acid sequence of SEQ ID NO: 28. In some embodiments, the transmembrane domain of the chimeric cytokine receptor comprises the amino acid sequence of SEQ ID NO: 29. In some embodiments, the transmembrane domain of the chimeric cytokine receptor comprises the amino acid sequence of SEQ ID NO: 30. In some embodiments, the transmembrane domain of the chimeric cytokine receptor comprises the amino acid sequence of SEQ ID NO: 31. In some embodiments, the transmembrane domain of the chimeric cytokine receptor comprises the amino acid sequence of SEQ ID NO: 32. In some embodiments, the transmembrane domain of the chimeric cytokine receptor comprises the amino acid sequence of SEQ ID NO: 33. In some embodiments, the transmembrane domain of the chimeric cytokine receptor comprises the amino acid sequence of SEQ ID NO: 34. In some embodiments, the transmembrane domain of the chimeric cytokine receptor comprises the amino acid sequence of SEQ ID NO: 35. In some embodiments, the transmembrane domain of the chimeric cytokine receptor comprises the amino acid sequence of SEQ ID NO: 36. In some embodiments, the transmembrane domain of the chimeric cytokine receptor comprises the amino acid sequence of SEQ ID NO: 37. In some embodiments, the transmembrane domain of the chimeric cytokine receptor comprises the amino acid sequence of SEQ ID NO: 38. In some embodiments, the transmembrane domain of the chimeric cytokine receptor comprises the amino acid sequence of SEQ ID NO: 39. In some embodiments, the transmembrane domain of the chimeric cytokine receptor comprises the amino acid sequence of SEQ ID NO: 40. In some embodiments, the transmembrane domain of the chimeric cytokine receptor comprises the amino acid sequence of SEQ ID NO: 41. In some embodiments, the transmembrane domain of the chimeric cytokine receptor comprises the amino acid sequence of SEQ ID NO: 42. In some embodiments, the transmembrane domain of the chimeric cytokine receptor comprises the amino acid sequence of SEQ ID NO: 43. In some embodiments, the transmembrane domain of the chimeric cytokine receptor comprises the amino acid sequence of SEQ ID NO: 44. In some embodiments, the transmembrane domain of the chimeric cytokine receptor comprises the amino acid sequence of SEQ ID NO: 45. In some embodiments, the transmembrane domain of the chimeric cytokine receptor comprises the amino acid sequence of SEQ ID NO: 46. In some embodiments, the transmembrane domain of the chimeric cytokine receptor comprises the amino acid sequence of SEQ ID NO: 47. In some embodiments, the transmembrane domain of the chimeric cytokine receptor comprises the amino acid sequence of SEQ ID NO: 48. In some embodiments, the transmembrane domain of the chimeric cytokine receptor comprises the amino acid sequence of SEQ ID NO: 49. In some embodiments, the transmembrane domain of the chimeric cytokine receptor comprises the amino acid sequence of SEQ ID NO: 50. In some embodiments, the transmembrane domain of the chimeric cytokine receptor comprises the amino acid sequence of SEQ ID NO: 51. In some embodiments, the transmembrane domain of the chimeric cytokine receptor comprises the amino acid sequence of SEQ ID NO: 52. In some embodiments, the transmembrane domain of the chimeric cytokine receptor comprises the amino acid sequence of SEQ ID NO: 53. In some embodiments, the transmembrane domain of the chimeric cytokine receptor comprises the amino acid sequence of SEQ ID NO: 54. In some embodiments, the transmembrane domain of the chimeric cytokine receptor comprises the amino acid sequence of SEQ ID NO: 55. In some embodiments, the transmembrane domain of the chimeric cytokine receptor comprises the amino acid sequence of SEQ ID NO: 56. In some embodiments, the transmembrane domain of the chimeric cytokine receptor comprises the amino acid sequence of SEQ ID NO: 57. In some embodiments, the transmembrane domain of the chimeric cytokine receptor comprises the amino acid sequence of SEQ ID NO: 58. In some embodiments, the transmembrane domain of the chimeric cytokine receptor comprises the amino acid sequence of SEQ ID NO: 59. In some embodiments, the transmembrane domain of the chimeric cytokine receptor comprises the amino acid sequence of SEQ ID NO: 60. In some embodiments, the transmembrane domain of the chimeric cytokine receptor comprises the amino acid sequence of SEQ ID NO: 61. In some embodiments, the transmembrane domain of the chimeric cytokine receptor comprises the amino acid sequence of SEQ ID NO: 62. In some embodiments, the transmembrane domain of the chimeric cytokine receptor comprises the amino acid sequence of SEQ ID NO: 63. In some embodiments, the transmembrane domain of the chimeric cytokine receptor comprises the amino acid sequence of SEQ ID NO: 64. In some embodiments, the transmembrane domain of the chimeric cytokine receptor comprises the amino acid sequence of SEQ ID NO: 65. In some embodiments, the transmembrane domain of the chimeric cytokine receptor comprises the amino acid sequence of SEQ ID NO: 66. In some embodiments, the transmembrane domain of the chimeric cytokine receptor comprises the amino acid sequence of SEQ ID NO: 67. In some embodiments, the transmembrane domain of the chimeric cytokine receptor comprises the amino acid sequence of SEQ ID NO: 68. In some embodiments, the transmembrane domain of the chimeric cytokine receptor comprises the amino acid sequence of SEQ ID NO: 69. In some embodiments, the transmembrane domain of the chimeric cytokine receptor comprises the amino acid sequence of SEQ ID NO: 70. In some embodiments, the transmembrane domain of the chimeric cytokine receptor comprises the amino acid sequence of SEQ ID NO: 71. In some embodiments, the transmembrane domain of the chimeric cytokine receptor comprises the amino acid sequence of SEQ ID NO: 72. In some embodiments, the transmembrane domain of the chimeric cytokine receptor comprises the amino acid sequence of SEQ ID NO: 73. In some embodiments, the transmembrane domain of the chimeric cytokine receptor comprises the amino acid sequence of SEQ ID NO: 74. In some embodiments, the transmembrane domain of the chimeric cytokine receptor comprises the amino acid sequence of SEQ ID NO: 75. In some embodiments, the transmembrane domain of the chimeric cytokine receptor comprises the amino acid sequence of SEQ ID NO: 76. In some embodiments, the transmembrane domain of the chimeric cytokine receptor comprises the amino acid sequence of SEQ ID NO: 77. In some embodiments, the transmembrane domain of the chimeric cytokine receptor comprises the amino acid sequence of SEQ ID NO: 78. In some embodiments, the transmembrane domain of the chimeric cytokine receptor comprises the amino acid sequence of SEQ ID NO: 79. In some embodiments, the transmembrane domain of the chimeric cytokine receptor comprises the amino acid sequence of SEQ ID NO: 160. In some embodiments, the transmembrane domain of the chimeric cytokine receptor comprises the amino acid sequence of SEQ ID NO: 217. In some embodiments, the transmembrane domain of the chimeric cytokine receptor comprises the amino acid sequence of SEQ ID NO: 218, SEQ ID NO: 219, SEQ ID NO: 220, SEQ ID NO: 221, SEQ ID NO: 222, SEQ ID NO: 223, SEQ ID NO: 224, SEQ ID NO: 225, SEQ ID NO: 226, SEQ ID NO: 227, SEQ ID NO: 228, SEQ ID NO: 229, SEQ ID NO: 230, SEQ ID NO: 231, SEQ ID NO: 232, SEQ ID NO: 233, or SEQ ID NO: 234. In some embodiments, the transmembrane domain of the chimeric cytokine receptor comprises an amino acid sequence that is at least 80%, 85%, 90%, 95%, 98%, or 99%, or 100% identical to the amino acid sequence of any one of SEQ ID NOs: 27-79, 160, and 217-234.

(60) In some embodiments, the chimeric cytokine receptor (CCR) comprises the binding domain comprising the amino acid sequence of SEQ ID NO: 3, 4 or 159, and the transmembrane and JAK2 binding domain comprising the amino acid sequence of SEQ ID NO: 64, 69, or 70. In some embodiments, the CCR is inducible. In some embodiments, the CCR comprises the binding domain comprising the amino acid sequence of SEQ ID NO: 3, 4 or 159, and the transmembrane and JAK2 binding domain comprising the amino acid sequence of SEQ ID NO: 38, 39, 40 or 53. In some embodiments, the CCR comprises the binding domain comprising the amino acid sequence of SEQ ID NO: 3, 4 or 159, and the transmembrane and JAK2 binding domain comprising the amino acid sequence of SEQ ID NO: 59, 60, 160, or 217. In some embodiments, the CCR is constitutively active. In some embodiments, the constitutively active CCR of the disclosure dimerizes without a TGF- ligand.

(61) TABLE-US-00003 TABLE3 ExemplaryTransmembrane+JAK2BindingDomainSequences TransmembraneandJAK2 SEQID bindingdomain Aminoacidsequence NO: GCSFR(614-710) LTLMTLTPEGSELHIILGLFGLLLLLTCLCGTAWLCCSPNRKNPLWP 27 SVPDPAHSSLGSWVPTIMEEDAFQLPGLGTPPITKLTVLEEDEKKP VPWE GP130(609-700) TTPKFAQGEIEAIVVPVCLAFLLTTLLGVLFCFNKRDLIKKHIWPNV 28 PDPSKSHIAQWSPHTPPRHNFNSKDQMYSDGNFTDVSWEIEAN D TPOR/MPLR(478-582) SDPTRVETATETAWISLVTALHLVLGLSAVLGLLLLRWQFPAHYRR 29 LRHALWPSLPDLHRVLGQYLRDTAALSPPKATVSDTCEEVEPSLLEI LPKSSERTPLPL TPOR/MPLR(N1) SDPTRVETATETWISLVTALHLVLGLSAVLGLLLLRWQFPAHYRRL 30 RHALWPSLPDLHRVLGQYLRDTAALSPPKATVSDTCEEVEPSLLEIL PKSSERTPLPL TPOR/MPLR(N2) SDPTRVETATETISLVTALHLVLGLSAVLGLLLLRWQFPAHYRRLRH 31 ALWPSLPDLHRVLGQYLRDTAALSPPKATVSDTCEEVEPSLLEILPK SSERTPLPL TPOR/MPLR(N2+1) SDPTRVETATETLISLVTALHLVLGLSAVLGLLLLRWQFPAHYRRLR 32 HALWPSLPDLHRVLGQYLRDTAALSPPKATVSDTCEEVEPSLLEILP KSSERTPLPL TPOR/MPLR(N3) SDPTRVETATETSLVTALHLVLGLSAVLGLLLLRWQFPAHYRRLRH 33 ALWPSLPDLHRVLGQYLRDTAALSPPKATVSDTCEEVEPSLLEILPK SSERTPLPL TPOR/MPLR(N4) SDPTRVETATETLVTALHLVLGLSAVLGLLLLRWQFPAHYRRLRHA 34 LWPSLPDLHRVLGQYLRDTAALSPPKATVSDTCEEVEPSLLEILPKS SERTPLPL TPOR/MPLR(N4+1) SDPTRVETATETILVTALHLVLGLSAVLGLLLLRWQFPAHYRRLRHA 35 LWPSLPDLHRVLGQYLRDTAALSPPKATVSDTCEEVEPSLLEILPKS SERTPLPL TPOR/MPLR(N5) SDPTRVETATETVTALHLVLGLSAVLGLLLLRWQFPAHYRRLRHAL 36 WPSLPDLHRVLGQYLRDTAALSPPKATVSDTCEEVEPSLLEILPKSS ERTPLPL TPOR/MPLR(N6) SDPTRVETATETTALHLVLGLSAVLGLLLLRWQFPAHYRRLRHAL 37 WPSLPDLHRVLGQYLRDTAALSPPKATVSDTCEEVEPSLLEILPKSS ERTPLPL TPOR/MPLR(N7) SDPTRVETATETALHLVLGLSAVLGLLLLRWQFPAHYRRLRHALW 38 PSLPDLHRVLGQYLRDTAALSPPKATVSDTCEEVEPSLLEILPKSSER TPLPL TPOR/MPLR(N8) SDPTRVETATETLHLVLGLSAVLGLLLLRWQFPAHYRRLRHALWPS 39 LPDLHRVLGQYLRDTAALSPPKATVSDTCEEVEPSLLEILPKSSERTP LPL TPOR/MPLR(N9) SDPTRVETATETHLVLGLSAVLGLLLLRWQFPAHYRRLRHALWPSL 40 PDLHRVLGQYLRDTAALSPPKATVSDTCEEVEPSLLEILPKSSERTPL PL TPOR/MPLR(N10) SDPTRVETATETLVLGLSAVLGLLLLRWQFPAHYRRLRHALWPSLP 41 DLHRVLGQYLRDTAALSPPKATVSDTCEEVEPSLLEILPKSSERTPLP L TPOR/MPLR(N11) SDPTRVETATETVLGLSAVLGLLLLRWQFPAHYRRLRHALWPSLP 42 DLHRVLGQYLRDTAALSPPKATVSDTCEEVEPSLLEILPKSSERTPLP L TPOR/MPLR(N12) SDPTRVETATETLGLSAVLGLLLLRWQFPAHYRRLRHALWPSLPDL 43 HRVLGQYLRDTAALSPPKATVSDTCEEVEPSLLEILPKSSERTPLPL TPOR/MPLR(N13) SDPTRVETATETGLSAVLGLLLLRWQFPAHYRRLRHALWPSLPDL 44 HRVLGQYLRDTAALSPPKATVSDTCEEVEPSLLEILPKSSERTPLPL TPOR/MPLR(N14) SDPTRVETATETLSAVLGLLLLRWQFPAHYRRLRHALWPSLPDLH 45 RVLGQYLRDTAALSPPKATVSDTCEEVEPSLLEILPKSSERTPLPL TPOR/MPLR(N15) SDPTRVETATETSAVLGLLLLRWQFPAHYRRLRHALWPSLPDLHR 46 VLGQYLRDTAALSPPKATVSDTCEEVEPSLLEILPKSSERTPLPL TPOR/MPLR(N16) SDPTRVETATETAVLGLLLLRWQFPAHYRRLRHALWPSLPDLHRV 47 LGQYLRDTAALSPPKATVSDTCEEVEPSLLEILPKSSERTPLPL TPOR/MPLR(N17) SDPTRVETATETVLGLLLLRWQFPAHYRRLRHALWPSLPDLHRVL 48 GQYLRDTAALSPPKATVSDTCEEVEPSLLEILPKSSERTPLPL TPOR/MPLR(N18) SDPTRVETATETLGLLLLRWQFPAHYRRLRHALWPSLPDLHRVLG 49 QYLRDTAALSPPKATVSDTCEEVEPSLLEILPKSSERTPLPL TPOR/MPLR(N+1) SDPTRVETATETAWLISLVTALHLVLGLSAVLGLLLLRWQFPAHYR 50 RLRHALWPSLPDLHRVLGQYLRDTAALSPPKATVSDTCEEVEPSLL EILPKSSERTPLPL TPOR/MPLR(N+2) SDPTRVETATETAWVLISLVTALHLVLGLSAVLGLLLLRWQFPAHY 51 RRLRHALWPSLPDLHRVLGQYLRDTAALSPPKATVSDTCEEVEPSL LEILPKSSERTPLPL TPOR/MPLR(N+3) SDPTRVETATETAWLVLISLVTALHLVLGLSAVLGLLLLRWQFPAH 52 YRRLRHALWPSLPDLHRVLGQYLRDTAALSPPKATVSDTCEEVEPS LLEILPKSSERTPLPL TPOR/MPLR(N+4) SDPTRVETATETAWILVLISLVTALHLVLGLSAVLGLLLLRWQFPAH 53 YRRLRHALWPSLPDLHRVLGQYLRDTAALSPPKATVSDTCEEVEPS LLEILPKSSERTPLPL TPOR/MPLR(N+5) SDPTRVETATETAWLILVLISLVTALHLVLGLSAVLGLLLLRWQFPA 54 HYRRLRHALWPSLPDLHRVLGQYLRDTAALSPPKATVSDTCEEVE PSLLEILPKSSERTPLPL TPOR/MPLR(N+6) SDPTRVETATETAWLLILVLISLVTALHLVLGLSAVLGLLLLRWQFP 55 AHYRRLRHALWPSLPDLHRVLGQYLRDTAALSPPKATVSDTCEEV EPSLLEILPKSSERTPLPL TPOR/MPLR(N+7) SDPTRVETATETAWVLLILVLISLVTALHLVLGLSAVLGLLLLRWQF 56 PAHYRRLRHALWPSLPDLHRVLGQYLRDTAALSPPKATVSDTCEE VEPSLLEILPKSSERTPLPL TPOR/MPLR(N+8) SDPTRVETATETAWLVLLILVLISLVTALHLVLGLSAVLGLLLLRWQF 57 PAHYRRLRHALWPSLPDLHRVLGQYLRDTAALSPPKATVSDTCEE VEPSLLEILPKSSERTPLPL TPOR/MPLR(478- SDPTRVETATETAWISLVTALHLVLGLSAVLGLLLLRKQFPAHYRRL 58 582;W515K) RHALWPSLPDLHRVLGQYLRDTAALSPPKATVSDTCEEVEPSLLEIL PKSSERTPLPL TPOR/MPLR(478- SDPTRVETATETAWISLVTALLLVLGLNAVLGLLLLRKQFPAHYRRL 59 582;H499L, RHALWPSLPDLHRVLGQYLRDTAALSPPKATVSDTCEEVEPSLLEIL S505N,W515K) PKSSERTPLPL TPOR/MPLR(478- SDPTRVETATETAWISLVTALHLVLGLNAVLGLLLLRKQFPAHYRR 60 582;S505N,W515K) LRHALWPSLPDLHRVLGQYLRDTAALSPPKATVSDTCEEVEPSLLEI LPKSSERTPLPL TPOR/MPLR(N91) SDPTRVETATEHLVLGLSAVLGLLLLRWQFPAHYRRLRHALWPSL 61 PDLHRVLGQYLRDTAALSPPKATVSDTCEEVEPSLLEILPKSSERTPL PL TPOR/MPLR(N92) SDPTRVETATHLVLGLSAVLGLLLLRWQFPAHYRRLRHALWPSLP 62 DLHRVLGQYLRDTAALSPPKATVSDTCEEVEPSLLEILPKSSERTPLP L TPOR/MPLR(N93) SDPTRVETAHLVLGLSAVLGLLLLRWQFPAHYRRLRHALWPSLPD 63 LHRVLGQYLRDTAALSPPKATVSDTCEEVEPSLLEILPKSSERTPLPL TPOR/MPLR(N94) SDPTRVETHLVLGLSAVLGLLLLRWQFPAHYRRLRHALWPSLPDL 64 HRVLGQYLRDTAALSPPKATVSDTCEEVEPSLLEILPKSSERTPLPL TPOR/MPLR(N95) SDPTRVEHLVLGLSAVLGLLLLRWQFPAHYRRLRHALWPSLPDLH 65 RVLGQYLRDTAALSPPKATVSDTCEEVEPSLLEILPKSSERTPLPL TPOR/MPLR(N9G) SDPTRVHLVLGLSAVLGLLLLRWQFPAHYRRLRHALWPSLPDLHR 66 VLGQYLRDTAALSPPKATVSDTCEEVEPSLLEILPKSSERTPLPL TPOR/MPLR(N97) SDPTRHLVLGLSAVLGLLLLRWQFPAHYRRLRHALWPSLPDLHRV 67 LGQYLRDTAALSPPKATVSDTCEEVEPSLLEILPKSSERTPLPL TPOR/MPLR(N98) SDPTHLVLGLSAVLGLLLLRWQFPAHYRRLRHALWPSLPDLHRVL 68 GQYLRDTAALSPPKATVSDTCEEVEPSLLEILPKSSERTPLPL TPOR/MPLR(N99) SDPHLVLGLSAVLGLLLLRWQFPAHYRRLRHALWPSLPDLHRVLG 69 QYLRDTAALSPPKATVSDTCEEVEPSLLEILPKSSERTPLPL TPOR/MPLR(N910) SDHLVLGLSAVLGLLLLRWQFPAHYRRLRHALWPSLPDLHRVLGQ 70 YLRDTAALSPPKATVSDTCEEVEPSLLEILPKSSERTPLPL TPOR/MPLR(N911) SHLVLGLSAVLGLLLLRWQFPAHYRRLRHALWPSLPDLHRVLGQY 71 LRDTAALSPPKATVSDTCEEVEPSLLEILPKSSERTPLPL TPOR/MPLR(N912) HLVLGLSAVLGLLLLRWQFPAHYRRLRHALWPSLPDLHRVLGQYL 72 RDTAALSPPKATVSDTCEEVEPSLLEILPKSSERTPLPL TPOR/MPLR(NC3) SDPTRVETATETAWISLVHLVLGLSAVLGLLLLRWQFPAHYRRLRH 73 ALWPSLPDLHRVLGQYLRDTAALSPPKATVSDTCEEVEPSLLEILPK SSERTPLPL TPOR/MPLR(NC5) SDPTRVETATETAWISHLVLGLSAVLGLLLLRWQFPAHYRRLRHAL 74 WPSLPDLHRVLGQYLRDTAALSPPKATVSDTCEEVEPSLLEILPKSS ERTPLPL TPOR/MPLR(NC5P) SDPTRVETATETAWISPHLVLGLSAVLGLLLLRWQFPAHYRRLRHA 75 LWPSLPDLHRVLGQYLRDTAALSPPKATVSDTCEEVEPSLLEILPKS SERTPLPL TPOR/MPLR(NC5PP) SDPTRVETATETAWISPPHLVLGLSAVLGLLLLRWQFPAHYRRLRH 76 ALWPSLPDLHRVLGQYLRDTAALSPPKATVSDTCEEVEPSLLEILPK SSERTPLPL TPOR/MPLR(NC6) SDPTRVETATETAWIHLVLGLSAVLGLLLLRWQFPAHYRRLRHAL 77 WPSLPDLHRVLGQYLRDTAALSPPKATVSDTCEEVEPSLLEILPKSS ERTPLPL TPOR/MPLR(NC6P) SDPTRVETATETAWIPHLVLGLSAVLGLLLLRWQFPAHYRRLRHAL 78 WPSLPDLHRVLGQYLRDTAALSPPKATVSDTCEEVEPSLLEILPKSS ERTPLPL TPOR/MPLR(NC6PP) SDPTRVETATETAWIPPHLVLGLSAVLGLLLLRWQFPAHYRRLRH 79 ALWPSLPDLHRVLGQYLRDTAALSPPKATVSDTCEEVEPSLLEILPK SSERTPLPL TPOR/MPLR(478-582; SDPTRVETATETAWISLVTALLLVLGLNAVLGLLLLRKQFPAHYRRL 217 H499L,S505N, RHALWPSLPDLHRVLGQYLRDTAALSPPRATVSDTCEEVEPSLLEIL W515K,K553R, PRSSERTPLPL K573R) TPOR/MPLR(478-582) SDPTRVETATETAWISLVTALHLVLGLNAVLGLLLLRKQFPAHYRR 160 S505N.W515K. LRHALWPSLPDLHRVLGQYLRDTAALSPPRATVSDTCEEVEPSLLE K553R.K573R ILPRSSERTPLPL TPOR/MPLR(478-582) SDPTRVETATETAWISLVTALHLVLGLSAVLGLLLLRWQFPAHYRR 218 K553R.K573R LRHALWPSLPDLHRVLGQYLRDTAALSPPRATVSDTCEEVEPSLLE ILPRSSERTPLPL TPOR/MPLR(N7) SDPTRVETATETALHLVLGLNAVLGLLLLRKQFPAHYRRLRHALWP 219 S505N.W515K SLPDLHRVLGQYLRDTAALSPPKATVSDTCEEVEPSLLEILPKSSERT PLPL TPOR/MPLR(N7) SDPTRVETATETALHLVLGLNAVLGLLLLRKQFPAHYRRLRHALWP 220 S505N.W515K. SLPDLHRVLGQYLRDTAALSPPRATVSDTCEEVEPSLLEILPRSSERT K553R,K573R PLPL TPOR/MPLR(N8) SDPTRVETATETLHLVLGLNAVLGLLLLRKQFPAHYRRLRHALWPS 221 S505N.W515K LPDLHRVLGQYLRDTAALSPPKATVSDTCEEVEPSLLEILPKSSERTP LPL TPOR/MPLR(N8) SDPTRVETATETLHLVLGLNAVLGLLLLRKQFPAHYRRLRHALWPS 222 S505N.W515K. LPDLHRVLGQYLRDTAALSPPRATVSDTCEEVEPSLLEILPRSSERT K553R,K573R PLPL TPOR/MPLR(N9) SDPTRVETATETHLVLGLNAVLGLLLLRKQFPAHYRRLRHALWPSL 223 S505N.W515K PDLHRVLGQYLRDTAALSPPKATVSDTCEEVEPSLLEILPKSSERTPL PL TPOR/MPLR(N9) SDPTRVETATETHLVLGLNAVLGLLLLRKQFPAHYRRLRHALWPSL 224 S505N.W515K. PDLHRVLGQYLRDTAALSPPRATVSDTCEEVEPSLLEILPRSSERTP K553R,BK573R LPL TPOR/MPLR(N+4) SDPTRVETATETAWILVLISLVTALHLVLGLNAVLGLLLLRKQFPAH 225 S505N.W515K YRRLRHALWPSLPDLHRVLGQYLRDTAALSPPKATVSDTCEEVEPS LLEILPKSSERTPLPL TPOR/MPLR(N+4) SDPTRVETATETAWILVLISLVTALHLVLGLNAVLGLLLLRKQFPAH 226 S505N.W515K. YRRLRHALWPSLPDLHRVLGQYLRDTAALSPPRATVSDTCEEVEPS K553R,K573R LLEILPRSSERTPLPL TPOR/MPLR(N91) SDPTRVETATEHLVLGLNAVLGLLLLRKQFPAHYRRLRHALWPSLP 227 S505N.W515K DLHRVLGQYLRDTAALSPPKATVSDTCEEVEPSLLEILPKSSERTPLP L TPOR/MPLR(N91) SDPTRVETATEHLVLGLNAVLGLLLLRKQFPAHYRRLRHALWPSLP 228 S505N.W515K. DLHRVLGQYLRDTAALSPPRATVSDTCEEVEPSLLEILPRSSERTPL K553R,K573R PL TPOR/MPLR(N94) SDPTRVETHLVLGLNAVLGLLLLRKQFPAHYRRLRHALWPSLPDLH 229 S505N.W515K RVLGQYLRDTAALSPPKATVSDTCEEVEPSLLEILPKSSERTPLPL TPOR/MPLR(N94) SDPTRVETHLVLGLNAVLGLLLLRKQFPAHYRRLRHALWPSLPDLH 230 S505N.W515K. RVLGQYLRDTAALSPPRATVSDTCEEVEPSLLEILPRSSERTPLPL K553R,K573R TPOR/MPLR(N99) SDPHLVLGLNAVLGLLLLRKQFPAHYRRLRHALWPSLPDLHRVLG 231 S505N.W515K QYLRDTAALSPPKATVSDTCEEVEPSLLEILPKSSERTPLPL TPOR/MPLR(N99) SDPHLVLGLNAVLGLLLLRKQFPAHYRRLRHALWPSLPDLHRVLG 232 S505N.W515K. QYLRDTAALSPPRATVSDTCEEVEPSLLEILPRSSERTPLPL K553R,K573R TPOR/MPLR(N910) SDHLVLGLNAVLGLLLLRKQFPAHYRRLRHALWPSLPDLHRVLGQ 233 S505N.W515K YLRDTAALSPPKATVSDTCEEVEPSLLEILPKSSERTPLPL TPOR/MPLR(N910) SDHLVLGLNAVLGLLLLRKQFPAHYRRLRHALWPSLPDLHRVLGQ 234 S505N.W515K. YLRDTAALSPPRATVSDTCEEVEPSLLEILPRSSERTPLPL K553R,K573R

(62) C. Janus Kinase (JAK)-Binding Domains

(63) The chimeric cytokine receptors of the disclosure comprise intracellular JAK-binding domains. The JAK-binding domain is coupled to the C-terminus of the transmembrane domain, either directly, or via a linker. The JAK-binding domain is coupled to the transmembrane domain on the intracellular side of the chimeric cytokine receptor.

(64) In some embodiments, the JAK-binding domain is a JAK-1-binding domain, a JAK-2 binding domain, a JAK-3 binding domain, or a TYK2 binding domain.

(65) In some embodiments, the JAK-binding domains of the chimeric cytokine receptors of the disclosure are naturally occurring, and derived from a naturally occurring receptor.

(66) In some embodiments, the JAK-binding domains of the chimeric cytokine receptors of the disclosure are synthetic.

(67) In some embodiments, the chimeric cytokine receptor comprises a transmembrane and JAK2 binding domain that is at least 80%, 85%, 90%, 95%, 98% or 99%, or 100% identical to any one of the amino acid sequences of SEQ ID NOs: 27-79, 160 and 217-234.

(68) Table 3 provides exemplary amino acid sequences for the transmembrane and JAK2 binding domains of the disclosure. In some embodiments, the transmembrane and JAK2 binding domain comprises one or more mutations, e.g., one or more deletions, insertions and/or substitutions of the wild type sequences. In some embodiments, the transmembrane and JAK2 binding domain comprises one or more substitutions at amino acid positions H499, S505 and W515 of the wild type TPOR/MPLR sequence. See Table 3. In some embodiments, the transmembrane and JAK2 binding domain comprises one or more substitutions at the amino acid positions K533 and K573 of the wild type TPOR/MPLR sequence. In some embodiments, the transmembrane and JAK2 binding domain, e.g., as shown in Table 3, may be combined with a TGFR2 ectodomain as disclosed herein, e.g., in Table 1, or a PD-1 ectodomain (such as a high affinity PD-1 ectodomain, as indicated in SEQ ID NO: 274 or 275 in Table 6) and a recruiting domain to form a chimeric cytokine receptor. In some embodiments, the transmembrane and JAK2 binding domain may be combined with a recruiting domain to form a chimeric cytokine receptor without an ectodomain, see e.g., SEQ ID NOs: 272 or 273. See also U.S. Ser. No. 16/804,917, filed on Feb. 28, 2020, and U.S. Ser. No. 16/804,545, filed on Feb. 28, 2020, both of which are incorporated herein by reference in their entireties.

(69) D. Recruiting Domains

(70) The chimeric cytokine receptors of the disclosure comprise cytoplasmic domains comprising recruiting domains (which may also be referred to as signaling domains). The recruiting domain can be a STAT-recruiting domain, an AP1recruiting domain, a Myc/Max recruiting domain; or an NFkB-recruiting domain. In some embodiments, the recruiting domain is a Signal Transducer and Activator of Transcription (STAT)recruiting (Stat-activating) domains from receptor tails (cytotails) or from cytokine receptor tails. These intracellular recruiting domains of the chimeric cytokine receptors of the disclosure allow for the propagation of Signal 3 in an immune cell comprising a CAR and a chimeric cytokine receptor (e.g. a CAR-T-cell with a chimeric cytokine receptor of the disclosure). Cytokine signaling propagated through the Stat-recruiting domain allows for the cytokine-based immune potentiation of the cell. In some embodiments, the immune-potentiation is homeostatic, e.g. signaling gives rise to increase in immune cells bearing the CAR. In some embodiments, the immune-potentiation is inflammatory, e.g. signaling gives rise to increase in the potency of the immune cells bearing the CAR. In some embodiments, the immune-potentiation prevents exhaustion, e.g. signaling maintains the long-term functionality of immune cells bearing the CAR.

(71) In some embodiments, the recruiting domains of the disclosure are synthetic, and do not resemble any naturally occurring receptor fragment.

(72) In some embodiments, the Stat-recruiting domains of the disclosure are synthetic, and do not resemble any naturally occurring receptor fragment.

(73) In other embodiments, the Stat-recruiting domains of the disclosure are derived from cytoplasmic tails of naturally occurring receptors, e.g. derived from naturally occurring cytokine receptors. In some embodiments, the chimeric cytokine receptor comprises a portion or a fragment of a naturally occurring receptor, e.g., the intracellular Stat-recruiting domain of the naturally occurring receptor, optionally with one or more mutations therein (e.g., one or more deletions, insertions and/or substitutions). These cytoplasmic tails of naturally occurring receptors may be the regions downstream of the JAK-activating domains of the transmembrane domain of the receptor. The Stat-recruiting domains of the chimeric cytokine receptors comprise at least one STAT-recruiting domain from at least one receptor. In some embodiments, the Stat-recruiting domain comprises at least one STAT1-recruiting domain. In some embodiments, the Stat-recruiting domain comprises at least one STAT2-recruiting domain. In some embodiments, the Stat-recruiting domain comprises at least one STAT3-recruiting domain. In some embodiments, the Stat-recruiting domain comprises at least one STAT4-recruiting domain. In some embodiments, the Stat-recruiting domain comprises at least one STAT5-recruiting domain. In some embodiments, the STAT-recruiting domain comprises at least one STAT6-recruiting domain. In some embodiments, the Stat-recruiting domain comprises at least one STAT7-recruiting domain.

(74) In some embodiments, the naturally occurring receptor from which the STAT-recruiting domain is derived, is a not a cytokine receptor.

(75) In some embodiments, the naturally occurring receptor from which the Stat-recruiting domain is derived, is a cytokine receptor. Exemplary cytokine receptors through which T-cell-immune potentiating cytokines signal include, but are not limited to IL-2 receptor, IL-7 receptor, IL-15 receptor, IL12 receptor, and IL-21 receptor. In some embodiments, the cytokine receptor from which the STAT-recruiting domain is derived contains phosphorylatable tyrosine residues downstream of the cognate JAK-binding motifs, and one or more signaling domains of interest may be fused downstream of the transmembrane domain to generate single or multiple signaling outputs. In alternative embodiments, the receptor from which the Stat-recruiting domain is derived, is not a cytokine receptor. By choosing the Stat-recruiting domain of the chimeric cytokine receptor, the receptor can be redirected to signaling of choice. In some embodiments, the chimeric cytokine receptor comprises two or more Stat-recruiting domains from more than one receptor. In some embodiments, the two or more Stat-recruiting domains are linked with or without a peptide linker.

(76) Table 4 provides exemplary receptors from which Stat-recruiting domains (signaling domains) of the chimeric cytokine receptors of the disclosure are derived. Table 5a provides exemplary amino acid sequences of recruiting domains of the disclosure.

(77) In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of the STAT-recruiting domain of SEQ ID NO: 80. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of the STAT-recruiting domain of SEQ ID NO: 81. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of the STAT-recruiting domain of SEQ ID NO: 82. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of the STAT-recruiting domain of SEQ ID NO: 83. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of the STAT-recruiting domain of SEQ ID NO: 84. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of the STAT-recruiting domain of SEQ ID NO: 85. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of the STAT-recruiting domain of SEQ ID NO: 86. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of the STAT-recruiting domain of SEQ ID NO: 87. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of the STAT-recruiting domain of SEQ ID NO: 88. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of the STAT-recruiting domain of SEQ ID NO: 89. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of the STAT-recruiting domain of SEQ ID NO: 90. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of the STAT-recruiting domain of SEQ ID NO: 91. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of the STAT-recruiting domain of SEQ ID NO: 92. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of the STAT-recruiting domain of SEQ ID NO: 93. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of the STAT-recruiting domain of SEQ ID NO: 94. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of the STAT-recruiting domain of SEQ ID NO: 95. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of the STAT-recruiting domain of SEQ ID NO: 96. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of the STAT-recruiting domain of SEQ ID NO: 97. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of the STAT-recruiting domain of SEQ ID NO: 98. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of the STAT-recruiting domain of SEQ ID NO: 99. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of the STAT-recruiting domain of SEQ ID NO: 100. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of the STAT-recruiting domain of SEQ ID NO: 101. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of the STAT-recruiting domain of SEQ ID NO: 102. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of the STAT-recruiting domain of SEQ ID NO: 103. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of the STAT-recruiting domain of SEQ ID NO: 104. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of the STAT-recruiting domain of SEQ ID NO: 105. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of the STAT-recruiting domain of SEQ ID NO: 106. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of the STAT-recruiting domain of SEQ ID NO: 107. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of the STAT-recruiting domain of SEQ ID NO: 108. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of the STAT-recruiting domain of SEQ ID NO: 109. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of the STAT-recruiting domain of SEQ ID NO: 110. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of the STAT-recruiting domain of SEQ ID NO: 111. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of the STAT-recruiting domain of SEQ ID NO: 112. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of the STAT-recruiting domain of SEQ ID NO: 113. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of the STAT-recruiting domain of SEQ ID NO: 114. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of the STAT-recruiting domain of SEQ ID NO: 115. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of the STAT-recruiting domain of SEQ ID NO: 116. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of the STAT-recruiting domain of SEQ ID NO: 117. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of the STAT-recruiting domain of SEQ ID NO: 118. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of the STAT-recruiting domain of SEQ ID NO: 119. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of the STAT-recruiting domain of SEQ ID NO: 120. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of the STAT-recruiting domain of SEQ ID NO: 121. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of the STAT-recruiting domain of SEQ ID NO: 122. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of the STAT-recruiting domain of SEQ ID NO: 161. In some embodiments, the chimeric cytokine receptor comprises a recruiting domain that comprises an amino acid sequence that is at least 80%, 85%, 90%, 95%, 98%, or 99%, or 100% identical to any one of the amino acid sequences of SEQ ID NOs: 80-122 and SEQ ID NO: 161.

(78) TABLE-US-00004 TABLE 4 Recruiting domain sources Source for recruiting domains BLNK IL2RG EGFR EpoR GHR IFNAR1 IFNAR2 IFNAR1/2 IFNLR1 IL10R1 IL12Rb1 IL12Rb2 IL21R IL2Rb IL2small IL7R IL7Ra IL9R IL15R IL21R

(79) TABLE-US-00005 TABLE5a RecruitingDomainSequences(CytotailSequences) SEQID Recruitingdomain Aminoacidsequence NO: IL7R(316-459) ARDEVEGFLQDTFPQQLEESEKQRLGGDVQSPNCPSEDVVITPES 80 FGRDSSLTCLAGNVSACDAPILSSSRSLDCRESGKNGPHVYQDLLL SLGTTNSTLPPPFSLQSGILTLNPVAQGQPILTSLGSNQEEAYVTM SSFYQNQ IL2Rb(333-551) VTQLLLQQDKVPEPASLSSNHSLTSCFTNQGYFFFHLPDALEIEAC 81 QVYFTYDPYSEEDPDEGVAGAPTGSSPQPLQPLSGEDDAYCTFPS RDDLLLFSPSLLGGPSPPSTAPGGSGAGEERMPPSLQERVPRDW DPQPLGPPTPGVPDLVDFQPPPELVLREAGEEVPDAGPREGVSFP WSRPPGQGEFRALNARLPLNTDAYLSLQELQGQDPTHLV IFNAR1(508-557) ISTIATVEETNQTDEDHKKYSSQTSQDSGNYSNEDESESKTSEELQ 82 QDFV IFNAR2(310-515) KKKVWDYNYDDESDSDTEAAPRTSGGGYTMHGLTVRPLGQASA 83 TSTESQLIDPESEEEPDLPEVDVELPTMPKDSPQQLELLSGPCERRK SPLQDPFPEEDYSSTEGSGGRITFNVDLNSVFLRVLDDEDSDDLEA PLMLSSHLEEMVDPEDPDNVQSNHLLASGEGTQPTFPSPSSEGL WSEDAPSDQSDTSESDVDLGDGYIMR IFNAR1/2(IFNAR1residues ISTIATVEETNQTDEDHKKYSSQTSQDSGNYSNEDESESKTSEELQ 84 508-557-IFNAR2residues QDFVKKKVWDYNYDDESDSDTEAAPRTSGGGYTMHGLTVRPLG 310-515) QASATSTESQLIDPESEEEPDLPEVDVELPTMPKDSPQQLELLSGP CERRKSPLQDPFPEEDYSSTEGSGGRITFNVDLNSVFLRVLDDEDS DDLEAPLMLSSHLEEMVDPEDPDNVQSNHLLASGEGTQPTFPSP SSEGLWSEDAPSDQSDTSESDVDLGDGYIMR IFNLR1(300-520) RGVRPTPRVRAPATQQTRWKKDLAEDEEEEDEEDTEDGVSFQPY 85 IEPPSFLGQEHQAPGHSEAGGVDSGRPRAPLVPSEGSSAWDSSD RSWASTVDSSWDRAGSSGYLAEKGPGQGPGGDGHQESLPPPEF SKDSGFLEELPEDNLSSWATWGTLPPEPNLVPGGPPVSLQTLTFC WESSPEEEEEARESEIEDSDAGSWGAESTQRTEDRGRTLGHYMA R CommonGamma IPPKGGALGEGPGASPCNQHSPYWAPPCYTLKPET 86 Chain(335-369) IL9R(356-521) TALLTCGPARPWKSVALEEEQEGPGTRLPGNLSSEDVLPAGCTEW 87 RVQTLAYLPQEDWAPTSLTRPAPPDSEGSRSSSSSSSSNNNNYCA LGCYGGWHLSALPGNTQSSGPIPALACGLSCDHQGLETQQGVA WVLAGHCQRPGLHEDLQGMLLPSVLSKARSWTF IL21R(322-538) PRSPAKRLQLTELQEPAELVESDGVPKPSFWPTAQNSGGSAYSEE 88 RDRPYGLVSIDTVTVLDAEGPCTWPCSCEDDGYPALDLDAGLEPS PGLEDPLLDAGTTVLSCGCVSAGSPGLGGPLGSLLDRLKPPLADGE DWAGGLPWGGRSPGGVSESEAGSPLAGLDMDTFDSGFVGSDCS SPVECDFTSPGDEGPPRSYLRQWVVIPPPLSSPGPQAS GHR(353-638) PDEKTEESDTDRLLSSDHEKSHSNLGVKDGDSGRTSCCEPDILETD 89 FNANDIHEGTSEVAQPQRLKGEADLLCLDQKNQNNSPYHDACPA TQQPSVIQAEKNKPQPLPTEGAESTHQAAHIQLSNPSSLSNIDFYA QVSDITPAGSVVLSPGQKNKAGMSQCDMHPEMVSLCQENFLM DNAYFCEADAKKCIPVAPHIKVESHIQPSLNQEDIYITTESLTTAAG RPGTGEHVPGSEMPVPDYTSIHIVQSPQGLILNATALPLPDKEFLS SCGYVSTDQLNKIMP EpoR(339-508) WGTMQAVEPGTDDEGPLLEPVGSEHAQDTYLVLDKWLLPRNPP 90 SEDLPGPGGSVDIVAMDEGSEASSCSSALASKPSPEGASAASFEYT ILDPSSQLLRPWTLCPELPPTPPHLKYLYLVVSDSGISTDYSSGDSQ GAQGGLSDGPYSNPYENSLIPAAEPLPPSYVACS murineIL2Rb(337-539) AVQLLLLQKDSAPLPSPSGHSQASCFTNQGYFFFHLPNALEIESCQ 91 VYFTYDPCVEEEVEEDGSRLPEGSPHPPLLPLAGEQDDYCAFPPRD DLLLFSPSLSTPNTAYGGSRAPEERSPLSLHEGLPSLASRDLMGLQR PLERMPEGDGEGLSANSSGEQASVPEGNLHGQDQDRGQGPILTL NTDAYLSLQELQAQDSVHLI murineIL7Ra(316-459) ARDEVESFLPNDLPAQPEELETQGHRAAVHSANRSPETSVSPPET 92 VRRESPLRCLARNLSTCNAPPLLSSRSPDYRDGDRNRPPVYQDLLP NSGNTNVPVPVPQPLPFQSGILIPVSQRQPISTSSVLNQEEAYVTM SSFYQNK EGFR(955-1186) VIQGDERMHLPSPTDSNFYRALMDEEDMDDVVDADEYLIPQQG 93 FFSSPSTSRTPLLSSLSATSNNSTVACIDRNGLQSCPIKEDSFLQRYS SDPTGALTEDSIDDTFLPVPEYINQSVPKRPAGSVQNPVYHNQPL NPAPSRDPHYQDPHSTAVGNPEYLNTVQPTCVNSTFDSPAHWA QKGSHQISLDNPDYQQDFFPKEAKPNGIFKGSTAENAEYLRVAPQ SSEFIGA EGFR(955- VIQGDERMHLPSPTDSNFFRALMDEEDMDDVVDADEYLIPQQG 94 1186;Y974F,d1045-1057) FFSSPSTSRTPLLSSLSATSNNSTVACIDRNGLQSCPIKEDSFLQRID DTFLPVPEYINQSVPKRPAGSVQNPVYHNQPLNPAPSRDPHYQD PHSTAVGNPEYLNTVQPTCVNSTFDSPAHWAQKGSHQISLDNPD YQQDFFPKEAKPNGIFKGSTAENAEYLRVAPQSSEFIGA EGFR(955-1009;Y974F) VIQGDERMHLPSPTDSNFFRALMDEEDMDDVVDADEYLIPQQG 95 FFSSPSTSRTP EGFR(1019-1085) NNSTVACIDRNGLQSCPIKEDSFLQRIDDTFLPVPEYINQSVPKRPA 96 GSVQNPV EGFR(1037- KEDSFLQRIDDTFLPVPEFINQSVPKRPAGSVQNPVYHNQPLNPA 97 1103;Y1068/1101F, PSRDPHFQD d1045-1057) EGFR(1066-1118; VPEFINQSVPKRPAGSVQNPVFHNQPLNPAPSRDPHYQDPHSTA 98 Y1068/1086F) VGNPEYLNTV EGFR(1122-1165) PEYLNTVQPTCVNSTFDSPAHWAQKGSHQISLDNPDYQQDFFPK 99 EAKPNGIFKG EGFR(1133-1186;Y1148F) WAQKGSHQISLDNPDFQQDFFPKEAKPNGIFKGSTAENAEYLRV 100 APQSSEFIGA IL12Rb2(775-825) SDPKPENPACPWTVLPAGDLPTHDGYLPSNIDDLPSHEAPLADSL 101 EELEPQ IL7R(376-416) ACDAPILSSSRSLDCRESGKNGPHVYQDLLLSLGTTNSTLP 102 IL7R(424-459) GILTLNPVAQGQPILTSLGSNQEEAYVTMSSFYQNQ 103 IL7R(376-416,424-459) ACDAPILSSSRSLDCRESGKNGPHVYQDLLLSLGTTNSTLPQGQPIL 104 TSLGSNQEEAYVTMSSFYQNQ IL7R(424-459;Y456F) GILTLNPVAQGQPILTSLGSNQEEAYVTMSSFFQNQ 105 IL7R(376-416,424- ACDAPILSSSRSLDCRESGKNGPHVYQDLLLSLGTTNSTLPQGQPIL 106 459,Y456F) TSLGSNQEEAYVTMSSFFQNQ IL2Rbsmall(393-433) DEGVAGAPTGSSPQPLQPLSGEDDAYCTFPSRDDLLLFSPS 107 IL2Rbsmall(518-551) GQGEFRALNARLPLNTDAYLSLQELQGQDPTHLV 108 IL2Rbsmall(339-379,393- QQDKVPEPASLSSNHSLTSCFTNQGYFFFHLPDALEIEACQDEGV 109 433) AGAPTGSSPQPLQPLSGEDDAYCTFPSRDDLLLFSPS IL2Rbsmall(339-379,518- QQDKVPEPASLSSNHSLTSCFTNQGYFFFHLPDALEIEACQ 110 551) GQGEFRALNARLPLNTDAYLSLQELQGQDPTHLV IL2Rbsmall(393-433,518- DEGVAGAPTGSSPQPLQPLSGEDDAYCTFPSRDDLLLFSPSGQGE 111 551) FRALNARLPLNTDAYLSLQELQGQDPTHLV IL2Rbsmall(339-379,393- QQDKVPEPASLSSNHSLTSCFTNQGYFFFHLPDALEIEACQDEGV 112 433,518-551) AGAPTGSSPQPLQPLSGEDDAYCTFPSRDDLLLFSPSGQGEFRAL NARLPLNTDAYLSLQELQGQDPTHLV IFNAR2small(310-352) KKKVWDYNYDDESDSDTEAAPRTSGGGYTMHGLTVRPLGQASA 113 IFNAR2small(486-515) EGLWSEDAPSDQSDTSESDVDLGDGYIMR 114 IFNAR2small(310-352,486- KKKVWDYNYDDESDSDTEAAPRTSGGGYTMHGLTVRPLGQASA 115 515) EGLWSEDAPSDQSDTSESDVDLGDGYIMR BLNK(53-208) ASESPADEEEQWSDDFDSDYENPDEHSDSEMYVMPAEENADDS 116 YEPPPVEQETRPVHPALPFARGEYIDNRSSQRHSPPFSKTLPSKPS WPSEKARLTSTLPALTALQKPQVPPKPKGLLEDEADYVVPVEDND ENYIHPTESSSPPPEKAPMVNR BLNK(53-208;Y72F) ASESPADEEEQWSDDFDSDFENPDEHSDSEMYVMPAEENADDS 117 YEPPPVEQETRPVHPALPFARGEYIDNRSSQRHSPPFSKTLPSKPS WPSEKARLTSTLPALTALQKPQVPPKPKGLLEDEADYVVPVEDND ENYIHPTESSSPPPEKAPMVNR BLNK(53-208;Y72F,Y96F) ASESPADEEEQWSDDFDSDFENPDEHSDSEMYVMPAEENADDS 118 FEPPPVEQETRPVHPALPFARGEYIDNRSSQRHSPPFSKTLPSKPS WPSEKARLTSTLPALTALQKPQVPPKPKGLLEDEADYVVPVEDND ENYIHPTESSSPPPEKAPMVNR EpoR(339-508) WGTMQAVEPGTDDEGPLLEPVGSEHAQDTYLVLDKWLLPRNPP 119 SEDLPGPGGSVDIVAMDEGSEASSCSSALASKPSPEGASAASFEYT ILDPSSQLLRPWTLCPELPPTPPHLKYLYLVVSDSGISTDYSSGDSQ GAQGGLSDGPYSNPYENSLIPAAEPLPPSYVACS IL12Rb2(714-862) VTPVFRHPPCSNWPQREKGIQGHQASEKDMMHSASSPPPPRAL 120 QAESRQLVDLYKVLESRGSDPKPENPACPWTVLPAGDLPTHDGYL PSNIDDLPSHEAPLADSLEELEPQHISLSVFPSSSLHPLTFSCGDKLT LDQLKMRCDSLML IL12Rb1(622-662) WDKGERTEPLEKTELPEGAPELALDTELSLEDGDRCKAKM 121 IL10R1(304-578) VSPELKNLDLHGSTDSGFGSTKPSLQTEEPQFLLPDPHPQADRTLG 122 NREPPVLGDSCSSGSSNSTDSGICLQEPSLSPSTGPTWEQQVGSN SRGQDDSGIDLVQNSEGRAGDTQGGSALGHHSPPEPEVPGEEDP AAVAFQGYLRQTRCAEEKATKTGCLEEESPLTDGLGPKFGRCLVD EAGLHPPALAKGYLKQDPLEMTLASSGAPTGQWNQPTEEWSLLA LSSCSDLGISDWSFAHDLAPLGCVAAPGGLLGSFNSDLVTLPLISSL QSSE IL7Ra(316- ARDEVEGFLQDTFPQQLEESEKQRLGGDVQSPNCPSEDVVITPES 161 459).IL12Rb2(775-825) FGRDSSLTCLAGNVSACDAPILSSSRSLDCRESGKNGPHVYQDLLL SLGTTNSTLPPPFSLQSGILTLNPVAQGQPILTSLGSNQEEAYVTM SSFYQNQSRSDPKPENPACPWTVLPAGDLPTHDGYLPSNIDDLPS HEAPLADSLEELEPQ *SR indicates an exemplary peptide linker

(80) In some embodiments, the Stat-recruiting domain of a chimeric cytokine receptor of the disclosure comprises a STAT-recruiting domain from one receptor.

(81) In order to generate multiple outputs, one or more STAT-recruiting domains may be joined in tandem to mimic signaling from one or more cytokines.

(82) In some embodiments, the STAT-recruiting domain comprises portions of more than one receptor, e.g. comprising more than one STAT-recruiting domain. In such embodiments, a tandem cytokine signaling domain is provided, allowing for enhanced signaling. Accordingly, in some embodiments, the STAT-recruiting domain of a monomer of the chimeric cytokine receptor of the disclosure comprises the STAT-recruiting domains from more than one receptor, e.g. comprises the STAT-recruiting domains from two, three, four, five, or even six receptors. For example, in some embodiments, STAT-recruiting domains can be linked in tandem to stimulate multiple pathways (e.g., the IL7R(316-459)-IL12Rb2(775-825) fragment fusion for pro-persistence STAT5 and pro-inflammatory STAT4; IL7R(316-459)-IL2Rbsmall(393-433,518-551) for pro-persistence; IL7R(316-459)-EGFR(1122-1165) for pro-persistence and anti-exhaustion; IL2Rbsmall(393-433,518-551)-EGFR(1122-1165) for pro-persistence and anti-exhaustion).

(83) When generating multiple outputs, the proximity of individual STAT-recruiting domains to the cell membrane can influence the strength of their respective signaling outputs. Table 5b shows examples of chimeric cytokine receptors with the dual outputs, where each output can be placed either proximal or distal to the cell membrane.

(84) TABLE-US-00006 TABLE 5b Examples of chimeric cytokine receptors with dual outputs Dual output STAT- Membrane Membrane recruiting domain proximal distal IL2Rbsmall(393-433, 518-551)/ IL2Rbsmall(393- IL21R(322-538) IL21R(322-538) 433, 518-551) IL21R(322-538)/ IL21R(322-538) IL2Rbsmall(393- IL2Rbsmall(393-433, 518-551) 433, 518-551) IL2Rbsmall(339-379, 393- IL2Rbsmall(339- IL21R(322-538) 433, 518-551)/IL21R(322-538) 379, 393-433, 518-551) IL21R(322-538)/ IL21R(322-538) IL2Rbsmall(339- IL2Rbsmall(339- 379, 393-433, 379, 393-433, 518-551) 518-551) IL7R (316-459)/IL21R(322-538) IL7R (316-459) IL21R(322-538) IL7R (316-459)/IL12Rb2(775- IL7R (316-459) IL12Rb2(775-825) 825) IL21R(322-538)/IL7R (316-459) IL21R(322-538) IL7R (316-459)

(85) Without being bound to theory or mechanism, in some embodiments, a JAK-protein (JAK1, JAK2, JAK3, or TYK2) is bound to a chimeric cytokine receptor of the disclosure (comprising a binding domain, a transmembrane domain, a JAK-binding domain, and a recruiting domain). In some embodiments, in the presence of (e.g. binding to) a TGF- ligand or an anti-TGF--receptor antibody, the chimeric cytokine receptor clusters and allows for the two bound JAK-proteins to become activated, which in turn phosphorylate tyrosine residues on the recruiting domain of the chimeric receptor. The phosphorylated recruiting domains are then capable of binding the recruited proteins (e.g. a phosphorylated STAT-recruiting domain binds a STAT-protein), which in turn effectuate transcription events in the nucleus.

(86) E. Exemplary TGF--Driven Chimeric Cytokine Receptors

(87) Context-dependent chimeric cytokine receptors of the disclosure may be expressed with a signal sequence, e.g. a CD8SS of SEQ ID NO: 1. Table 6 shows exemplary context-dependent cytokine receptor sequences of the disclosure. The receptors may be expressed with a signal sequence, e.g. a CD8SS of SEQ ID NO: 1.

(88) In some embodiments, the chimeric cytokine receptor of the disclosure comprises a TGF- binding domain comprising an amino acid sequence of any one of SEQ ID NOs: 3-20, and 159, a transmembrane and JAK2 binding domain comprising an amino acid sequence of any one of SEQ ID NOs: 27-79, 160 and 217-234, and a recruiting domain comprising an amino acid sequences of any one of SEQ ID NOs: 80-122 and 161. In some embodiments, the chimeric cytokine receptor does not comprise a signal sequence.

(89) In some embodiments, the chimeric cytokine receptor of the disclosure comprises a TGF- binding domain comprising the amino acid sequence selected from the group consisting of SEQ ID NOs: 3, 4, and 159, a TPOR/MPLR transmembrane and JAK2 binding domain comprising the amino acid sequence selected from the group consisting of SEQ ID NOs: 38, 39, 40, 53, 59, 60, 61, 64, 69, 70, 160 and 217-234, and a recruiting domain comprising the amino acid sequence selected from the group consisting of SEQ ID NOs: 80, 99, 111, 112, and 161. Optionally, the chimeric cytokine receptor comprises a signal sequence that comprises for example the amino acid sequence of SEQ ID NO:1.

(90) In some embodiments, the chimeric cytokine receptor comprises a binding domain comprising the amino acid sequence of SEQ ID NO: 3, 4 or 159, a transmembrane and JAK2 binding domain comprising the amino acid sequence of SEQ ID NO: 64, 69, or 70, and a recruiting domain comprising the amino acid sequence of SEQ ID NO: 80, 99, 111, 112, or 161. In some embodiments, the chimeric cytokine receptor is inducible. In some embodiments, the chimeric cytokine receptor comprises a binding domain comprising the amino acid sequence of SEQ ID NO: 3, 4 or 159, a transmembrane and JAK2 binding domain comprising the amino acid sequence of SEQ ID NO: 38, 39, 40 or 53, and a recruiting domain comprising the amino acid sequence of SEQ ID NO: 80, 99, 111, 112, or 161. In some embodiments, the chimeric cytokine receptor comprises a binding domain comprising the amino acid sequence of SEQ ID NO: 3, 4 or 159, a transmembrane and JAK2 binding domain comprising the amino acid sequence of SEQ ID NO: 59, 60, 160, or 217, and a recruiting domain comprising the amino acid sequence of SEQ ID NO: 80, 99, 111, 112, or 161. In some embodiments, the chimeric cytokine receptor is constitutively active. In some embodiments, the constitutively active chimeric cytokine receptor of the disclosure dimerizes without binding to a TGF ligand or an anti-TGFR antibody. In some embodiments, the chimeric cytokine receptor of the disclosure inhibits TGFR-mediated signaling and/or activates STAT-mediated signaling, either constitutively or induced by TGF-, or an anti-TGFR antibody. In some embodiments, the chimeric cytokine receptor is constitutively active and/or exhibits further enhanced activities or properties in the presence of a TGF-R ligand, e.g., TGF-, or an anti-TGF-R antibody. In some embodiments, the TGF-R is TGF-R2, and the antibody is an anti-TGF-R2 antibody.

(91) In some embodiments, the chimeric cytokine receptor does not comprise a signal sequence. In some embodiments, the chimeric cytokine receptor comprises the TGFR2 endogenous signal sequence or a signal sequence that comprise, e.g., the amino acid sequence of SEQ ID NO:1.

(92) In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of SEQ ID NO: 123. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of SEQ ID NO: 124. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of SEQ ID NO: 125. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of SEQ ID NO: 126. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of SEQ ID NO: 127. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of SEQ ID NO: 128. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of SEQ ID NO: 129. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of SEQ ID NO: 130. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of SEQ ID NO: 131. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of SEQ ID NO: 132. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of SEQ ID NO: 133. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of SEQ ID NO: 134. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of SEQ ID NO: 135. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of SEQ ID NO: 136. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of SEQ ID NO: 137. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of SEQ ID NO: 138. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of SEQ ID NO: 139. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of SEQ ID NO: 140. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of SEQ ID NO: 141. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of SEQ ID NO: 142. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of SEQ ID NO: 143. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of SEQ ID NO: 144. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of SEQ ID NO: 145. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of SEQ ID NO: 146. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of SEQ ID NO: 147. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of SEQ ID NO: 148. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of SEQ ID NO: 149. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of SEQ ID NO: 150. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of SEQ ID NO: 151. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of SEQ ID NO: 162. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of SEQ ID NO: 163. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of SEQ ID NO: 164. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of SEQ ID NO:165. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of SEQ ID NO:166. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of SEQ ID NO:167. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of SEQ ID NO:168. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of SEQ ID NO:169. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of SEQ ID NO:170. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of SEQ ID NO:171. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of SEQ ID NO:172. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of SEQ ID NO:173. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of SEQ ID NO:174. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of SEQ ID NO:175. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of SEQ ID NO:176. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of SEQ ID NO:177. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of SEQ ID NO:178. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of SEQ ID NO:179. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of SEQ ID NO:180. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of SEQ ID NO:181. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of SEQ ID NO:182. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of SEQ ID NO:183. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of SEQ ID NO:184. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of SEQ ID NO:185. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of SEQ ID NO:186. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of SEQ ID NO:187. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of SEQ ID NO:188. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of SEQ ID NO:189. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of SEQ ID NO:190. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of SEQ ID NO:191. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of SEQ ID NO:192. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of SEQ ID NO:193. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of SEQ ID NO:194. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of SEQ ID NO:195. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of SEQ ID NO:196. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of SEQ ID NO:197. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of SEQ ID NO:198. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of SEQ ID NO:199. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of SEQ ID NO:200. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of SEQ ID NO:201. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of SEQ ID NO:202. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of SEQ ID NO:203. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of SEQ ID NO:204. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of SEQ ID NO:205. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of SEQ ID NO:206. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of SEQ ID NO:207. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of SEQ ID NO:208. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of SEQ ID NO:209. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of SEQ ID NO:210. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of SEQ ID NO:211. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of SEQ ID NO:212. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of SEQ ID NO:213. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of SEQ ID NO:214. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of SEQ ID NO:215. In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of SEQ ID NO:216.

(93) In some embodiments, the chimeric cytokine receptor (CCR) comprises a binding domain comprising the amino acid sequence of SEQ ID NO: 159, a transmembrane and JAK2 binding domain comprising the amino acid sequence of SEQ ID NO: 40, and a recruiting domain comprising the amino acid sequence of SEQ ID NO: 80, 99, 111, 112, or 161. In some embodiments, the CCR comprises a binding domain comprising the amino acid sequence of SEQ ID NO: 159, a transmembrane and JAK2 binding domain comprising the amino acid sequence of SEQ ID NO: 53, and a recruiting domain comprising the amino acid sequence of SEQ ID NO: 80, 99, 111, 112, or 161. In some embodiments, the CCR comprises a binding domain comprising the amino acid sequence of SEQ ID NO: 4, a transmembrane and JAK2 binding domain comprising the amino acid sequence of SEQ ID NO: 38, and a recruiting domain comprising the amino acid sequence of SEQ ID NO: 80, 99, 111, 112, or 161. In some embodiments, the CCR comprises a binding domain comprising the amino acid sequence of SEQ ID NO: 4, a transmembrane and JAK2 binding domain comprising the amino acid sequence of SEQ ID NO: 39, and a recruiting domain comprising the amino acid sequence of SEQ ID NO: 80, 99, 111, 112, or 161. In some embodiments, the CCR comprises a binding domain comprising the amino acid sequence of SEQ ID NO: 4, a transmembrane and JAK2 binding domain comprising the amino acid sequence of SEQ ID NO: 40, and a recruiting domain comprising the amino acid sequence of SEQ ID NO: 80, 99, 111, 112, or 161. In some embodiments, the CCR comprises a binding domain comprising the amino acid sequence of SEQ ID NO: 4, a transmembrane and JAK2 binding domain comprising the amino acid sequence of SEQ ID NO: 53, and a recruiting domain comprising the amino acid sequence of SEQ ID NO: 80, 99, 111, 112, or 161. In some embodiments, the CCR comprises a binding domain comprising the amino acid sequence of SEQ ID NO: 159, a transmembrane and JAK2 binding domain comprising the amino acid sequence of SEQ ID NO: 70, and a recruiting domain comprising the amino acid sequence of SEQ ID NO: 80, 99, 111, 112, or 161. In some embodiments, the CCR comprises a binding domain comprising the amino acid sequence of SEQ ID NO: 159, a transmembrane and JAK2 binding domain comprising the amino acid sequence of SEQ ID NO: 69, and a recruiting domain comprising the amino acid sequence of SEQ ID NO: 80, 99, 111, 112, or 161. In some embodiments, the CCR comprises a binding domain comprising the amino acid sequence of SEQ ID NO: 4, a transmembrane and JAK2 binding domain comprising the amino acid sequence of SEQ ID NO: 64, and a recruiting domain comprising the amino acid sequence of SEQ ID NO: 80, 99, 111, 112, or 161. In some embodiments, the CCR comprises a binding domain comprising the amino acid sequence of SEQ ID NO: 4, a transmembrane and JAK2 binding domain comprising the amino acid sequence of SEQ ID NO: 69, and a recruiting domain comprising the amino acid sequence of SEQ ID NO: 80, 99, 111, 112, or 161. In some embodiments, the CCR comprises a binding domain comprising the amino acid sequence of SEQ ID NO: 4, a transmembrane and JAK2 binding domain comprising the amino acid sequence of SEQ ID NO: 70, and a recruiting domain comprising the amino acid sequence of SEQ ID NO: 80, 99, 111, 112, or 161. In some embodiments, the CCR comprises a binding domain comprising the amino acid sequence of SEQ ID NO: 159, a transmembrane and JAK2 binding domain comprising the amino acid sequence of SEQ ID NO: 160 or 219, and a recruiting domain comprising the amino acid sequence of SEQ ID NO: 80, 99, 111, 112, or 161. In some embodiments, the CCR comprises a binding domain comprising the amino acid sequence of SEQ ID NO: 159, a transmembrane and JAK2 binding domain comprising the amino acid sequence of SEQ ID NO: 223, 224, and a recruiting domain comprising the amino acid sequence of SEQ ID NO: 80, 99, 111, 112, or 161. In some embodiments, the CCR comprises a binding domain comprising the amino acid sequence of SEQ ID NO: 159, a transmembrane and JAK2 binding domain comprising the amino acid sequence of SEQ ID NO: 225 or 226, and a recruiting domain comprising the amino acid sequence of SEQ ID NO: 80, 99, 111, 112, or 161. In some embodiments, the CCR comprises a binding domain comprising the amino acid sequence of SEQ ID NO: 4, a transmembrane and JAK2 binding domain comprising the amino acid sequence of SEQ ID NO: 60 or 160, and a recruiting domain comprising the amino acid sequence of SEQ ID NO: 80, 99, 111, 112, or 161. In some embodiments, the CCR comprises a binding domain comprising the amino acid sequence of SEQ ID NO: 4, a transmembrane and JAK2 binding domain comprising the amino acid sequence of SEQ ID NO: 223, 224, and a recruiting domain comprising the amino acid sequence of SEQ ID NO: 80, 99, 111, 112, or 161. In some embodiments, the CCR comprises a binding domain comprising the amino acid sequence of SEQ ID NO: 4, a transmembrane and JAK2 binding domain comprising the amino acid sequence of SEQ ID NO: 225 or 226, and a recruiting domain comprising the amino acid sequence of SEQ ID NO: 80, 99, 111, 112, or 161

(94) In some embodiments, the chimeric cytokine receptor of the disclosure comprises the amino acid sequence of SEQ ID NO:272, SEQ ID NO:273, SEQ ID NO:274, or SEQ ID NO:275. In some embodiments, the chimeric cytokine receptor comprises an amino acid sequence that is at least 80%, 85%, 90%, 95%, 98%, or 99%, or 100% identical to any one of the amino acid sequences of SEQ ID NOs: 123-216 and SEQ ID NOs: 272-275.

(95) TABLE-US-00007 TABLE6 Exemplarychimericcytokinereceptorsequences(assembledinducibleor constitutivelyactiveTGF-receptorchimericcytokinereceptors): SEQID Receptor Aminoacidsequence NO: CD8SS-TGFbR2(1- MALPVTALLLPLALLLHAARPMGRGLLRGLWPLHIVLWTRIASTIP 123 166).TPOR/MPLR(478- PHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCM 582).IL7Ra(316- SNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILED 459).IL12Rb2(775-825) AASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDLLL UnderlinedindicatesCD8SS VIFQSDPTRVETATETAWISLVTALHLVLGLSAVLGLLLLRWQFPA HYRRLRHALWPSLPDLHRVLGQYLRDTAALSPPKATVSDTCEEVE PSLLEILPKSSERTPLPLARDEVEGFLQDTFPQQLEESEKQRLGGDV QSPNCPSEDVVITPESFGRDSSLTCLAGNVSACDAPILSSSRSLDCR ESGKNGPHVYQDLLLSLGTTNSTLPPPFSLQSGILTLNPVAQGQPIL TSLGSNQEEAYVTMSSFYQNQSDPKPENPACPWTVLPAGDLPTH DGYLPSNIDDLPSHEAPLADSLEELEPQ CD8SS-TGFbR2(1- MALPVTALLLPLALLLHAARPMGRGLLRGLWPLHIVLWTRIASTIP 124 166).TPOR/MPLR(478- PHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCM 582;N-1).IL7Ra(316- SNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILED 459).IL12Rb2(775-825) AASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDLLL UnderlinedindicatesCD8SS VIFQSDPTRVETATETWISLVTALHLVLGLSAVLGLLLLRWQFPAH YRRLRHALWPSLPDLHRVLGQYLRDTAALSPPKATVSDTCEEVEPS LLEILPKSSERTPLPLARDEVEGFLQDTFPQQLEESEKQRLGGDVQS PNCPSEDVVITPESFGRDSSLTCLAGNVSACDAPILSSSRSLDCRES GKNGPHVYQDLLLSLGTTNSTLPPPFSLQSGILTLNPVAQGQPILTS LGSNQEEAYVTMSSFYQNQSDPKPENPACPWTVLPAGDLPTHD GYLPSNIDDLPSHEAPLADSLEELEPQ CD8SS-TGFbR2(1- MALPVTALLLPLALLLHAARPMGRGLLRGLWPLHIVLWTRIASTIP 125 166).TPOR/MPLR(478- PHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCM 582;N-2).IL7Ra(316- SNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILED 459).IL12Rb2(775-825) AASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDLLL UnderlinedindicatesCD8SS VIFQSDPTRVETATETISLVTALHLVLGLSAVLGLLLLRWQFPAHYR RLRHALWPSLPDLHRVLGQYLRDTAALSPPKATVSDTCEEVEPSLL EILPKSSERTPLPLARDEVEGFLQDTFPQQLEESEKQRLGGDVQSP NCPSEDVVITPESFGRDSSLTCLAGNVSACDAPILSSSRSLDCRESG KNGPHVYQDLLLSLGTTNSTLPPPFSLQSGILTLNPVAQGQPILTSL GSNQEEAYVTMSSFYQNQSDPKPENPACPWTVLPAGDLPTHDG YLPSNIDDLPSHEAPLADSLEELEPQ CD8SS-TGFbR2(1- MALPVTALLLPLALLLHAARPMGRGLLRGLWPLHIVLWTRIASTIP 126 166).TPOR/MPLR(478- PHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCM 582;N-2+1).IL7Ra(316- SNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILED 459).IL12Rb2(775-825) AASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDLLL UnderlinedindicatesCD8SS VIFQSDPTRVETATETLISLVTALHLVLGLSAVLGLLLLRWQFPAHY RRLRHALWPSLPDLHRVLGQYLRDTAALSPPKATVSDTCEEVEPSL LEILPKSSERTPLPLARDEVEGFLQDTFPQQLEESEKQRLGGDVQS PNCPSEDVVITPESFGRDSSLTCLAGNVSACDAPILSSSRSLDCRES GKNGPHVYQDLLLSLGTTNSTLPPPFSLQSGILTLNPVAQGQPILTS LGSNQEEAYVTMSSFYQNQSDPKPENPACPWTVLPAGDLPTHD GYLPSNIDDLPSHEAPLADSLEELEPQ CD8SS-TGFbR2(1- MALPVTALLLPLALLLHAARPMGRGLLRGLWPLHIVLWTRIASTIP 127 166).TPOR/MPLR(478- PHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCM 582;N-3).IL7Ra(316- SNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILED 459).IL12Rb2(775-825) AASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDLLL UnderlinedindicatesCD8SS VIFQSDPTRVETATETSLVTALHLVLGLSAVLGLLLLRWQFPAHYRR LRHALWPSLPDLHRVLGQYLRDTAALSPPKATVSDTCEEVEPSLLEI LPKSSERTPLPLARDEVEGFLQDTFPQQLEESEKQRLGGDVQSPN CPSEDVVITPESFGRDSSLTCLAGNVSACDAPILSSSRSLDCRESGK NGPHVYQDLLLSLGTTNSTLPPPFSLQSGILTLNPVAQGQPILTSLG SNQEEAYVTMSSFYQNQSDPKPENPACPWTVLPAGDLPTHDGY LPSNIDDLPSHEAPLADSLEELEPQ CD8SS-TGFbR2(1- MALPVTALLLPLALLLHAARPMGRGLLRGLWPLHIVLWTRIASTIP 128 166).TPOR/MPLR(478- PHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCM 582;N-4).IL7Ra(316- SNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILED 459).IL12Rb2(775-825) AASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDLLL UnderlinedindicatesCD8SS VIFQSDPTRVETATETLVTALHLVLGLSAVLGLLLLRWQFPAHYRRL RHALWPSLPDLHRVLGQYLRDTAALSPPKATVSDTCEEVEPSLLEIL PKSSERTPLPLARDEVEGFLQDTFPQQLEESEKQRLGGDVQSPNC PSEDVVITPESFGRDSSLTCLAGNVSACDAPILSSSRSLDCRESGKN GPHVYQDLLLSLGTTNSTLPPPFSLQSGILTLNPVAQGQPILTSLGS NQEEAYVTMSSFYQNQSDPKPENPACPWTVLPAGDLPTHDGYL PSNIDDLPSHEAPLADSLEELEPQ CD8SS-TGFbR2(1- MALPVTALLLPLALLLHAARPMGRGLLRGLWPLHIVLWTRIASTIP 129 166).TPOR/MPLR(478- PHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCM 582;N-4+1).IL7Ra(316- SNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILED 459).IL12Rb2(775-825) AASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDLLL UnderlinedindicatesCD8SS VIFQSDPTRVETATETILVTALHLVLGLSAVLGLLLLRWQFPAHYRR LRHALWPSLPDLHRVLGQYLRDTAALSPPKATVSDTCEEVEPSLLEI LPKSSERTPLPLARDEVEGFLQDTFPQQLEESEKQRLGGDVQSPN CPSEDVVITPESFGRDSSLTCLAGNVSACDAPILSSSRSLDCRESGK NGPHVYQDLLLSLGTTNSTLPPPFSLQSGILTLNPVAQGQPILTSLG SNQEEAYVTMSSFYQNQSDPKPENPACPWTVLPAGDLPTHDGY LPSNIDDLPSHEAPLADSLEELEPQ CD8SS-TGFbR2(1- MALPVTALLLPLALLLHAARPMGRGLLRGLWPLHIVLWTRIASTIP 130 166).TPOR/MPLR(478- PHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCM 582;N-5).IL7Ra(316- SNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILED 459).IL12Rb2(775-825) AASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDLLL UnderlinedindicatesCD8SS VIFQSDPTRVETATETVTALHLVLGLSAVLGLLLLRWQFPAHYRRL RHALWPSLPDLHRVLGQYLRDTAALSPPKATVSDTCEEVEPSLLEIL PKSSERTPLPLARDEVEGFLQDTFPQQLEESEKQRLGGDVQSPNC PSEDVVITPESFGRDSSLTCLAGNVSACDAPILSSSRSLDCRESGKN GPHVYQDLLLSLGTTNSTLPPPFSLQSGILTLNPVAQGQPILTSLGS NQEEAYVTMSSFYQNQSDPKPENPACPWTVLPAGDLPTHDGYL PSNIDDLPSHEAPLADSLEELEPQ CD8SS-TGFbR2(1- MALPVTALLLPLALLLHAARPMGRGLLRGLWPLHIVLWTRIASTIP 131 166).TPOR/MPLR(478- PHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCM 582;N-6).IL7Ra(316- SNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILED 459).IL12Rb2(775-825) AASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDLLL UnderlinedindicatesCD8SS VIFQSDPTRVETATETTALHLVLGLSAVLGLLLLRWQFPAHYRRLR HALWPSLPDLHRVLGQYLRDTAALSPPKATVSDTCEEVEPSLLEILP KSSERTPLPLARDEVEGFLQDTFPQQLEESEKQRLGGDVQSPNCP SEDVVITPESFGRDSSLTCLAGNVSACDAPILSSSRSLDCRESGKNG PHVYQDLLLSLGTTNSTLPPPFSLQSGILTLNPVAQGQPILTSLGSN QEEAYVTMSSFYQNQSDPKPENPACPWTVLPAGDLPTHDGYLPS NIDDLPSHEAPLADSLEELEPQ CD8SS-TGFbR2(1- MALPVTALLLPLALLLHAARPMGRGLLRGLWPLHIVLWTRIASTIP 132 166).TPOR/MPLR(478- PHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCM 582;N-7).IL7Ra(316- SNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILED 459).IL12Rb2(775-825) AASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDLLL UnderlinedindicatesCD8SS VIFQSDPTRVETATETALHLVLGLSAVLGLLLLRWQFPAHYRRLRH ALWPSLPDLHRVLGQYLRDTAALSPPKATVSDTCEEVEPSLLEILPK SSERTPLPLARDEVEGFLQDTFPQQLEESEKQRLGGDVQSPNCPS EDVVITPESFGRDSSLTCLAGNVSACDAPILSSSRSLDCRESGKNGP HVYQDLLLSLGTTNSTLPPPFSLQSGILTLNPVAQGQPILTSLGSNQ EEAYVTMSSFYQNQSDPKPENPACPWTVLPAGDLPTHDGYLPSN IDDLPSHEAPLADSLEELEPQ CD8SS-TGFbR2(1- MALPVTALLLPLALLLHAARPMGRGLLRGLWPLHIVLWTRIASTIP 133 166).TPOR/MPLR(478- PHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCM 582;N-8).IL7Ra(316- SNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILED 459).IL12Rb2(775-825) AASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDLLL UnderlinedindicatesCD8SS VIFQSDPTRVETATETLHLVLGLSAVLGLLLLRWQFPAHYRRLRHA LWPSLPDLHRVLGQYLRDTAALSPPKATVSDTCEEVEPSLLEILPKS SERTPLPLARDEVEGFLQDTFPQQLEESEKQRLGGDVQSPNCPSE DVVITPESFGRDSSLTCLAGNVSACDAPILSSSRSLDCRESGKNGPH VYQDLLLSLGTTNSTLPPPFSLQSGILTLNPVAQGQPILTSLGSNQE EAYVTMSSFYQNQSDPKPENPACPWTVLPAGDLPTHDGYLPSNI DDLPSHEAPLADSLEELEPQ CD8SS-TGFbR2(1- MALPVTALLLPLALLLHAARPMGRGLLRGLWPLHIVLWTRIASTIP 134 166).TPOR/MPLR(478- PHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCM 582;N-9).IL7Ra(316- SNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILED 459).IL12Rb2(775-825) AASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDLLL UnderlinedindicatesCD8SS VIFQSDPTRVETATETHLVLGLSAVLGLLLLRWQFPAHYRRLRHAL WPSLPDLHRVLGQYLRDTAALSPPKATVSDTCEEVEPSLLEILPKSS ERTPLPLARDEVEGFLQDTFPQQLEESEKQRLGGDVQSPNCPSED VVITPESFGRDSSLTCLAGNVSACDAPILSSSRSLDCRESGKNGPHV YQDLLLSLGTTNSTLPPPFSLQSGILTLNPVAQGQPILTSLGSNQEE AYVTMSSFYQNQSDPKPENPACPWTVLPAGDLPTHDGYLPSNID DLPSHEAPLADSLEELEPQ CD8SS-TGFbR2(1- MALPVTALLLPLALLLHAARPMGRGLLRGLWPLHIVLWTRIASTIP 135 166).TPOR/MPLR(478- PHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCM 582;N-10).IL7Ra(316- SNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILED 459).IL12Rb2(775-825) AASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDLLL UnderlinedindicatesCD8SS VIFQSDPTRVETATETLVLGLSAVLGLLLLRWQFPAHYRRLRHALW PSLPDLHRVLGQYLRDTAALSPPKATVSDTCEEVEPSLLEILPKSSER TPLPLARDEVEGFLQDTFPQQLEESEKQRLGGDVQSPNCPSEDVV ITPESFGRDSSLTCLAGNVSACDAPILSSSRSLDCRESGKNGPHVYQ DLLLSLGTTNSTLPPPFSLQSGILTLNPVAQGQPILTSLGSNQEEAY VTMSSFYQNQSDPKPENPACPWTVLPAGDLPTHDGYLPSNIDDL PSHEAPLADSLEELEPQ CD8SS-TGFbR2(1- MALPVTALLLPLALLLHAARPMGRGLLRGLWPLHIVLWTRIASTIP 136 166).TPOR/MPLR(478- PHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCM 582;N-11).IL7Ra(316- SNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILED 459).IL12Rb2(775-825) AASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDLLL UnderlinedindicatesCD8SS VIFQSDPTRVETATETVLGLSAVLGLLLLRWQFPAHYRRLRHALW PSLPDLHRVLGQYLRDTAALSPPKATVSDTCEEVEPSLLEILPKSSER TPLPLARDEVEGFLQDTFPQQLEESEKQRLGGDVQSPNCPSEDVV ITPESFGRDSSLTCLAGNVSACDAPILSSSRSLDCRESGKNGPHVYQ DLLLSLGTTNSTLPPPFSLQSGILTLNPVAQGQPILTSLGSNQEEAY VTMSSFYQNQSDPKPENPACPWTVLPAGDLPTHDGYLPSNIDDL PSHEAPLADSLEELEPQ CD8SS-TGFbR2(1- MALPVTALLLPLALLLHAARPMGRGLLRGLWPLHIVLWTRIASTIP 137 166).TPOR/MPLR(478- PHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCM 582;N-12).IL7Ra(316- SNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILED 459).IL12Rb2(775-825) AASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDLLL UnderlinedindicatesCD8SS VIFQSDPTRVETATETLGLSAVLGLLLLRWQFPAHYRRLRHALWPS LPDLHRVLGQYLRDTAALSPPKATVSDTCEEVEPSLLEILPKSSERTP LPLARDEVEGFLQDTFPQQLEESEKQRLGGDVQSPNCPSEDVVIT PESFGRDSSLTCLAGNVSACDAPILSSSRSLDCRESGKNGPHVYQD LLLSLGTTNSTLPPPFSLQSGILTLNPVAQGQPILTSLGSNQEEAYVT MSSFYQNQSDPKPENPACPWTVLPAGDLPTHDGYLPSNIDDLPS HEAPLADSLEELEPQ CD8SS-TGFbR2(1- MALPVTALLLPLALLLHAARPMGRGLLRGLWPLHIVLWTRIASTIP 138 166).TPOR/MPLR(478- PHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCM 582;N-13).IL7Ra(316- SNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILED 459).IL12Rb2(775-825) AASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDLLL UnderlinedindicatesCD8SS VIFQSDPTRVETATETGLSAVLGLLLLRWQFPAHYRRLRHALWPSL PDLHRVLGQYLRDTAALSPPKATVSDTCEEVEPSLLEILPKSSERTPL PLARDEVEGFLQDTFPQQLEESEKQRLGGDVQSPNCPSEDVVITP ESFGRDSSLTCLAGNVSACDAPILSSSRSLDCRESGKNGPHVYQDL LLSLGTTNSTLPPPFSLQSGILTLNPVAQGQPILTSLGSNQEEAYVT MSSFYQNQSDPKPENPACPWTVLPAGDLPTHDGYLPSNIDDLPS HEAPLADSLEELEPQ CD8SS-TGFbR2(1- MALPVTALLLPLALLLHAARPMGRGLLRGLWPLHIVLWTRIASTIP 139 166).TPOR/MPLR(478- PHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCM 582;N-14).IL7Ra(316- SNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILED 459).IL12Rb2(775-825) AASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDLLL UnderlinedindicatesCD8SS VIFQSDPTRVETATETLSAVLGLLLLRWQFPAHYRRLRHALWPSLP DLHRVLGQYLRDTAALSPPKATVSDTCEEVEPSLLEILPKSSERTPLP LARDEVEGFLQDTFPQQLEESEKQRLGGDVQSPNCPSEDVVITPE SFGRDSSLTCLAGNVSACDAPILSSSRSLDCRESGKNGPHVYQDLL LSLGTTNSTLPPPFSLQSGILTLNPVAQGQPILTSLGSNQEEAYVTM SSFYQNQSDPKPENPACPWTVLPAGDLPTHDGYLPSNIDDLPSHE APLADSLEELEPQ CD8SS-TGFbR2(1- MALPVTALLLPLALLLHAARPMGRGLLRGLWPLHIVLWTRIASTIP 140 166).TPOR/MPLR(478- PHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCM 582;N-15).IL7Ra(316- SNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILED 459).IL12Rb2(775-825) AASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDLLL UnderlinedindicatesCD8SS VIFQSDPTRVETATETSAVLGLLLLRWQFPAHYRRLRHALWPSLPD LHRVLGQYLRDTAALSPPKATVSDTCEEVEPSLLEILPKSSERTPLPL ARDEVEGFLQDTFPQQLEESEKQRLGGDVQSPNCPSEDVVITPES FGRDSSLTCLAGNVSACDAPILSSSRSLDCRESGKNGPHVYQDLLL SLGTTNSTLPPPFSLQSGILTLNPVAQGQPILTSLGSNQEEAYVTM SSFYQNQSDPKPENPACPWTVLPAGDLPTHDGYLPSNIDDLPSHE APLADSLEELEPQ CD8SS-TGFbR2(1- MALPVTALLLPLALLLHAARPMGRGLLRGLWPLHIVLWTRIASTIP 141 166).TPOR/MPLR(478- PHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCM 582;N-16).IL7Ra(316- SNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILED 459).IL12Rb2(775-825) AASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDLLL UnderlinedindicatesCD8SS VIFQSDPTRVETATETAVLGLLLLRWQFPAHYRRLRHALWPSLPDL HRVLGQYLRDTAALSPPKATVSDTCEEVEPSLLEILPKSSERTPLPLA RDEVEGFLQDTFPQQLEESEKQRLGGDVQSPNCPSEDVVITPESF GRDSSLTCLAGNVSACDAPILSSSRSLDCRESGKNGPHVYQDLLLS LGTTNSTLPPPFSLQSGILTLNPVAQGQPILTSLGSNQEEAYVTMS SFYQNQSDPKPENPACPWTVLPAGDLPTHDGYLPSNIDDLPSHE APLADSLEELEPQ CD8SS-TGFbR2(1- MALPVTALLLPLALLLHAARPMGRGLLRGLWPLHIVLWTRIASTIP 142 166).TPOR/MPLR(478- PHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCM 582;N-17).IL7Ra(316- SNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILED 459).IL12Rb2(775-825) AASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDLLL UnderlinedindicatesCD8SS VIFQSDPTRVETATETVLGLLLLRWQFPAHYRRLRHALWPSLPDLH RVLGQYLRDTAALSPPKATVSDTCEEVEPSLLEILPKSSERTPLPLAR DEVEGFLQDTFPQQLEESEKQRLGGDVQSPNCPSEDVVITPESFG RDSSLTCLAGNVSACDAPILSSSRSLDCRESGKNGPHVYQDLLLSL GTTNSTLPPPFSLQSGILTLNPVAQGQPILTSLGSNQEEAYVTMSS FYQNQSDPKPENPACPWTVLPAGDLPTHDGYLPSNIDDLPSHEA PLADSLEELEPQ CD8SS-TGFbR2(1- MALPVTALLLPLALLLHAARPMGRGLLRGLWPLHIVLWTRIASTIP 143 166).TPOR/MPLR(478- PHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCM 582;N-18).IL7Ra(316- SNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILED 459).IL12Rb2(775-825) AASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDLLL UnderlinedindicatesCD8SS VIFQSDPTRVETATETLGLLLLRWQFPAHYRRLRHALWPSLPDLHR VLGQYLRDTAALSPPKATVSDTCEEVEPSLLEILPKSSERTPLPLARD EVEGFLQDTFPQQLEESEKQRLGGDVQSPNCPSEDVVITPESFGR DSSLTCLAGNVSACDAPILSSSRSLDCRESGKNGPHVYQDLLLSLGT TNSTLPPPFSLQSGILTLNPVAQGQPILTSLGSNQEEAYVTMSSFY QNQSDPKPENPACPWTVLPAGDLPTHDGYLPSNIDDLPSHEAPL ADSLEELEPQ CD8SS-TGFbR2(1- MALPVTALLLPLALLLHAARPMGRGLLRGLWPLHIVLWTRIASTIP 144 166).TPOR/MPLR(478- PHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCM 582;N+1).IL7Ra(316- SNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILED 459).IL12Rb2(775-825) AASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDLLL UnderlinedindicatesCD8SS VIFQSDPTRVETATETAWLISLVTALHLVLGLSAVLGLLLLRWQFPA HYRRLRHALWPSLPDLHRVLGQYLRDTAALSPPKATVSDTCEEVE PSLLEILPKSSERTPLPLARDEVEGFLQDTFPQQLEESEKQRLGGDV QSPNCPSEDVVITPESFGRDSSLTCLAGNVSACDAPILSSSRSLDCR ESGKNGPHVYQDLLLSLGTTNSTLPPPFSLQSGILTLNPVAQGQPIL TSLGSNQEEAYVTMSSFYQNQSDPKPENPACPWTVLPAGDLPTH DGYLPSNIDDLPSHEAPLADSLEELEPQ CD8SS-TGFbR2(1- MALPVTALLLPLALLLHAARPMGRGLLRGLWPLHIVLWTRIASTIP 145 166).TPOR/MPLR(478- PHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCM 582;N+2).IL7Ra(316- SNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILED 459).IL12Rb2(775-825) AASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDLLL UnderlinedindicatesCD8SS VIFQSDPTRVETATETAWVLISLVTALHLVLGLSAVLGLLLLRWQFP AHYRRLRHALWPSLPDLHRVLGQYLRDTAALSPPKATVSDTCEEV EPSLLEILPKSSERTPLPLARDEVEGFLQDTFPQQLEESEKQRLGGD VQSPNCPSEDVVITPESFGRDSSLTCLAGNVSACDAPILSSSRSLDC RESGKNGPHVYQDLLLSLGTTNSTLPPPFSLQSGILTLNPVAQGQP ILTSLGSNQEEAYVTMSSFYQNQSDPKPENPACPWTVLPAGDLPT HDGYLPSNIDDLPSHEAPLADSLEELEPQ CD8SS-TGFbR2(1- MALPVTALLLPLALLLHAARPMGRGLLRGLWPLHIVLWTRIASTIP 146 166).TPOR/MPLR(478- PHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCM 582;N+3).IL7Ra(316- SNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILED 459).IL12Rb2(775-825) AASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDLLL UnderlinedindicatesCD8SS VIFQSDPTRVETATETAWLVLISLVTALHLVLGLSAVLGLLLLRWQF PAHYRRLRHALWPSLPDLHRVLGQYLRDTAALSPPKATVSDTCEE VEPSLLEILPKSSERTPLPLARDEVEGFLQDTFPQQLEESEKQRLGG DVQSPNCPSEDVVITPESFGRDSSLTCLAGNVSACDAPILSSSRSLD CRESGKNGPHVYQDLLLSLGTTNSTLPPPFSLQSGILTLNPVAQGQ PILTSLGSNQEEAYVTMSSFYQNQSDPKPENPACPWTVLPAGDLP THDGYLPSNIDDLPSHEAPLADSLEELEPQ CD8SS-TGFbR2(1- MALPVTALLLPLALLLHAARPMGRGLLRGLWPLHIVLWTRIASTIP 147 166).TPOR/MPLR(478- PHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCM 582;N+4).IL7Ra(316- SNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILED 459).IL12Rb2(775-825) AASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDLLL UnderlinedindicatesCD8SS VIFQSDPTRVETATETAWILVLISLVTALHLVLGLSAVLGLLLLRWQ FPAHYRRLRHALWPSLPDLHRVLGQYLRDTAALSPPKATVSDTCE EVEPSLLEILPKSSERTPLPLARDEVEGFLQDTFPQQLEESEKQRLG GDVQSPNCPSEDVVITPESFGRDSSLTCLAGNVSACDAPILSSSRSL DCRESGKNGPHVYQDLLLSLGTTNSTLPPPFSLQSGILTLNPVAQG QPILTSLGSNQEEAYVTMSSFYQNQSDPKPENPACPWTVLPAGD LPTHDGYLPSNIDDLPSHEAPLADSLEELEPQ CD8SS-TGFbR2(1- MALPVTALLLPLALLLHAARPMGRGLLRGLWPLHIVLWTRIASTIP 148 166).TPOR/MPLR(478- PHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCM 582;N+5).IL7Ra(316- SNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILED 459).IL12Rb2(775-825) AASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDLLL UnderlinedindicatesCD8SS VIFQSDPTRVETATETAWLILVLISLVTALHLVLGLSAVLGLLLLRW QFPAHYRRLRHALWPSLPDLHRVLGQYLRDTAALSPPKATVSDTC EEVEPSLLEILPKSSERTPLPLARDEVEGFLQDTFPQQLEESEKQRLG GDVQSPNCPSEDVVITPESFGRDSSLTCLAGNVSACDAPILSSSRSL DCRESGKNGPHVYQDLLLSLGTTNSTLPPPFSLQSGILTLNPVAQG QPILTSLGSNQEEAYVTMSSFYQNQSDPKPENPACPWTVLPAGD LPTHDGYLPSNIDDLPSHEAPLADSLEELEPQ CD8SS-TGFbR2(1- MALPVTALLLPLALLLHAARPMGRGLLRGLWPLHIVLWTRIASTIP 149 166).TPOR/MPLR(478- PHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCM 582;N+6).IL7Ra(316- SNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILED 459).IL12Rb2(775-825) AASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDLLL UnderlinedindicatesCD8SS VIFQSDPTRVETATETAWLLILVLISLVTALHLVLGLSAVLGLLLLRW QFPAHYRRLRHALWPSLPDLHRVLGQYLRDTAALSPPKATVSDTC EEVEPSLLEILPKSSERTPLPLARDEVEGFLQDTFPQQLEESEKQRLG GDVQSPNCPSEDVVITPESFGRDSSLTCLAGNVSACDAPILSSSRSL DCRESGKNGPHVYQDLLLSLGTTNSTLPPPFSLQSGILTLNPVAQG QPILTSLGSNQEEAYVTMSSFYQNQSDPKPENPACPWTVLPAGD LPTHDGYLPSNIDDLPSHEAPLADSLEELEPQ CD8SS-TGFbR2(1- MALPVTALLLPLALLLHAARPMGRGLLRGLWPLHIVLWTRIASTIP 150 166).TPOR/MPLR(478- PHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCM 582;N+7).IL7Ra(316- SNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILED 459).IL12Rb2(775-825) AASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDLLL UnderlinedindicatesCD8SS VIFQSDPTRVETATETAWVLLILVLISLVTALHLVLGLSAVLGLLLLR WQFPAHYRRLRHALWPSLPDLHRVLGQYLRDTAALSPPKATVSD TCEEVEPSLLEILPKSSERTPLPLARDEVEGFLQDTFPQQLEESEKQR LGGDVQSPNCPSEDVVITPESFGRDSSLTCLAGNVSACDAPILSSS RSLDCRESGKNGPHVYQDLLLSLGTTNSTLPPPFSLQSGILTLNPVA QGQPILTSLGSNQEEAYVTMSSFYQNQSDPKPENPACPWTVLPA GDLPTHDGYLPSNIDDLPSHEAPLADSLEELEPQ CD8SS-TGFbR2(1- MALPVTALLLPLALLLHAARPMGRGLLRGLWPLHIVLWTRIASTIP 151 166).TPOR/MPLR(478- PHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCM 582;N+8).IL7Ra(316- SNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILED 459).IL12Rb2(775-825) AASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDLLL UnderlinedindicatesCD8SS VIFQSDPTRVETATETAWLVLLILVLISLVTALHLVLGLSAVLGLLLLR WQFPAHYRRLRHALWPSLPDLHRVLGQYLRDTAALSPPKATVSD TCEEVEPSLLEILPKSSERTPLPLARDEVEGFLQDTFPQQLEESEKQR LGGDVQSPNCPSEDVVITPESFGRDSSLTCLAGNVSACDAPILSSS RSLDCRESGKNGPHVYQDLLLSLGTTNSTLPPPFSLQSGILTLNPVA QGQPILTSLGSNQEEAYVTMSSFYQNQSDPKPENPACPWTVLPA GDLPTHDGYLPSNIDDLPSHEAPLADSLEELEPQ CD8SS-TGFbR2(1- MALPVTALLLPLALLLHAARPMGRGLLRGLWPLHIVLWTRIASTIP 162 166).TPOR/MPLR(478- PHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCM 582).IL7Ra(316- SNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILED 459).IL12Rb2(775-825) AASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDLLL UnderlinedindicatesCD8SS VIFQSDPTRVETATETAWISLVTALHLVLGLSAVLGLLLLRWQFPA HYRRLRHALWPSLPDLHRVLGQYLRDTAALSPPKATVSDTCEEVE PSLLEILPKSSERTPLPLLEARDEVEGFLQDTFPQQLEESEKQRLGG DVQSPNCPSEDVVITPESFGRDSSLTCLAGNVSACDAPILSSSRSLD CRESGKNGPHVYQDLLLSLGTTNSTLPPPFSLQSGILTLNPVAQGQ PILTSLGSNQEEAYVTMSSFYQNQSRSDPKPENPACPWTVLPAG DLPTHDGYLPSNIDDLPSHEAPLADSLEELEPQ CD8SS-TGFbR2(1- MALPVTALLLPLALLLHAARPMGRGLLRGLWPLHIVLWTRIASTIP 163 166).TPOR/MPLR(478-582) PHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCM S505N.W515K.IL7Ra(316- SNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILED 459).IL12Rb2(775-825) AASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDLLL UnderlinedindicatesCD8SS VIFQSDPTRVETATETAWISLVTALHLVLGLNAVLGLLLLRKQFPAH YRRLRHALWPSLPDLHRVLGQYLRDTAALSPPKATVSDTCEEVEPS LLEILPKSSERTPLPLLEARDEVEGFLQDTFPQQLEESEKQRLGGDV QSPNCPSEDVVITPESFGRDSSLTCLAGNVSACDAPILSSSRSLDCR ESGKNGPHVYQDLLLSLGTTNSTLPPPFSLQSGILTLNPVAQGQPIL TSLGSNQEEAYVTMSSFYQNQSRSDPKPENPACPWTVLPAGDLP THDGYLPSNIDDLPSHEAPLADSLEELEPQ CD8SS-TGFbR2(1- MALPVTALLLPLALLLHAARPMGRGLLRGLWPLHIVLWTRIASTIP 164 166).TPOR/MPLR(478-582) PHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCM S505N.W515K.IL2Rbsmall SNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILED (393-433,518-551) AASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDLLL UnderlinedindicatesCD8SS VIFQSDPTRVETATETAWISLVTALHLVLGLNAVLGLLLLRKQFPAH YRRLRHALWPSLPDLHRVLGQYLRDTAALSPPKATVSDTCEEVEPS LLEILPKSSERTPLPLLEDEGVAGAPTGSSPQPLQPLSGEDDAYCTF PSRDDLLLFSPSGQGEFRALNARLPLNTDAYLSLQELQGQDPTHLV CD8SS-TGFbR2(1- MALPVTALLLPLALLLHAARPMGRGLLRGLWPLHIVLWTRIASTIP 165 166).TPOR/MPLR(478-582) PHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCM S505N.W515K. SNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILED K553R.K573R.IL7Ra(316- AASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDLLL 459).IL12Rb2(775-825) VIFQSDPTRVETATETAWISLVTALHLVLGLNAVLGLLLLRKQFPAH UnderlinedindicatesCD8SS YRRLRHALWPSLPDLHRVLGQYLRDTAALSPPRATVSDTCEEVEPS LLEILPRSSERTPLPLLEARDEVEGFLQDTFPQQLEESEKQRLGGDV QSPNCPSEDVVITPESFGRDSSLTCLAGNVSACDAPILSSSRSLDCR ESGKNGPHVYQDLLLSLGTTNSTLPPPFSLQSGILTLNPVAQGQPIL TSLGSNQEEAYVTMSSFYQNQSRSDPKPENPACPWTVLPAGDLP THDGYLPSNIDDLPSHEAPLADSLEELEPQ CD8SS-TGFbR2(1- MALPVTALLLPLALLLHAARPMGRGLLRGLWPLHIVLWTRIASTIP 166 166).TPOR/MPLR(478-582) PHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCM S505N.W515K. SNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILED K553R.K573R. AASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDLLL IL2Rbsmall(393-433, VIFQSDPTRVETATETAWISLVTALHLVLGLNAVLGLLLLRKQFPAH 518-551) YRRLRHALWPSLPDLHRVLGQYLRDTAALSPPRATVSDTCEEVEPS UnderlinedindicatesCD8SS LLEILPRSSERTPLPLLEDEGVAGAPTGSSPQPLQPLSGEDDAYCTF PSRDDLLLFSPSGQGEFRALNARLPLNTDAYLSLQELQGQDPTHLV TGFbR2(1- MGRGLLRGLWPLHIVLWTRIASTIPPHVQKSVNNDMIVTDNNGA 167 166).TPOR/MPLR(478-582) VKFPQLCKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWR S505N.W515K.IL2Rbsmall KNDENITLETVCHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFM (393-433,518-551) CSCSSDECNDNIIFSEEYNTSNPDLLLVIFQSDPTRVETATETAWISL VTALHLVLGLNAVLGLLLLRKQFPAHYRRLRHALWPSLPDLHRVLG QYLRDTAALSPPKATVSDTCEEVEPSLLEILPKSSERTPLPLLEDEGV AGAPTGSSPQPLQPLSGEDDAYCTFPSRDDLLLFSPSGQGEFRAL NARLPLNTDAYLSLQELQGQDPTHLV TGFbR2(1- MGRGLLRGLWPLHIVLWTRIASTIPPHVQKSVNNDMIVTDNNGA 168 166).TPOR/MPLR(478-582) VKFPQLCKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWR S505N.W515K. KNDENITLETVCHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFM K553R.K573R. CSCSSDECNDNIIFSEEYNTSNPDLLLVIFQSDPTRVETATETAWISL IL2Rbsmall(393-433, VTALHLVLGLNAVLGLLLLRKQFPAHYRRLRHALWPSLPDLHRVLG 518-551) QYLRDTAALSPPRATVSDTCEEVEPSLLEILPRSSERTPLPLLEDEGV AGAPTGSSPQPLQPLSGEDDAYCTFPSRDDLLLFSPSGQGEFRAL NARLPLNTDAYLSLQELQGQDPTHLV CD8SS-TGFbR2(1- MALPVTALLLPLALLLHAARPMGRGLLRGLWPLHIVLWTRIASTIP 169 166).TPOR/MPLR(478-582) PHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCM S505N.W515K.IL7Ra(316- SNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILED 459) AASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDLLL UnderlinedindicatesCD8SS VIFQSDPTRVETATETAWISLVTALHLVLGLNAVLGLLLLRKQFPAH YRRLRHALWPSLPDLHRVLGQYLRDTAALSPPKATVSDTCEEVEPS LLEILPKSSERTPLPLLEARDEVEGFLQDTFPQQLEESEKQRLGGDV QSPNCPSEDVVITPESFGRDSSLTCLAGNVSACDAPILSSSRSLDCR ESGKNGPHVYQDLLLSLGTTNSTLPPPFSLQSGILTLNPVAQGQPIL TSLGSNQEEAYVTMSSFYQNQ CD8SS-TGFbR2(1- MALPVTALLLPLALLLHAARPMGRGLLRGLWPLHIVLWTRIASTIP 170 166).TPOR/MPLR(478-582) PHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCM S505N.W515K.K553R.K573R. SNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILED IL7Ra(316-459) AASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDLLL UnderlinedindicatesCD8SS VIFQSDPTRVETATETAWISLVTALHLVLGLNAVLGLLLLRKQFPAH YRRLRHALWPSLPDLHRVLGQYLRDTAALSPPRATVSDTCEEVEPS LLEILPRSSERTPLPLLEARDEVEGFLQDTFPQQLEESEKQRLGGDV QSPNCPSEDVVITPESFGRDSSLTCLAGNVSACDAPILSSSRSLDCR ESGKNGPHVYQDLLLSLGTTNSTLPPPFSLQSGILTLNPVAQGQPIL TSLGSNQEEAYVTMSSFYQNQ CD8SS-TGFbR2(1- MALPVTALLLPLALLLHAARPMGRGLLRGLWPLHIVLWTRIASTIP 171 166).TPOR/MPLR(478-582) PHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCM S505N.W515K. SNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILED IL2Rbsmall(339-379, AASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDLLL 393-433,518-551) VIFQSDPTRVETATETAWISLVTALLLVLGLNAVLGLLLLRKQFPAH UnderlinedindicatesCD8SS YRRLRHALWPSLPDLHRVLGQYLRDTAALSPPKATVSDTCEEVEPS LLEILPKSSERTPLPLLEQQDKVPEPASLSSNHSLTSCFTNQGYFFFH LPDALEIEACQDEGVAGAPTGSSPQPLQPLSGEDDAYCTFPSRDD LLLFSPSGQGEFRALNARLPLNTDAYLSLQELQGQDPTHLV CD8SS-TGFbR2(1- MALPVTALLLPLALLLHAARPMGRGLLRGLWPLHIVLWTRIASTIP 172 166).TPOR/MPLR(478- PHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCM 582;N-1).IL7Ra(316- SNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILED 459).IL12Rb2(775-825) AASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDLLL UnderlinedindicatesCD8SS VIFQSDPTRVETATETWISLVTALHLVLGLSAVLGLLLLRWQFPAH YRRLRHALWPSLPDLHRVLGQYLRDTAALSPPKATVSDTCEEVEPS LLEILPKSSERTPLPLLEARDEVEGFLQDTFPQQLEESEKQRLGGDV QSPNCPSEDVVITPESFGRDSSLTCLAGNVSACDAPILSSSRSLDCR ESGKNGPHVYQDLLLSLGTTNSTLPPPFSLQSGILTLNPVAQGQPIL TSLGSNQEEAYVTMSSFYQNQSRSDPKPENPACPWTVLPAGDLP THDGYLPSNIDDLPSHEAPLADSLEELEPQ CD8SS-TGFbR2(1- MALPVTALLLPLALLLHAARPMGRGLLRGLWPLHIVLWTRIASTIP 173 166).TPOR/MPLR(478- PHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCM 582;N-2).IL7Ra(316- SNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILED 459).IL12Rb2(775-825) AASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDLLL UnderlinedindicatesCD8SS VIFQSDPTRVETATETISLVTALHLVLGLSAVLGLLLLRWQFPAHYR RLRHALWPSLPDLHRVLGQYLRDTAALSPPKATVSDTCEEVEPSLL EILPKSSERTPLPLLEARDEVEGFLQDTFPQQLEESEKQRLGGDVQ SPNCPSEDVVITPESFGRDSSLTCLAGNVSACDAPILSSSRSLDCRE SGKNGPHVYQDLLLSLGTTNSTLPPPFSLQSGILTLNPVAQGQPILT SLGSNQEEAYVTMSSFYQNQSRSDPKPENPACPWTVLPAGDLPT HDGYLPSNIDDLPSHEAPLADSLEELEPQ CD8SS-TGFbR2(1- MALPVTALLLPLALLLHAARPMGRGLLRGLWPLHIVLWTRIASTIP 174 166).TPOR/MPLR(478- PHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCM 582;N-2+1).IL7Ra(316- SNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILED 459).IL12Rb2(775-825) AASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDLLL VIFQSDPTRVETATETLISLVTALHLVLGLSAVLGLLLLRWQFPAHY RRLRHALWPSLPDLHRVLGQYLRDTAALSPPKATVSDTCEEVEPSL LEILPKSSERTPLPLLEARDEVEGFLQDTFPQQLEESEKQRLGGDVQ SPNCPSEDVVITPESFGRDSSLTCLAGNVSACDAPILSSSRSLDCRE SGKNGPHVYQDLLLSLGTTNSTLPPPFSLQSGILTLNPVAQGQPILT SLGSNQEEAYVTMSSFYQNQSRSDPKPENPACPWTVLPAGDLPT HDGYLPSNIDDLPSHEAPLADSLEELEPQ CD8SS-TGFbR2(1- MALPVTALLLPLALLLHAARPMGRGLLRGLWPLHIVLWTRIASTIP 175 166).TPOR/MPLR(478- PHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCM 582;N-3).IL7Ra(316- SNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILED 459).IL12Rb2(775-825) AASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDLLL VIFQSDPTRVETATETSLVTALHLVLGLSAVLGLLLLRWQFPAHYRR LRHALWPSLPDLHRVLGQYLRDTAALSPPKATVSDTCEEVEPSLLEI LPKSSERTPLPLLEARDEVEGFLQDTFPQQLEESEKQRLGGDVQSP NCPSEDVVITPESFGRDSSLTCLAGNVSACDAPILSSSRSLDCRESG KNGPHVYQDLLLSLGTTNSTLPPPFSLQSGILTLNPVAQGQPILTSL GSNQEEAYVTMSSFYQNQSRSDPKPENPACPWTVLPAGDLPTH DGYLPSNIDDLPSHEAPLADSLEELEPQ CD8SS-TGFbR2(1- MALPVTALLLPLALLLHAARPMGRGLLRGLWPLHIVLWTRIASTIP 176 166).TPOR/MPLR(478- PHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCM 582;N-4).IL7Ra(316- SNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILED 459).IL12Rb2(775-825) AASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDLLL UnderlinedindicatesCD8SS VIFQSDPTRVETATETLVTALHLVLGLSAVLGLLLLRWQFPAHYRRL RHALWPSLPDLHRVLGQYLRDTAALSPPKATVSDTCEEVEPSLLEIL PKSSERTPLPLLEARDEVEGFLQDTFPQQLEESEKQRLGGDVQSP NCPSEDVVITPESFGRDSSLTCLAGNVSACDAPILSSSRSLDCRESG KNGPHVYQDLLLSLGTTNSTLPPPFSLQSGILTLNPVAQGQPILTSL GSNQEEAYVTMSSFYQNQSRSDPKPENPACPWTVLPAGDLPTH DGYLPSNIDDLPSHEAPLADSLEELEPQ CD8SS-TGFbR2(1- MALPVTALLLPLALLLHAARPMGRGLLRGLWPLHIVLWTRIASTIP 177 166).TPOR/MPLR(478- PHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCM 582;N-4+1).IL7Ra(316- SNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILED 459).IL12Rb2(775-825) AASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDLLL UnderlinedindicatesCD8SS VIFQSDPTRVETATETILVTALHLVLGLSAVLGLLLLRWQFPAHYRR LRHALWPSLPDLHRVLGQYLRDTAALSPPKATVSDTCEEVEPSLLEI LPKSSERTPLPLLEARDEVEGFLQDTFPQQLEESEKQRLGGDVQSP NCPSEDVVITPESFGRDSSLTCLAGNVSACDAPILSSSRSLDCRESG KNGPHVYQDLLLSLGTTNSTLPPPFSLQSGILTLNPVAQGQPILTSL GSNQEEAYVTMSSFYQNQSRSDPKPENPACPWTVLPAGDLPTH DGYLPSNIDDLPSHEAPLADSLEELEPQ CD8SS-TGFbR2(1- MALPVTALLLPLALLLHAARPMGRGLLRGLWPLHIVLWTRIASTIP 178 166).TPOR/MPLR(478- PHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCM 582;N-5).IL7Ra(316- SNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILED 459).IL12Rb2(775-825) AASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDLLL VIFQSDPTRVETATETVTALHLVLGLSAVLGLLLLRWQFPAHYRRL RHALWPSLPDLHRVLGQYLRDTAALSPPKATVSDTCEEVEPSLLEIL PKSSERTPLPLLEARDEVEGFLQDTFPQQLEESEKQRLGGDVQSP NCPSEDVVITPESFGRDSSLTCLAGNVSACDAPILSSSRSLDCRESG KNGPHVYQDLLLSLGTTNSTLPPPFSLQSGILTLNPVAQGQPILTSL GSNQEEAYVTMSSFYQNQSRSDPKPENPACPWTVLPAGDLPTH DGYLPSNIDDLPSHEAPLADSLEELEPQ CD8SS-TGFbR2(1- MALPVTALLLPLALLLHAARPMGRGLLRGLWPLHIVLWTRIASTIP 179 166).TPOR/MPLR(478- PHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCM 582;N-6).IL7Ra(316- SNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILED 459).IL12Rb2(775-825) AASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDLLL UnderlinedindicatesCD8SS VIFQSDPTRVETATETTALHLVLGLSAVLGLLLLRWQFPAHYRRLR HALWPSLPDLHRVLGQYLRDTAALSPPKATVSDTCEEVEPSLLEILP KSSERTPLPLLEARDEVEGFLQDTFPQQLEESEKQRLGGDVQSPN CPSEDVVITPESFGRDSSLTCLAGNVSACDAPILSSSRSLDCRESGK NGPHVYQDLLLSLGTTNSTLPPPFSLQSGILTLNPVAQGQPILTSLG SNQEEAYVTMSSFYQNQSRSDPKPENPACPWTVLPAGDLPTHD GYLPSNIDDLPSHEAPLADSLEELEPQ CD8SS-TGFbR2(1- MALPVTALLLPLALLLHAARPMGRGLLRGLWPLHIVLWTRIASTIP 180 166).TPOR/MPLR(478- PHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCM 582;N-7).IL7Ra(316- SNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILED 459).IL12Rb2(775-825) AASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDLLL VIFQSDPTRVETATETALHLVLGLSAVLGLLLLRWQFPAHYRRLRH ALWPSLPDLHRVLGQYLRDTAALSPPKATVSDTCEEVEPSLLEILPK SSERTPLPLLEARDEVEGFLQDTFPQQLEESEKQRLGGDVQSPNC PSEDVVITPESFGRDSSLTCLAGNVSACDAPILSSSRSLDCRESGKN GPHVYQDLLLSLGTTNSTLPPPFSLQSGILTLNPVAQGQPILTSLGS NQEEAYVTMSSFYQNQSRSDPKPENPACPWTVLPAGDLPTHDG YLPSNIDDLPSHEAPLADSLEELEPQ CD8SS-TGFbR2(1- MALPVTALLLPLALLLHAARPMGRGLLRGLWPLHIVLWTRIASTIP 181 166).TPOR/MPLR(478- PHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCM 582;N-8).IL7Ra(316- SNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILED 459).IL12Rb2(775-825) AASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDLLL UnderlinedindicatesCD8SS VIFQSDPTRVETATETLHLVLGLSAVLGLLLLRWQFPAHYRRLRHA LWPSLPDLHRVLGQYLRDTAALSPPKATVSDTCEEVEPSLLEILPKS SERTPLPLLEARDEVEGFLQDTFPQQLEESEKQRLGGDVQSPNCP SEDVVITPESFGRDSSLTCLAGNVSACDAPILSSSRSLDCRESGKNG PHVYQDLLLSLGTTNSTLPPPFSLQSGILTLNPVAQGQPILTSLGSN QEEAYVTMSSFYQNQSRSDPKPENPACPWTVLPAGDLPTHDGYL PSNIDDLPSHEAPLADSLEELEPQ CD8SS-TGFbR2(1- MALPVTALLLPLALLLHAARPMGRGLLRGLWPLHIVLWTRIASTIP 182 166).TPOR/MPLR(478- PHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCM 582;N-9).IL7Ra(316- SNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILED 459).IL12Rb2(775-825) AASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDLLL UnderlinedindicatesCD8SS VIFQSDPTRVETATETHLVLGLSAVLGLLLLRWQFPAHYRRLRHAL WPSLPDLHRVLGQYLRDTAALSPPKATVSDTCEEVEPSLLEILPKSS ERTPLPLLEARDEVEGFLQDTFPQQLEESEKQRLGGDVQSPNCPS EDVVITPESFGRDSSLTCLAGNVSACDAPILSSSRSLDCRESGKNGP HVYQDLLLSLGTTNSTLPPPFSLQSGILTLNPVAQGQPILTSLGSNQ EEAYVTMSSFYQNQSRSDPKPENPACPWTVLPAGDLPTHDGYLP SNIDDLPSHEAPLADSLEELEPQ CD8SS-TGFbR2(1- MALPVTALLLPLALLLHAARPMGRGLLRGLWPLHIVLWTRIASTIP 183 166).TPOR/MPLR(478- PHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCM 582;N-10).IL7Ra(316- SNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILED 459).IL12Rb2(775-825) AASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDLLL UnderlinedindicatesCD8SS VIFQSDPTRVETATETLVLGLSAVLGLLLLRWQFPAHYRRLRHALW PSLPDLHRVLGQYLRDTAALSPPKATVSDTCEEVEPSLLEILPKSSER TPLPLLEARDEVEGFLQDTFPQQLEESEKQRLGGDVQSPNCPSED VVITPESFGRDSSLTCLAGNVSACDAPILSSSRSLDCRESGKNGPHV YQDLLLSLGTTNSTLPPPFSLQSGILTLNPVAQGQPILTSLGSNQEE AYVTMSSFYQNQSRSDPKPENPACPWTVLPAGDLPTHDGYLPSN IDDLPSHEAPLADSLEELEPQ CD8SS-TGFbR2(1- MALPVTALLLPLALLLHAARPMGRGLLRGLWPLHIVLWTRIASTIP 184 166).TPOR/MPLR(478- PHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCM 582;N-11).IL7Ra(316- SNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILED 459).IL12Rb2(775-825) AASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDLLL UnderlinedindicatesCD8SS VIFQSDPTRVETATETVLGLSAVLGLLLLRWQFPAHYRRLRHALW PSLPDLHRVLGQYLRDTAALSPPKATVSDTCEEVEPSLLEILPKSSER TPLPLLEARDEVEGFLQDTFPQQLEESEKQRLGGDVQSPNCPSED VVITPESFGRDSSLTCLAGNVSACDAPILSSSRSLDCRESGKNGPHV YQDLLLSLGTTNSTLPPPFSLQSGILTLNPVAQGQPILTSLGSNQEE AYVTMSSFYQNQSRSDPKPENPACPWTVLPAGDLPTHDGYLPSN IDDLPSHEAPLADSLEELEPQ CD8SS-TGFbR2(1- MALPVTALLLPLALLLHAARPMGRGLLRGLWPLHIVLWTRIASTIP 185 166).TPOR/MPLR(478- PHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCM 582;N-12).IL7Ra(316- SNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILED 459).IL12Rb2(775-825) AASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDLLL UnderlinedindicatesCD8SS VIFQSDPTRVETATETLGLSAVLGLLLLRWQFPAHYRRLRHALWPS LPDLHRVLGQYLRDTAALSPPKATVSDTCEEVEPSLLEILPKSSERTP LPLLEARDEVEGFLQDTFPQQLEESEKQRLGGDVQSPNCPSEDVV ITPESFGRDSSLTCLAGNVSACDAPILSSSRSLDCRESGKNGPHVYQ DLLLSLGTTNSTLPPPFSLQSGILTLNPVAQGQPILTSLGSNQEEAY VTMSSFYQNQSRSDPKPENPACPWTVLPAGDLPTHDGYLPSNID DLPSHEAPLADSLEELEPQ CD8SS-TGFbR2(1- MALPVTALLLPLALLLHAARPMGRGLLRGLWPLHIVLWTRIASTIP 186 166).TPOR/MPLR(478- PHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCM 582;N-13).IL7Ra(316- SNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILED 459).IL12Rb2(775-825) AASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDLLL UnderlinedindicatesCD8SS VIFQSDPTRVETATETGLSAVLGLLLLRWQFPAHYRRLRHALWPSL PDLHRVLGQYLRDTAALSPPKATVSDTCEEVEPSLLEILPKSSERTPL PLLEARDEVEGFLQDTFPQQLEESEKQRLGGDVQSPNCPSEDVVI TPESFGRDSSLTCLAGNVSACDAPILSSSRSLDCRESGKNGPHVYQ DLLLSLGTTNSTLPPPFSLQSGILTLNPVAQGQPILTSLGSNQEEAY VTMSSFYQNQSRSDPKPENPACPWTVLPAGDLPTHDGYLPSNID DLPSHEAPLADSLEELEPQ CD8SS-TGFbR2(1- MALPVTALLLPLALLLHAARPMGRGLLRGLWPLHIVLWTRIASTIP 187 166).TPOR/MPLR(478- PHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCM 582;N-14).IL7Ra(316- SNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILED 459).IL12Rb2(775-825) AASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDLLL UnderlinedindicatesCD8SS VIFQSDPTRVETATETLSAVLGLLLLRWQFPAHYRRLRHALWPSLP DLHRVLGQYLRDTAALSPPKATVSDTCEEVEPSLLEILPKSSERTPLP LLEARDEVEGFLQDTFPQQLEESEKQRLGGDVQSPNCPSEDVVIT PESFGRDSSLTCLAGNVSACDAPILSSSRSLDCRESGKNGPHVYQD LLLSLGTTNSTLPPPFSLQSGILTLNPVAQGQPILTSLGSNQEEAYVT MSSFYQNQSRSDPKPENPACPWTVLPAGDLPTHDGYLPSNIDDL PSHEAPLADSLEELEPQ CD8SS-TGFbR2(1- MALPVTALLLPLALLLHAARPMGRGLLRGLWPLHIVLWTRIASTIP 188 166).TPOR/MPLR(478- PHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCM 582;N-15).IL7Ra(316- SNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILED 459).IL12Rb2(775-825) AASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDLLL UnderlinedindicatesCD8SS VIFQSDPTRVETATETSAVLGLLLLRWQFPAHYRRLRHALWPSLPD LHRVLGQYLRDTAALSPPKATVSDTCEEVEPSLLEILPKSSERTPLPL LEARDEVEGFLQDTFPQQLEESEKQRLGGDVQSPNCPSEDVVITP ESFGRDSSLTCLAGNVSACDAPILSSSRSLDCRESGKNGPHVYQDL LLSLGTTNSTLPPPFSLQSGILTLNPVAQGQPILTSLGSNQEEAYVT MSSFYQNQSRSDPKPENPACPWTVLPAGDLPTHDGYLPSNIDDL PSHEAPLADSLEELEPQ CD8SS-TGFbR2(1- MALPVTALLLPLALLLHAARPMGRGLLRGLWPLHIVLWTRIASTIP 189 166).TPOR/MPLR(478- PHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCM 582;N-16).IL7Ra(316- SNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILED 459).IL12Rb2(775-825) AASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDLLL UnderlinedindicatesCD8SS VIFQSDPTRVETATETAVLGLLLLRWQFPAHYRRLRHALWPSLPDL HRVLGQYLRDTAALSPPKATVSDTCEEVEPSLLEILPKSSERTPLPLL EARDEVEGFLQDTFPQQLEESEKQRLGGDVQSPNCPSEDVVITPE SFGRDSSLTCLAGNVSACDAPILSSSRSLDCRESGKNGPHVYQDLL LSLGTTNSTLPPPFSLQSGILTLNPVAQGQPILTSLGSNQEEAYVTM SSFYQNQSRSDPKPENPACPWTVLPAGDLPTHDGYLPSNIDDLPS HEAPLADSLEELEPQ CD8SS-TGFbR2(1- MALPVTALLLPLALLLHAARPMGRGLLRGLWPLHIVLWTRIASTIP 190 166).TPOR/MPLR(478- PHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCM 582;N-17).IL7Ra(316- SNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILED 459).IL12Rb2(775-825) AASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDLLL UnderlinedindicatesCD8SS VIFQSDPTRVETATETVLGLLLLRWQFPAHYRRLRHALWPSLPDLH RVLGQYLRDTAALSPPKATVSDTCEEVEPSLLEILPKSSERTPLPLLE ARDEVEGFLQDTFPQQLEESEKQRLGGDVQSPNCPSEDVVITPES FGRDSSLTCLAGNVSACDAPILSSSRSLDCRESGKNGPHVYQDLLL SLGTTNSTLPPPFSLQSGILTLNPVAQGQPILTSLGSNQEEAYVTM SSFYQNQSRSDPKPENPACPWTVLPAGDLPTHDGYLPSNIDDLPS HEAPLADSLEELEPQ CD8SS-TGFbR2(1- MALPVTALLLPLALLLHAARPMGRGLLRGLWPLHIVLWTRIASTIP 191 166).TPOR/MPLR(478- PHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCM 582;N-18).IL7Ra(316- SNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILED 459).IL12Rb2(775-825) AASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDLLL UnderlinedindicatesCD8SS VIFQSDPTRVETATETLGLLLLRWQFPAHYRRLRHALWPSLPDLHR VLGQYLRDTAALSPPKATVSDTCEEVEPSLLEILPKSSERTPLPLLEA RDEVEGFLQDTFPQQLEESEKQRLGGDVQSPNCPSEDVVITPESF GRDSSLTCLAGNVSACDAPILSSSRSLDCRESGKNGPHVYQDLLLS LGTTNSTLPPPFSLQSGILTLNPVAQGQPILTSLGSNQEEAYVTMS SFYQNQSRSDPKPENPACPWTVLPAGDLPTHDGYLPSNIDDLPSH EAPLADSLEELEPQ CD8SS-TGFbR2(1- MALPVTALLLPLALLLHAARPMGRGLLRGLWPLHIVLWTRIASTIP 192 166).TPOR/MPLR(478- PHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCM 582;N+1).IL7Ra(316- SNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILED 459).IL12Rb2(775-825) AASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDLLL UnderlinedindicatesCD8SS VIFQSDPTRVETATETAWLISLVTALHLVLGLSAVLGLLLLRWQFPA HYRRLRHALWPSLPDLHRVLGQYLRDTAALSPPKATVSDTCEEVE PSLLEILPKSSERTPLPLLEARDEVEGFLQDTFPQQLEESEKQRLGG DVQSPNCPSEDVVITPESFGRDSSLTCLAGNVSACDAPILSSSRSLD CRESGKNGPHVYQDLLLSLGTTNSTLPPPFSLQSGILTLNPVAQGQ PILTSLGSNQEEAYVTMSSFYQNQSRSDPKPENPACPWTVLPAGD LPTHDGYLPSNIDDLPSHEAPLADSLEELEPQ CD8SS-TGFbR2(1- MALPVTALLLPLALLLHAARPMGRGLLRGLWPLHIVLWTRIASTIP 193 166).TPOR/MPLR(478- PHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCM 582;N+2).IL7Ra(316- SNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILED 459).IL12Rb2(775-825) AASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDLLL UnderlinedindicatesCD8SS VIFQSDPTRVETATETAWVLISLVTALHLVLGLSAVLGLLLLRWQFP AHYRRLRHALWPSLPDLHRVLGQYLRDTAALSPPKATVSDTCEEV EPSLLEILPKSSERTPLPLLEARDEVEGFLQDTFPQQLEESEKQRLGG DVQSPNCPSEDVVITPESFGRDSSLTCLAGNVSACDAPILSSSRSLD CRESGKNGPHVYQDLLLSLGTTNSTLPPPFSLQSGILTLNPVAQGQ PILTSLGSNQEEAYVTMSSFYQNQSRSDPKPENPACPWTVLPAGD LPTHDGYLPSNIDDLPSHEAPLADSLEELEPQ CD8SS-TGFbR2(1- MALPVTALLLPLALLLHAARPMGRGLLRGLWPLHIVLWTRIASTIP 194 166).TPOR/MPLR(478- PHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCM 582;N+3).IL7Ra(316- SNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILED 459).IL12Rb2(775-825) AASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDLLL UnderlinedindicatesCD8SS VIFQSDPTRVETATETAWLVLISLVTALHLVLGLSAVLGLLLLRWQF PAHYRRLRHALWPSLPDLHRVLGQYLRDTAALSPPKATVSDTCEE VEPSLLEILPKSSERTPLPLLEARDEVEGFLQDTFPQQLEESEKQRLG GDVQSPNCPSEDVVITPESFGRDSSLTCLAGNVSACDAPILSSSRSL DCRESGKNGPHVYQDLLLSLGTTNSTLPPPFSLQSGILTLNPVAQG QPILTSLGSNQEEAYVTMSSFYQNQSRSDPKPENPACPWTVLPA GDLPTHDGYLPSNIDDLPSHEAPLADSLEELEPQ CD8SS-TGFbR2(1- MALPVTALLLPLALLLHAARPMGRGLLRGLWPLHIVLWTRIASTIP 195 166).TPOR/MPLR(478- PHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCM 582;N+4).IL7Ra(316- SNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILED 459).IL12Rb2(775-825) AASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDLLL UnderlinedindicatesCD8SS VIFQSDPTRVETATETAWILVLISLVTALHLVLGLSAVLGLLLLRWQ FPAHYRRLRHALWPSLPDLHRVLGQYLRDTAALSPPKATVSDTCE EVEPSLLEILPKSSERTPLPLLEARDEVEGFLQDTFPQQLEESEKQRL GGDVQSPNCPSEDVVITPESFGRDSSLTCLAGNVSACDAPILSSSR SLDCRESGKNGPHVYQDLLLSLGTTNSTLPPPFSLQSGILTLNPVA QGQPILTSLGSNQEEAYVTMSSFYQNQSRSDPKPENPACPWTVL PAGDLPTHDGYLPSNIDDLPSHEAPLADSLEELEPQ CD8SS-TGFbR2(1- MALPVTALLLPLALLLHAARPMGRGLLRGLWPLHIVLWTRIASTIP 196 166).TPOR/MPLR(478- PHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCM 582;N+5).IL7Ra(316- SNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILED 459).IL12Rb2(775-825) AASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDLLL UnderlinedindicatesCD8SS VIFQSDPTRVETATETAWLILVLISLVTALHLVLGLSAVLGLLLLRW QFPAHYRRLRHALWPSLPDLHRVLGQYLRDTAALSPPKATVSDTC EEVEPSLLEILPKSSERTPLPLLEARDEVEGFLQDTFPQQLEESEKQR LGGDVQSPNCPSEDVVITPESFGRDSSLTCLAGNVSACDAPILSSS RSLDCRESGKNGPHVYQDLLLSLGTTNSTLPPPFSLQSGILTLNPVA QGQPILTSLGSNQEEAYVTMSSFYQNQSRSDPKPENPACPWTVL PAGDLPTHDGYLPSNIDDLPSHEAPLADSLEELEPQ CD8SS-TGFbR2(1- MALPVTALLLPLALLLHAARPMGRGLLRGLWPLHIVLWTRIASTIP 197 166).TPOR/MPLR(478- PHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCM 582;N+6).IL7Ra(316- SNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILED 459).IL12Rb2(775-825) AASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDLLL UnderlinedindicatesCD8SS VIFQSDPTRVETATETAWLLILVLISLVTALHLVLGLSAVLGLLLLRW QFPAHYRRLRHALWPSLPDLHRVLGQYLRDTAALSPPKAWSDTC EEVEPSLLEILPKSSERTPLPLLEARDEVEGFLQDTFPQQLEESEKQR LGGDVQSPNCPSEDVVITPESFGRDSSLTCLAGNVSACDAPILSSS RSLDCRESGKNGPHVYQDLLLSLGTTNSTLPPPFSLQSGILTLNPVA QGQPILTSLGSNQEEAYVTMSSFYQNQSRSDPKPENPACPWTVL PAGDLPTHDGYLPSNIDDLPSHEAPLADSLEELEPQ CD8SS-TGFbR2(1- MALPVTALLLPLALLLHAARPMGRGLLRGLWPLHIVLWTRIASTIP 198 166).TPOR/MPLR(478- PHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCM 582;N+7).IL7Ra(316- SNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILED 459).IL12Rb2(775-825) AASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDLLL UnderlinedindicatesCD8SS VIFQSDPTRVETATETAWVLLILVLISLVTALHLVLGLSAVLGLLLLR WQFPAHYRRLRHALWPSLPDLHRVLGQYLRDTAALSPPKATVSD TCEEVEPSLLEILPKSSERTPLPLLEARDEVEGFLQDTFPQQLEESEK QRLGGDVQSPNCPSEDVVITPESFGRDSSLTCLAGNVSACDAPILS SSRSLDCRESGKNGPHVYQDLLLSLGTTNSTLPPPFSLQSGILTLNP VAQGQPILTSLGSNQEEAYVTMSSFYQNQSRSDPKPENPACPWT VLPAGDLPTHDGYLPSNIDDLPSHEAPLADSLEELEPQ CD8SS-TGFbR2(1- MALPVTALLLPLALLLHAARPMGRGLLRGLWPLHIVLWTRIASTIP 199 166).TPOR/MPLR(478- PHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCM 582;N+8).IL7Ra(316- SNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILED 459).IL12Rb2(775-825) AASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDLLL UnderlinedindicatesCD8SS VIFQSDPTRVETATETAWLVLLILVLISLVTALHLVLGLSAVLGLLLLR WQFPAHYRRLRHALWPSLPDLHRVLGQYLRDTAALSPPKATVSD TCEEVEPSLLEILPKSSERTPLPLLEARDEVEGFLQDTFPQQLEESEK QRLGGDVQSPNCPSEDVVITPESFGRDSSLTCLAGNVSACDAPILS SSRSLDCRESGKNGPHVYQDLLLSLGTTNSTLPPPFSLQSGILTLNP VAQGQPILTSLGSNQEEAYVTMSSFYQNQSRSDPKPENPACPWT VLPAGDLPTHDGYLPSNIDDLPSHEAPLADSLEELEPQ CD8SS-TGFbR2(1- MALPVTALLLPLALLLHAARPMGRGLLRGLWPLHIVLWTRIASTIP 200 166).TPOR/MPLR(478- PHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCM 582;N-9-1).IL7Ra(316- SNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILED 459).IL12Rb2(775-825) AASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDLLL UnderlinedindicatesCD8SS VIFQSDPTRVETATEHLVLGLSAVLGLLLLRWQFPAHYRRLRHAL WPSLPDLHRVLGQYLRDTAALSPPKATVSDTCEEVEPSLLEILPKSS ERTPLPLLEARDEVEGFLQDTFPQQLEESEKQRLGGDVQSPNCPS EDVVITPESFGRDSSLTCLAGNVSACDAPILSSSRSLDCRESGKNGP HVYQDLLLSLGTTNSTLPPPFSLQSGILTLNPVAQGQPILTSLGSNQ EEAYVTMSSFYQNQSRSDPKPENPACPWTVLPAGDLPTHDGYLP SNIDDLPSHEAPLADSLEELEPQ CD8SS-TGFbR2(1- MALPVTALLLPLALLLHAARPMGRGLLRGLWPLHIVLWTRIASTIP 201 166).TPOR/MPLR(478- PHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCM 582;N-9-2).IL7Ra(316- SNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILED 459).IL12Rb2(775-825) AASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDLLL UnderlinedindicatesCD8SS VIFQSDPTRVETATHLVLGLSAVLGLLLLRWQFPAHYRRLRHALW PSLPDLHRVLGQYLRDTAALSPPKATVSDTCEEVEPSLLEILPKSSER TPLPLLEARDEVEGFLQDTFPQQLEESEKQRLGGDVQSPNCPSED VVITPESFGRDSSLTCLAGNVSACDAPILSSSRSLDCRESGKNGPHV YQDLLLSLGTTNSTLPPPFSLQSGILTLNPVAQGQPILTSLGSNQEE AYVTMSSFYQNQSRSDPKPENPACPWTVLPAGDLPTHDGYLPSN IDDLPSHEAPLADSLEELEPQ CD8SS-TGFbR2(1- MALPVTALLLPLALLLHAARPMGRGLLRGLWPLHIVLWTRIASTIP 202 166).TPOR/MPLR(478- PHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCM 582;N-9-3).IL7Ra(316- SNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILED 459).IL12Rb2(775-825) AASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDLLL UnderlinedindicatesCD8SS VIFQSDPTRVETAHLVLGLSAVLGLLLLRWQFPAHYRRLRHALWP SLPDLHRVLGQYLRDTAALSPPKATVSDTCEEVEPSLLEILPKSSERT PLPLLEARDEVEGFLQDTFPQQLEESEKQRLGGDVQSPNCPSEDV VITPESFGRDSSLTCLAGNVSACDAPILSSSRSLDCRESGKNGPHVY QDLLLSLGTTNSTLPPPFSLQSGILTLNPVAQGQPILTSLGSNQEEA YVTMSSFYQNQSRSDPKPENPACPWTVLPAGDLPTHDGYLPSNI DDLPSHEAPLADSLEELEPQ CD8SS-TGFbR2(1- MALPVTALLLPLALLLHAARPMGRGLLRGLWPLHIVLWTRIASTIP 203 166).TPOR/MPLR(478- PHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCM 582;N-9-4).IL7Ra(316- SNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILED 459).IL12Rb2(775-825) AASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDLLL UnderlinedindicatesCD8SS VIFQSDPTRVETHLVLGLSAVLGLLLLRWQFPAHYRRLRHALWPSL PDLHRVLGQYLRDTAALSPPKATVSDTCEEVEPSLLEILPKSSERTPL PLLEARDEVEGFLQDTFPQQLEESEKQRLGGDVQSPNCPSEDVVI TPESFGRDSSLTCLAGNVSACDAPILSSSRSLDCRESGKNGPHVYQ DLLLSLGTTNSTLPPPFSLQSGILTLNPVAQGQPILTSLGSNQEEAY VTMSSFYQNQSRSDPKPENPACPWTVLPAGDLPTHDGYLPSNID DLPSHEAPLADSLEELEPQ CD8SS-TGFbR2(1- MALPVTALLLPLALLLHAARPMGRGLLRGLWPLHIVLWTRIASTIP 204 166).TPOR/MPLR(478- PHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCM 582;N-9-5).IL7Ra(316- SNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILED 459).IL12Rb2(775-825) AASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDLLL UnderlinedindicatesCD8SS VIFQSDPTRVEHLVLGLSAVLGLLLLRWQFPAHYRRLRHALWPSLP DLHRVLGQYLRDTAALSPPKATVSDTCEEVEPSLLEILPKSSERTPLP LLEARDEVEGFLQDTFPQQLEESEKQRLGGDVQSPNCPSEDVVIT PESFGRDSSLTCLAGNVSACDAPILSSSRSLDCRESGKNGPHVYQD LLLSLGTTNSTLPPPFSLQSGILTLNPVAQGQPILTSLGSNQEEAYVT MSSFYQNQSRSDPKPENPACPWTVLPAGDLPTHDGYLPSNIDDL PSHEAPLADSLEELEPQ CD8SS-TGFbR2(1- MALPVTALLLPLALLLHAARPMGRGLLRGLWPLHIVLWTRIASTIP 205 166).TPOR/MPLR(478- PHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCM 582;N-9-6).IL7Ra(316- SNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILED 459).IL12Rb2(775-825) AASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDLLL UnderlinedindicatesCD8SS VIFQSDPTRVHLVLGLSAVLGLLLLRWQFPAHYRRLRHALWPSLP DLHRVLGQYLRDTAALSPPKATVSDTCEEVEPSLLEILPKSSERTPLP LLEARDEVEGFLQDTFPQQLEESEKQRLGGDVQSPNCPSEDVVIT PESFGRDSSLTCLAGNVSACDAPILSSSRSLDCRESGKNGPHVYQD LLLSLGTTNSTLPPPFSLQSGILTLNPVAQGQPILTSLGSNQEEAYVT MSSFYQNQSRSDPKPENPACPWTVLPAGDLPTHDGYLPSNIDDL PSHEAPLADSLEELEPQ CD8SS-TGFbR2(1- MALPVTALLLPLALLLHAARPMGRGLLRGLWPLHIVLWTRIASTIP 206 166).TPOR/MPLR(478- PHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCM 582;N-9-7).IL7Ra(316- SNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILED 459).IL12Rb2(775-825) AASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDLLL UnderlinedindicatesCD8SS VIFQSDPTRHLVLGLSAVLGLLLLRWQFPAHYRRLRHALWPSLPDL HRVLGQYLRDTAALSPPKATVSDTCEEVEPSLLEILPKSSERTPLPLL EARDEVEGFLQDTFPQQLEESEKQRLGGDVQSPNCPSEDVVITPE SFGRDSSLTCLAGNVSACDAPILSSSRSLDCRESGKNGPHVYQDLL LSLGTTNSTLPPPFSLQSGILTLNPVAQGQPILTSLGSNQEEAYVTM SSFYQNQSRSDPKPENPACPWTVLPAGDLPTHDGYLPSNIDDLPS HEAPLADSLEELEPQ CD8SS-TGFbR2(1- MALPVTALLLPLALLLHAARPMGRGLLRGLWPLHIVLWTRIASTIP 207 166).TPOR/MPLR(478- PHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCM 582;N-9-8).IL7Ra(316- SNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILED 459).IL12Rb2(775-825) AASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDLLL UnderlinedindicatesCD8SS VIFQSDPTHLVLGLSAVLGLLLLRWQFPAHYRRLRHALWPSLPDLH RVLGQYLRDTAALSPPKATVSDTCEEVEPSLLEILPKSSERTPLPLLE ARDEVEGFLQDTFPQQLEESEKQRLGGDVQSPNCPSEDVVITPES FGRDSSLTCLAGNVSACDAPILSSSRSLDCRESGKNGPHVYQDLLL SLGTTNSTLPPPFSLQSGILTLNPVAQGQPILTSLGSNQEEAYVTM SSFYQNQSRSDPKPENPACPWTVLPAGDLPTHDGYLPSNIDDLPS HEAPLADSLEELEPQ CD8SS-TGFbR2(1- MALPVTALLLPLALLLHAARPMGRGLLRGLWPLHIVLWTRIASTIP 208 166).TPOR/MPLR(478- PHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCM 582;N-9-9).IL7Ra(316- SNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILED 459).IL12Rb2(775-825) AASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDLLL UnderlinedindicatesCD8SS VIFQSDPHLVLGLSAVLGLLLLRWQFPAHYRRLRHALWPSLPDLH RVLGQYLRDTAALSPPKATVSDTCEEVEPSLLEILPKSSERTPLPLLE ARDEVEGFLQDTFPQQLEESEKQRLGGDVQSPNCPSEDVVITPES FGRDSSLTCLAGNVSACDAPILSSSRSLDCRESGKNGPHVYQDLLL SLGTTNSTLPPPFSLQSGILTLNPVAQGQPILTSLGSNQEEAYVTM SSFYQNQSRSDPKPENPACPWTVLPAGDLPTHDGYLPSNIDDLPS HEAPLADSLEELEPQ CD8SS-TGFbR2(1- MALPVTALLLPLALLLHAARPMGRGLLRGLWPLHIVLWTRIASTIP 209 166).TPOR/MPLR(478- PHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCM 582;N-9-10).IL7Ra(316- SNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILED 459).IL12Rb2(775-825) AASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDLLL UnderlinedindicatesCD8SS VIFQSDHLVLGLSAVLGLLLLRWQFPAHYRRLRHALWPSLPDLHR VLGQYLRDTAALSPPKATVSDTCEEVEPSLLEILPKSSERTPLPLLEA RDEVEGFLQDTFPQQLEESEKQRLGGDVQSPNCPSEDVVITPESF GRDSSLTCLAGNVSACDAPILSSSRSLDCRESGKNGPHVYQDLLLS LGTTNSTLPPPFSLQSGILTLNPVAQGQPILTSLGSNQEEAYVTMS SFYQNQSRSDPKPENPACPWTVLPAGDLPTHDGYLPSNIDDLPSH EAPLADSLEELEPQ CD8SS-TGFbR2(1- MALPVTALLLPLALLLHAARPMGRGLLRGLWPLHIVLWTRIASTIP 210 166).TPOR/MPLR(478- PHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCM 582;N-9-11).IL7Ra(316- SNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILED 459).IL12Rb2(775-825) AASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDLLL UnderlinedindicatesCD8SS VIFQSHLVLGLSAVLGLLLLRWQFPAHYRRLRHALWPSLPDLHRVL GQYLRDTAALSPPKATVSDTCEEVEPSLLEILPKSSERTPLPLLEARD EVEGFLQDTFPQQLEESEKQRLGGDVQSPNCPSEDVVITPESFGR DSSLTCLAGNVSACDAPILSSSRSLDCRESGKNGPHVYQDLLLSLGT TNSTLPPPFSLQSGILTLNPVAQGQPILTSLGSNQEEAYVTMSSFY QNQSRSDPKPENPACPWTVLPAGDLPTHDGYLPSNIDDLPSHEA PLADSLEELEPQ CD8SS-TGFbR2(1- MALPVTALLLPLALLLHAARPMGRGLLRGLWPLHIVLWTRIASTIP 211 166).TPOR/MPLR(478- PHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCM 582;N-9-12).IL7Ra(316- SNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILED 459).IL12Rb2(775-825) AASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDLLL UnderlinedindicatesCD8SS VIFQHLVLGLSAVLGLLLLRWQFPAHYRRLRHALWPSLPDLHRVL GQYLRDTAALSPPKATVSDTCEEVEPSLLEILPKSSERTPLPLLEARD EVEGFLQDTFPQQLEESEKQRLGGDVQSPNCPSEDVVITPESFGR DSSLTCLAGNVSACDAPILSSSRSLDCRESGKNGPHVYQDLLLSLGT TNSTLPPPFSLQSGILTLNPVAQGQPILTSLGSNQEEAYVTMSSFY QNQSRSDPKPENPACPWTVLPAGDLPTHDGYLPSNIDDLPSHEA PLADSLEELEPQ CD8SS- MALPVTALLLPLALLLHAARPQLCKFCDVRFSTCDNQKSCMSNCSI 212 TGFbR2AN25.TPOR/MPLR TSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILEDAASP (478-582;N-9).IL7Ra(316- KCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDLLLVIFQ 459).IL12Rb2(775-825) SDPTRVETATETHLVLGLSAVLGLLLLRWQFPAHYRRLRHALWPSL UnderlinedindicatesCD8SS PDLHRVLGQYLRDTAALSPPKATVSDTCEEVEPSLLEILPKSSERTPL PLLEARDEVEGFLQDTFPQQLEESEKQRLGGDVQSPNCPSEDVVI TPESFGRDSSLTCLAGNVSACDAPILSSSRSLDCRESGKNGPHVYQ DLLLSLGTTNSTLPPPFSLQSGILTLNPVAQGQPILTSLGSNQEEAY VTMSSFYQNQSRSDPKPENPACPWTVLPAGDLPTHDGYLPSNID DLPSHEAPLADSLEELEPQ CD8SS- MALPVTALLLPLALLLHAARPQLCKFCDVRFSTCDNQKSCMSNCSI 213 TGFbR2.box-tangle-solidup.N25.TPOR/MPLR TSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILEDAASP (478-582;N+4).IL7Ra(316- KCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDLLLVIFQ 459).IL12Rb2(775-825) SDPTRVETATETAWILVLISLVTALHLVLGLSAVLGLLLLRWQFPAH UnderlinedindicatesCD8SS YRRLRHALWPSLPDLHRVLGQYLRDTAALSPPKATVSDTCEEVEPS LLEILPKSSERTPLPLLEARDEVEGFLQDTFPQQLEESEKQRLGGDV QSPNCPSEDVVITPESFGRDSSLTCLAGNVSACDAPILSSSRSLDCR ESGKNGPHVYQDLLLSLGTTNSTLPPPFSLQSGILTLNPVAQGQPIL TSLGSNQEEAYVTMSSFYQNQSRSDPKPENPACPWTVLPAGDLP THDGYLPSNIDDLPSHEAPLADSLEELEPQ CD8SS- MALPVTALLLPLALLLHAARPQLCKFCDVRFSTCDNQKSCMSNCSI 214 TGFbR2.box-tangle-solidup.N25.TPOR/MPLR TSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILEDAASP (478-582;N-9-4).IL7Ra KCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDLLLVIFQ (316-459).IL12Rb2(775-825) SDPTRVETHLVLGLSAVLGLLLLRWQFPAHYRRLRHALWPSLPDL UnderlinedindicatesCD8SS HRVLGQYLRDTAALSPPKATVSDTCEEVEPSLLEILPKSSERTPLPLL EARDEVEGFLQDTFPQQLEESEKQRLGGDVQSPNCPSEDVVITPE SFGRDSSLTCLAGNVSACDAPILSSSRSLDCRESGKNGPHVYQDLL LSLGTTNSTLPPPFSLQSGILTLNPVAQGQPILTSLGSNQEEAYVTM SSFYQNQSRSDPKPENPACPWTVLPAGDLPTHDGYLPSNIDDLPS HEAPLADSLEELEPQ CD8SS- MALPVTALLLPLALLLHAARPQLCKFCDVRFSTCDNQKSCMSNCSI 215 TGFbR2.box-tangle-solidup.N25.TPOR/MPLR TSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILEDAASP (478-582;N-9-9).IL7Ra KCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDLLLVIFQ (316-459).IL12Rb2(775-825) SDPHLVLGLSAVLGLLLLRWQFPAHYRRLRHALWPSLPDLHRVLG UnderlinedindicatesCD8SS QYLRDTAALSPPKATVSDTCEEVEPSLLEILPKSSERTPLPLLEARDE VEGFLQDTFPQQLEESEKQRLGGDVQSPNCPSEDVVITPESFGRD SSLTCLAGNVSACDAPILSSSRSLDCRESGKNGPHVYQDLLLSLGTT NSTLPPPFSLQSGILTLNPVAQGQPILTSLGSNQEEAYVTMSSFYQ NQSRSDPKPENPACPWTVLPAGDLPTHDGYLPSNIDDLPSHEAPL ADSLEELEPQ CD8SS- MALPVTALLLPLALLLHAARPQLCKFCDVRFSTCDNQKSCMSNCSI 216 TGFbR2.box-tangle-solidup.N25.TPOR/MPLR TSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILEDAASP (478-582;N-9-10).IL7Ra KCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDLLLVIFQ (316-459).IL12Rb2(775-825) SDHLVLGLSAVLGLLLLRWQFPAHYRRLRHALWPSLPDLHRVLGQ UnderlinedindicatesCD8SS YLRDTAALSPPKATVSDTCEEVEPSLLEILPKSSERTPLPLLEARDEV EGFLQDTFPQQLEESEKQRLGGDVQSPNCPSEDVVITPESFGRDS SLTCLAGNVSACDAPILSSSRSLDCRESGKNGPHVYQDLLLSLGTT NSTLPPPFSLQSGILTLNPVAQGQPILTSLGSNQEEAYVTMSSFYQ NQSRSDPKPENPACPWTVLPAGDLPTHDGYLPSNIDDLPSHEAPL ADSLEELEPQ CD8SS-TPOR/MPLR(478- MALPVTALLLPLALLLHAARPSDPTRVETATETAWISLVTALLLVLG 272 582;H499L,S505N,W515K, LNAVLGLLLLRKQFPAHYRRLRHALWPSLPDLHRVLGQYLRDTAA K553R,K573R).IL2Rb(339- LSPPRATVSDTCEEVEPSLLEILPRSSERTPLPLLEQQDKVPEPASLS 379,393-433,518-551) SNHSLTSCFTNQGYFFFHLPDALEIEACQDEGVAGAPTGSSPQPL UnderlinedindicatesCD8SS QPLSGEDDAYCTFPSRDDLLLFSPSGQGEFRALNARLPLNTDAYLS LQELQGQDPTHLV CD8SS-TPOR/MPLR(478- MALPVTALLLPLALLLHAARPSDPTRVETATETAWISLVTALHLVL 273 582;S505N,W515K,K553R, GLNAVLGLLLLRKQFPAHYRRLRHALWPSLPDLHRVLGQYLRDTA K573R).IL2Rb(393-433,518- ALSPPRATVSDTCEEVEPSLLEILPRSSERTPLPLLEDEGVAGAPTGS 551) SPQPLQPLSGEDDAYCTFPSRDDLLLFSPSGQGEFRALNARLPLNT UnderlinedindicatesCD8SS DAYLSLQELQGQDPTHLV CD8SS- MALPVTALLLPLALLLHAARPPGWFLDSPDRPWNPPTFSPALLVV 274 HAPD1.TPOR/MPLR(478- TEGDNATFTCSFSNTSESFHVIWHRESPSGQTDTLAAFPEDRSQP 582;H499L,S505N,W515K, GQDCRFRVTQLPNGRDFHMSVVRARRNDSGTYVCGVISLAPKIQI K553R,K573R).IL2Rb(339- KESLRAELRVTERRAEVPTAHPSPSPRPAGQFQTLVSDPTRVETAT 379,393-433,518-551) ETAWISLVTALLLVLGLNAVLGLLLLRKQFPAHYRRLRHALWPSLP UnderlinedindicatesCD8SS DLHRVLGQYLRDTAALSPPRATVSDTCEEVEPSLLEILPRSSERTPL Italicizedmarkshigh-affinity PLLEQQDKVPEPASLSSNHSLTSCFTNQGYFFFHLPDALEIEACQD PD-1ectodomain EGVAGAPTGSSPQPLQPLSGEDDAYCTFPSRDDLLLFSPSGQGEF RALNARLPLNTDAYLSLQELQGQDPTHLV CD8SS- MALPVTALLLPLALLLHAARPPGWFLDSPDRPWNPPTFSPALLVV 275 HAPD1.TPOR/MPLR(478- TEGDNATFTCSFSNTSESFHVIWHRESPSGQTDTLAAFPEDRSQP 582;S505N,W515K,K553R, GQDCRFRVTQLPNGRDFHMSVVRARRNDSGTYVCGVISLAPKIQI K573R).IL2Rb(393-433, KESLRAELRVTERRAEVPTAHPSPSPRPAGQFQTLVSDPTRVETAT 518-551) ETAWISLVTALHLVLGLNAVLGLLLLRKQFPAHYRRLRHALWPSLP Underlinedindicates DLHRVLGQYLRDTAALSPPRATVSDTCEEVEPSLLEILPRSSERTPL CD8SSItalicizedmarkshigh- PLLEDEGVAGAPTGSSPQPLQPLSGEDDAYCTFPSRDDLLLFSPSG affinityPD-1ectodomain QGEFRALNARLPLNTDAYLSLQELQGQDPTHLV *The underlined LE and SR indicate exemplary peptide linkers.

(96) F. Expression of Chimeric Cytokine Receptors

(97) Provided herein are polynucleotides encoding any one of the chimeric cytokine receptors provided herein. Likewise, provided herein are expression vectors comprising such polynucleotides. In some embodiments, the vector is a viral vector. In some embodiments, the vector is not a viral vector.

(98) In some embodiments, the vector comprises a polynucleotide encoding a chimeric cytokine receptor, and a polynucleotide expressing a chimeric antigen receptor (CAR).

(99) In some embodiments, expression of the chimeric cytokine receptor and the CAR are expressed as a single polypeptide chain, separated by a linker. FIGS. 2A, 3, 4A, 5A, 6A, 8A, and 11A show schematics of a vector that can be used to co-express the chimeric cytokine receptor and CAR of the disclosure. One or more STAT-recruiting domains may be joined in tandem to mimic signaling from one or more cytokines.

(100) II. CAR-Bearing Immune Cells

(101) Provided herein are engineered immune cells comprising a polynucleotide encoding a chimeric antigen receptor and a chimeric cytokine receptor of the disclosure; and provided herein are engineered immune cells expressing a chimeric antigen receptor (CAR-I cell) and a chimeric cytokine receptor of the disclosure. Examples of immune cells include T-cells, e.g., alpha/beta T-cells and gamma/delta T-cells, B cells, natural killer (NK) cells, natural killer T (NKT) cells, invariant NKT cells, mast cells, myeloid-derived phagocytes, dendritic cells, killer dendritic cells, macrophages, and monocytes. Immune cells also refer to cells derived from, for example without limitation, a stem cell. The stem cells can be adult stem cells, non-human embryonic stem cells, more particularly non-human stem cells, cord blood stem cells, progenitor cells, bone marrow stem cells, induced pluripotent stem cells, totipotent stem cells or hematopoietic stem cells.

(102) Accordingly in some embodiments, provided herein are CAR-T cells comprising a chimeric cytokine receptor of the disclosure.

(103) In some embodiments, a CAR can comprise an extracellular ligand-binding domain (e.g., a single chain variable fragment (scFv)), a transmembrane domain, and an intracellular signaling domain. In some embodiments, the extracellular ligand-binding domain, transmembrane domain, and intracellular signaling domain are in one polypeptide, i.e., in a single chain. Multichain CARs and polypeptides are also provided herein. In some embodiments, the multichain CARs comprise: a first polypeptide comprising a transmembrane domain and at least one extracellular ligand-binding domain, and a second polypeptide comprising a transmembrane domain and at least one intracellular signaling domain, wherein the polypeptides assemble together to form a multichain CAR.

(104) The extracellular ligand-binding domain of a CAR specifically binds to a target of interest. The target of interest can be any molecule of interest, including, for example, without limitation any one or more of those presented in Table 8.

(105) TABLE-US-00008 TABLE 8 List of targets of interest BCMA EGFRvIII Flt-3 WT-1 CD20 CD23 CD30 CD38 CD70 CD33 CD133 MHC- WT1 TSPAN10 MHC-PRAME Liv1 ADAM10 CHRNA2 LeY NKG2D CS1 CD44v6 ROR1 CD19 Claudin-18.2 (Claudin-18A2 or Claudin18 isoform 2) DLL3 (Delta-like protein 3, Drosophila Delta homolog 3, Delta3) Muc17 (Mucin17, Muc3, Muc3) FAP alpha (Fibroblast Activation Protein alpha) Ly6G6D (Lymphocyte antigen 6 complex locus protein G6d c6orf23 G6D MEGT1 NG25) RNF43 (E3 ubiquitin-protein ligase RNF43, RING finger protein 43) ErbB2 (HER2/neu) carcinoembryonic antigen (CEA) epithelial cell adhesion molecule (EpCAM) epidermal growth factor receptor (EGFR) CD40 disialoganglioside GD2 GD3 C-type lectin-like molecule-1 (CLL-1) ductal-epithelial mucine gp36 TAG-72 glycosphingolipids glioma-associated antigen -human chorionic gonadotropin alphafetoprotein (AFP) lectin-reactive AFP thyroglobulin RAGE-1 MN-CA IX human telomerase reverse transcriptase RU1 RU2 (AS) intestinal carboxyl esterase mut hsp70-2 M-CSF prostase prostase specific antigen (PSA) PAP NY-ESO-1 LAGA-la p53 prostein PSMA survivin and telomerase prostate-carcinoma tumor antigen-1 (PCTA-1) MAGE ELF2M neutrophil elastase ephrin B2 CD22 insulin growth factor (IGFl)-l IGF-II IGFI receptor mesothelin a major histocompatibility complex (MHC) molecule presenting a tumor-specific peptide epitope 5T4 O 1 Nkp30 tumor stromal antigens the extra domain A (EDA) and extra domain B (EDB) of fibronectin and the AI domain of tenascin-C (TnC AI) and fibroblast associated protein (fap) LRP6 melamona-associated Chondroitin Sulfate Proteoglycan (MCSP) MARTI MUC1 LMP2 Idiotype NY-ESO-1 Ras mutant gp100 proteinase 3 bcr-abl tyrosinase hTERT EphA2 ML-TAP ERG NA17 PAX3 ALK Androgen receptor a lineage-specific or tissue specific antigen such as CD3 CD4 CD8 CD24 CD25 CD34 CD79 CD116 CD117 CD135 CD123 CD138 CTLA-4 B7-1 (CD80) B7-2 (CD86) endoglin a major histocompatibility complex (MHC) molecule MUC16 PSCA Trop2 CD171 (L1CAM) CA9 STEAP1 VEGFR2

(106) In some embodiments, the extracellular ligand-binding domain of a CAR comprises an scFv comprising the light chain variable (VL) region and the heavy chain variable (VH) region of a target antigen specific monoclonal antibody joined by a flexible linker. Single chain variable region fragments are made by linking light and/or heavy chain variable regions by using a short linking peptide (Bird et al., Science 242:423-426, 1988) (e.g. glycine-serine containing linkers). In general, linkers can be short, flexible polypeptides and are generally comprised of about 20 or fewer amino acid residues. Linkers can in turn be modified for additional functions, such as attachment of drugs or attachment to solid supports. The single chain variants can be produced either recombinantly or synthetically. For synthetic production of scFv, an automated synthesizer can be used. For recombinant production of scFv, a suitable plasmid containing polynucleotide that encodes the scFv can be introduced into a suitable host cell, either eukaryotic, such as yeast, plant, insect or mammalian cells, or prokaryotic, such as E. coli. Polynucleotides encoding the scFv of interest can be made by routine manipulations such as ligation of polynucleotides. The resultant scFv can be isolated using standard protein purification techniques known in the art.

(107) The intracellular signaling domain of a CAR according to the invention is responsible for intracellular signaling following the binding of extracellular ligand-binding domain to the target resulting in the activation of the immune cell and immune response (Signals 1 and/or 2). The intracellular signaling domain has the ability to activate at least one of the normal effector functions of the immune cell in which the CAR is expressed. For example, the effector function of a T cell can be a cytolytic activity or helper activity including the secretion of cytokines.

(108) In some embodiments, an intracellular signaling domain for use in a CAR can be the cytoplasmic sequences of, for example without limitation, the T cell receptor and co-receptors that act in concert to initiate signal transduction following antigen receptor engagement, as well as any derivative or variant of these sequences and any synthetic sequence that has the same functional capability. Intracellular signaling domains comprise two distinct classes of cytoplasmic signaling sequences: those that initiate antigen-dependent primary activation, and those that act in an antigen-independent manner to provide a secondary or co-stimulatory signal. Primary cytoplasmic signaling sequences can comprise signaling motifs which are known as immunoreceptor tyrosine-based activation motifs of ITAMs. ITAMs are well defined signaling motifs found in the intracytoplasmic tail of a variety of receptors that serve as binding sites for syk/zap70 class tyrosine kinases. Examples of ITAM used in the invention can include as non-limiting examples those derived from TCR, FcR, FcR, FcR, CD3, CD3, CD3, CD5, CD22, CD79a, CD79b and CD66d. In some embodiments, the intracellular signaling domain of the CAR can comprise the CD3 signaling domain. In some embodiments the intracellular signaling domain of the CAR of the invention comprises a domain of a co-stimulatory molecule.

(109) In some embodiments, the intracellular signaling domain of a CAR of the invention comprises a part of co-stimulatory molecule selected from the group consisting of fragment of 41BB (GenBank: AAA53133.) and CD28 (NP_006130.1).

(110) CARs are expressed on the surface membrane of the cell. Thus, the CAR comprises a transmembrane domain. Suitable transmembrane domains for a CAR disclosed herein have the ability to (a) be expressed at the surface of a cell, preferably an immune cell such as, for example without limitation, lymphocyte cells or Natural killer (NK) cells, and (b) interact with the ligand-binding domain and intracellular signaling domain for directing cellular response of immune cell against a predefined target cell. The transmembrane domain can be derived either from a natural or from a synthetic source. The transmembrane domain can be derived from any membrane-bound or transmembrane protein. As non-limiting examples, the transmembrane polypeptide can be a subunit of the T cell receptor such as , , or , polypeptide constituting CD3 complex, IL-2 receptor p55 (a chain), p75 ( chain) or chain, subunit chain of Fc receptors, in particular Fc receptor III or CD proteins. Alternatively, the transmembrane domain can be synthetic and can comprise predominantly hydrophobic residues such as leucine and valine. In some embodiments said transmembrane domain is derived from the human CD8a chain (e.g., NP_001139345.1). The transmembrane domain can further comprise a stalk domain between the extracellular ligand-binding domain and said transmembrane domain. A stalk domain may comprise up to 300 amino acids, preferably 10 to 100 amino acids and most preferably 25 to 50 amino acids. Stalk region may be derived from all or part of naturally occurring molecules, such as from all or part of the extracellular region of CD8, CD4, or CD28, or from all or part of an antibody constant region. Alternatively the stalk domain may be a synthetic sequence that corresponds to a naturally occurring stalk sequence, or may be an entirely synthetic stalk sequence. In some embodiments said stalk domain is a part of human CD8a chain (e.g., NP_001139345.1). In another particular embodiment, said transmembrane and hinge domains comprise a part of human CD8a chain. In some embodiments, CARs disclosed herein can comprise an extracellular ligand-binding domain that specifically binds BCMA, CD8a human hinge and transmembrane domains, the CD3(signaling domain, and 4-1BB signaling domain.

(111) In some embodiments, a CAR can be introduced into an immune cell as a transgene via a plasmid vector. In some embodiments, the plasmid vector can also contain, for example, a selection marker which provides for identification and/or selection of cells which received the vector.

(112) Table 7 provides exemplary sequences of CAR components that can be used in the CARs disclosed herein.

(113) TABLE-US-00009 TABLE7 ExemplarySequences SEQ Domain Aminoacidsequence IDNO: V5epitopetag KPIPNPLLGLDST 152 2173scFv EIQLVQSGAEVKKPGESLRISCKGSGFNIEDYYIR 153 WVRQMPGKGLEWMGRIDPENDETKYGPIFQGH VTISADTSINTVYLQWSSLKASDTAMYYCAFRG GVYWGQGTTVTVSSGGGGSGGGGSGGGGSGGG GSDVVMTQSPDSLAVSLGERATINCKSSQSLLDS DGKTYLNWLQQKPGQPPKRLISLVSKLDSGVPD RFSGSGSGTDFTLTISSLQAEDVAVYYCWQGTHF PGTFGGGTKVEIK CD8hingeand TTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAV 154 transmembrane HTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYC 4-1BBintracellular KRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPE 155 signaling EEEGGCEL CD3zintracellular RVKFSRSADAPAYQQGQNQLYNELNLGRREEYD 156 signaling VLDKRRGRDPEMGGKPRRKNPQEGLYNELQKD KMAEAYSEIGMKGERRRGKGHDGLYQGLSTAT KDTYDALHMQALPPR BFP(bluefluorescent MSELIKENMHMKLYMEGTVDNHHFKCTSEGEG 157 protein) KPYEGTQTMRIKVVEGGPLPFAFDILATSFLYGS KTFINHTQGIPDFFKQSFPEGFTWERVTTYEDGG VLTATQDTSLQDGCLIYNVKIRGVNFTSNGPVM QKKTLGWEAFTETLYPADGGLEGRNDMALKLV GGSHLIANIKTTYRSKKPAKNLKMPGVYYVDYR LERIKEANNETYVEQHEVAVARYCDLPSKLGHK LN P2A GSGATNFSLLKQAGDVEENPGP 158

(114) In some embodiments, the CAR-immune cell (e.g., CAR-T cell) of the disclosure comprises a polynucleotide encoding a suicide polypeptide, such as for example RQR8. See, e.g., WO2013153391A, which is hereby incorporated by reference in its entirety. In some embodiments, a suicide polypeptide is expressed on the surface of the cell. In some embodiments, a suicide polypeptide is included in the CAR construct. In some embodiments, a suicide polypeptide is not part of the CAR construct.

(115) In some embodiments, the extracellular domain of any one of CARs disclosed herein may comprise one or more epitopes specific for (specifically recognized by) a monoclonal antibody. These epitopes are also referred to herein as mAb-specific epitopes. Exemplary mAb-specific epitopes are disclosed in International Patent Publication No. WO 2016/120216, which is incorporated herein in its entirety. In these embodiments, the extracellular domains of the CARs comprise antigen binding domains that specifically bind to a target of interest and one or more epitopes that bind to one or more monoclonal antibodies (mAbs). CARs comprising the mAb-specific epitopes can be single-chain or multi-chain.

(116) The inclusion of epitopes specific for monoclonal antibodies in the extracellular domain of the CARs described herein allows sorting and depletion of engineered immune cells expressing the CARs. In some embodiments, allowing for depletion provides a safety switch in case of deleterious effects, e.g., upon administration to a subject.

(117) Methods of preparing immune cells for use in immunotherapy are also provided herein. In some embodiments, the methods comprise introducing a chimeric cytokine receptor and a CAR into immune cells, and expanding the cells. In some embodiments, the invention relates to a method of engineering an immune cell comprising: providing a cell and expressing a chimeric cytokine receptor, and expressing at the surface of the cell at least one CAR. In some embodiments, the method comprises: transfecting the cell with at least one polynucleotide encoding a chimeric cytokine receptor, and at least one polynucleotide encoding a CAR, and expressing the polynucleotides in the cell. In some embodiments, the method comprises: transfecting the cell with at least one polynucleotide encoding a chimeric cytokine receptor, at least one polynucleotide encoding a CAR, and expressing the polynucleotides in the cell. In some embodiments, the chimeric cytokine receptor and the CAR reside on one polynucleotide.

(118) In some embodiments, the one or more polynucleotides encoding the chimeric cytokine receptor and CAR are present in one or more expression vectors for stable expression in the cells. In some embodiments, the polynucleotides are present in viral vectors for stable expression in the cells. In some embodiments, the one or more polynucleotides are inserted into the cellular genome by random integration, and in other embodiments, inserted into specific locations of the cellular genome by site-specific integration. In some embodiments, the viral vectors may be for example, lentiviral vectors or adenoviral vectors. In some embodiments, the one or more polynucleotides are present in non-viral vectors.

(119) In some embodiments, polynucleotides encoding polypeptides according to the present disclosure can be mRNA which is introduced directly into the cells, for example by electroporation. In some embodiments, CytoPulse electroporation technology, such as PulseAgile, can be used to transiently permeabilize living cells for delivery of material into the cells (e.g. U.S. Pat. No. 6,078,490; PCT/US2011/000827; and PCT/US2004/005237). Parameters can be modified in order to determine conditions for high transfection efficiency with minimal mortality.

(120) Also provided herein are methods of transfecting an immune cell, e.g a T-cell. In some embodiments, the method comprises: contacting a T-cell with RNA and applying to the T-cell an agile pulse sequence. In some embodiments, a method of transfecting an immune cell (e.g. T-cell) comprising contacting the immune cell with RNA and applying to the cell an agile pulse sequence.

(121) In some embodiments, the method can further comprise a step of genetically modifying a cell by inactivating at least one gene expressing, for example without limitation, a component of the TCR, a target for an immunosuppressive agent, an HLA gene, and/or an immune checkpoint protein such as, for example, PDCD1 or CTLA-4. By inactivating a gene it is intended that the gene of interest is not expressed in a functional protein form. In some embodiments, the gene to be inactivated is selected from the group consisting of, for example without limitation, TCR, TCR, CD52, GR, deoxycytidine kinase (DCK), TGF-B, and CTLA-4. In some embodiments the method comprises inactivating one or more genes by introducing into the cells a rare-cutting endonuclease able to selectively inactivate a gene by selective DNA cleavage. In some embodiments the rare-cutting endonuclease can be, for example, a transcription activator-like effector nuclease (TALE-nuclease) or CRISPR-based endonuclease (e.g Cas-9 or Cas12a).

(122) In another aspect, a step of genetically modifying cells can comprise: modifying immune cells (e.g. T-cells) by inactivating at least one gene expressing a target for an immunosuppressive agent, and; expanding the cells, optionally in presence of the immunosuppressive agent.

(123) In some embodiments, the engineered immune cells (e.g. T-cells) provided herein exhibit improved cytotoxicity, increased expansion, and/or increased levels of memory phenotype markers upon contact with a TGF- ligand or anti-TGF--receptor antibody that binds to the binding domain of the chimeric cytokine receptor relative to engineered immune cells that do not express the chimeric cytokine receptor.

(124) In some embodiments, the engineered immune cells (e.g. T-cells) provided herein exhibit (i) increased in vivo persistence, (ii) increased STAT activation, (iii) increased cytotoxicity, (iv) increased levels of memory phenotype markers, (v) increased expansion (proliferation), or combinations of these functional features, upon contact with a TGF- ligand or anti-TGF--receptor antibody that binds to the binding domain of the chimeric cytokine receptor relative to engineered immune cells that do not express the chimeric cytokine receptor. In some embodiments, the improvement in the one or more functional features described herein is dose-dependent, i.e., the functional activity of the immune cell comprising the chimeric cytokine receptors increases upon contact with increasing doses of the PD-L1/PD-L2/TGF-B or an antibody to the respective receptor. In some embodiments, STATs activated by the engineered immune cell comprising one or more chimeric cytokine receptors disclosed are STAT1, STAT2, STAT3, STAT4, STAT5, STAT6, or combinations thereof. In one embodiment, memory phenotype markers that are increased or maintained by the immune cell comprising the chimeric cytokine receptor of the disclosure include stem cell memory (Tscm) markers and central memory (Tcm) markers.

(125) In some embodiments, the improvement in one or more functional features exhibited by an engineered immune cell comprising a chimeric cytokine receptor provided herein is at least about 2 fold, 2.5 fold, 3 fold, 3.5 fold, 4 fold, 4.5 fold, 5 fold, 6 fold, 7 fold, 8 fold, 9 fold, 10 fold, 15 fold, 20 fold, 25 fold, 30 fold, 40 fold, 50 fold, 60 fold, 70 fold, 80 fold, 90 fold, 100 fold, 125 fold, 150 fold, 200 fold, 250 fold, 300 fold, 350 fold, 400 fold, 450 fold, or even about 10-500 fold, including values and ranges therebetween, compared to an immune cell that does not express the chimeric cytokine receptor.

(126) In some embodiments, the improvement in one or more functional features exhibited by an engineered immune cell comprising a chimeric cytokine receptor provided herein is at least about 10%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 70%, 75%, 80%, 90%, 100%, 125%, 150%, 200%, 250%, 300%, 350%, 400%, or even about 80%-500%, including values and ranges therebetween, compared to an engineered immune cell that does not express the chimeric cytokine receptor.

(127) III. Therapeutic Methods

(128) Provided herein are pharmaceutical compositions comprising cells bearing the chimeric cytokine receptors and CARs of the disclosure.

(129) Engineered chimeric cytokine receptor-bearing and CAR-bearing immune cells (e.g. T-cells) obtained by the methods described above, or cell lines derived from such engineered immune cells, can be used as a medicament. In some embodiments, such a medicament can be used for treating a disorder such as for example a viral disease, a bacterial disease, a cancer, an inflammatory disease, an immune disease, or an agingassociated disease. In some embodiments, the cancer is a solid cancer. In some embodiments the cancer is a liquid cancer. The cancer can be selected from the group consisting of gastric cancer, sarcoma, lymphoma, leukemia, head and neck cancer, thymic cancer, epithelial cancer, salivary cancer, liver cancer, stomach cancer, thyroid cancer, lung cancer, small cell lung cancer, ovarian cancer, breast cancer, prostate cancer, esophageal cancer, pancreatic cancer, glioma, glioblastoma, leukemia, multiple myeloma, renal cell carcinoma, bladder cancer, cervical cancer, choriocarcinoma, colon cancer, oral cancer, skin cancer, and melanoma. In some embodiments, the subject is a previously treated adult subject with locally advanced or metastatic melanoma, squamous cell head and neck cancer (SCHNC), ovarian carcinoma, sarcoma, or relapsed or refractory classic Hodgkin's Lymphoma (cHL).

(130) In some embodiments, engineered immune cells, or cell line derived from the engineered immune cells, can be used in the manufacture of a medicament for treatment of a disorder in a subject in need thereof. In some embodiments, the disorder can be, for example, a cancer, an autoimmune disorder, or an infection.

(131) Also provided herein are methods for treating subjects in need of such treatment.

(132) As used herein, the term subject refers to any vertebrate including, without limitation, humans and other primates (e.g., chimpanzees, cynomologous monkeys, and other apes and monkey species), farm animals (e.g., cattle, sheep, pigs, goats and horses), domestic mammals (e.g., dogs and cats), laboratory animals (e.g., rabbits, rodents such as mice, rats, and guinea pigs), and birds (e.g., domestic, wild and game birds such as chickens, turkeys and other gallinaceous birds, ducks, geese, and the like). In some embodiments, the subject is a mammal. In exemplary embodiments, the subject is a human.

(133) In some embodiments the method comprises providing immune cells of the disclosure, bearing the chimeric cytokine receptors and CARs described herein to a subject in need thereof.

(134) In some embodiments, chimeric cytokine receptor and CAR-bearing T-cells of the invention can undergo robust in vivo T-cell expansion and can persist for an extended amount of time.

(135) Methods of treatment of the invention can be ameliorating, curative or prophylactic. The method of the invention may be either part of an autologous immunotherapy or part of an allogenic immunotherapy treatment.

(136) In another aspect, the invention provides a method of inhibiting tumor growth or progression in a subject who has a tumor, comprising administering to the subject an effective amount of chimeric cytokine receptor-expressing and CAR-expressing immune cells as described herein. In another aspect, the invention provides a method of inhibiting or preventing metastasis of cancer cells in a subject, comprising administering to the subject in need thereof an effective amount of engineered immune cells as described herein. In another aspect, the invention provides a method of inducing tumor regression in a subject who has a tumor, comprising administering to the subject an effective amount of engineered immune cells as described herein. In some embodiments, the subject is further administered with an anti-TGF-R antibody, in particular, an anti-TGF-R2 antibody.

(137) In some embodiments, the engineered T-cells herein can be administered parenterally in a subject. In some embodiments, the engineered T-cells disclosed herein can be administered intravenously in a subject.

(138) Also provided is the use of any of the engineered T-cells provided herein in the manufacture of a medicament for the treatment of cancer or for inhibiting tumor growth or progression in a subject in need thereof.

(139) In some embodiments, treatment can be administrated into subjects undergoing an immunosuppressive treatment. Indeed, the invention preferably relies on cells or population of cells, which have been made resistant to at least one immunosuppressive agent due to the inactivation of a gene encoding a receptor for such immunosuppressive agent. In this aspect, the immunosuppressive treatment should help the selection and expansion of the T-cells according to the invention within the subject. The administration of the cells or population of cells according to the invention may be carried out in any convenient manner, including by aerosol inhalation, injection, ingestion, transfusion, implantation or transplantation. The compositions described herein may be administered to a subject subcutaneously, intradermally, intratumorally, intranodally, intramedullary, intramuscularly, by intravenous or intralymphatic injection, or intraperitoneally. Cells bearing the chimeric cytokine receptors and/or CARs of the disclosure or the pharmaceutical compositions thereof may be administered via one or more of the following routes of administration: intravenous, intraocular, intravitreal, intramuscular, subcutaneous, topical, oral, transdermal, intraperitoneal, intraorbital, by implantation, by inhalation, intrathecal, intraventricular, via the ear, or intranasal.

(140) In some embodiments the administration of the cells or population of cells (bearing the chimeric cytokine receptors and CARs of the disclosure) can comprise administration of, for example, about 10.sup.4 to about 10.sup.9 cells per kg body weight including all integer values of cell numbers within those ranges. In some embodiments the administration of the cells or population of cells can comprise administration of about 10.sup.4 to 10.sup.5 cells per kg body weight, 10.sup.5 to 10.sup.6 cells per kg body weight, 10.sup.6 to 10.sup.7 cells per kg body weight, 10.sup.7 to 10.sup.8 cells per kg body weight, or 10.sup.8 to 10.sup.9 cells per kg body weight. The cells or population of cells can be administrated in one or more doses. In some embodiments, said effective amount of cells can be administrated as a single dose. In some embodiments, said effective amount of cells can be administrated as more than one dose over a period time. Timing of administration is within the judgment of managing physician and depends on the clinical condition of the subject. The cells or population of cells may be obtained from any source, such as a blood bank or a donor. While individual needs vary, determination of optimal ranges of effective amounts of a given cell type for a particular disease or condition is within the skill of the art. An effective amount means an amount which provides a therapeutic or prophylactic benefit. The dosage administrated will be dependent upon the age, health and weight of the recipient, kind of concurrent treatment, if any, frequency of treatment and the nature of the effect desired. In some embodiments, an effective amount of cells or composition comprising those cells are administrated parenterally. In some embodiments, administration can be an intravenous administration. In some embodiments, administration can be directly done by injection within a tumor.

(141) The methods can further comprise administering one or more agents to a subject prior to administering the engineered immune cells bearing a CAR and a chimeric cytokine receptor provided herein. In certain embodiments, the agent is a lymphodepleting (preconditioning) regimen. For example, methods of lymphodepleting a subject in need of such therapy comprise administering to the subject specified beneficial doses of cyclophosphamide (between 200 mg/m.sup.2/day and 2000 mg/m.sup.2/day, about 100 mg/m.sup.2/day and about 2000 mg/m.sup.2/day; e.g., about 100 mg/m.sup.2/day, about 200 mg/m.sup.2/day, about 300 mg/m.sup.2/day, about 400 mg/m.sup.2/day, about 500 mg/m.sup.2/day, about 600 mg/m.sup.2/day, about 700 mg/m.sup.2/day, about 800 mg/m.sup.2/day, about 900 mg/m.sup.2/day, about 1000 mg/m.sup.2/day, about 1500 mg/m.sup.2/day or about 2000 mg/m.sup.2/day) and specified doses of fludarabine (between 20 mg/m.sup.2/day and 900 mg/m.sup.2/day, between about 10 mg/m.sup.2/day and about 900 mg/m.sup.2/day; e.g., about 10 mg/m.sup.2/day, about 20 mg/m.sup.2/day, about 30 mg/m.sup.2/day, about 40 mg/m.sup.2/day, about 40 mg/m.sup.2/day, about 50 mg/m.sup.2/day, about 60 mg/m.sup.2/day, about 70 mg/m.sup.2/day, about 80 mg/m.sup.2/day, about 90 mg/m.sup.2/day, about 100 mg/m.sup.2/day, about 500 mg/m.sup.2/day or about 900 mg/m.sup.2/day). An exemplary dosing regimen involves treating a subject comprising administering daily to the patient about 300 mg/m.sup.2/day of cyclophosphamide in combination or before or after administering about 30 mg/m.sup.2/day of fludarabine for three days prior to administration of a therapeutically effective amount of engineered immune cells to the patient.

(142) In some embodiments, notably in the case when the engineered cells provided herein have been gene edited to eliminate or minimize surface expression of CD52, lymphodepletion further comprises administration of an anti-CD52 antibody, such as alemtuzumab. In some embodiments, the CD52 antibody is administered at a dose of about 1-20 mg/day IV, e.g., about 13 mg/day IV for 1, 2, 3 or more days. The antibody can be administered in combination with, before, or after administration of other elements of a lymphodepletion regime (e.g., cyclophosphamide and/or fludarabine).

(143) In certain embodiments, compositions comprising CAR-expressing immune effector cells disclosed herein may be administered in conjunction with any number of chemotherapeutic agents.

(144) IV. Kits and Articles of Manufacture

(145) The present disclosure provides kits comprising any one or more of the chimeric cytokine receptors and chimeric cytokine receptor-bearing cells described herein, and pharmaceutical compositions thereof. The present disclosure also provides articles of manufacture comprising any one or more of the chimeric cytokine receptors and chimeric cytokine receptors-bearing CAR-I-cells described herein, pharmaceutical compositions thereof, and kits described herein.

(146) The following examples are included for illustrative purposes and are not intended to limit the scope of the disclosure.

(147) All patent and non-patent documents referenced throughout this disclosure are incorporated by reference herein in their entirety for all purposes.

EXAMPLES

Example 1: Construction and Testing of Chimeric Cytokine Receptor-CAR Constructs Having a TGFR1 or TGFR2 Dominant Negative Truncation

(148) FIG. 1 shows a schematic of the inducible chimeric cytokine receptor of the disclosure. To couple simultaneous TGF- engagement with cytokine signaling, a chimeric cytokine receptor was constructed, composed of the following modules: (i) a binding domain comprising an extracellular portion of a TGF- receptor, or a TGF- antigen binding domain; (ii) a transmembrane domain with an intracellular portion having a JAK2-activating domain and (iii) STAT-recruiting domains comprising STAT-recruiting (STAT-activating) domains from cytokine receptor tails (cytotails). As shown as an example in FIG. 1, the binding domain comprises the extracellular domain of TGFR2.

(149) A HEK293T cell reporter assay was used to test the inducibility and magnitude of cytokine signaling using chimeric cytokine receptors for either neutralizing the TGF- signaling or activating the STAT response, which can be used as a surrogate measurement for the cytokine ICD activation and cytokine signaling. Briefly, 20,000 HEK293T-cells were plated into each well of a poly-L-lysine-coated 96-well flat-bottom plate and cultured overnight at 37 C. with 5% CO.sub.2. A chimeric cytokine receptor-CAR construct (2.5 ng), a TGF- or STAT-response element that drives Firefly Luciferase (100 ng; Promega), and Renilla Luciferase control reporter vector (1 ng; Promega) were mixed to a final volume of 5 l in Opti-MEM (Gibco) (DNA mix).

(150) Cells were transfected with a BFP-EGFRvIII CAR construct where a BFP gene is in place of the chimeric cytokine receptor as a negative control. A dominant negative truncation of TGFR2 (TGFR2 DN) and a dominant negative truncation of TGF1 (TGFR1 DN) were also constructed as additional controls to examine dominant negative effects in the absence of an intracellular cytokine signal. After incubating the DNA mixes with premixed 0.3 l Lipofectamine 2000 (Invitrogen) and 5 l Opti-MEM at room temperature for 20 minutes, the mixture having a total volume of 10 l was added to each well containing HEK293T cells. One day after transfection, a commercially available TGF-1 ligand (BioLegend, hereinafter in Examples 1-4 referred to as TGF-) was added to the culture for stimulation, to various final concentrations. After 20-24 hours of stimulation, TGF- or STAT5 reporter activity was evaluated using the Dual-Glo Luciferase Assay System (Promega). Fold induction of TGF- or STAT5 reporter activity was normalized to that of HEK293T cells that were transfected with only a reporter vector, and left untreated.

(151) FIG. 2A shows a schematic of the lentiviral vector used to co-express the dominant negative truncations of the TGFR1 or TGFR2 chimeric cytokine receptor with the 2.sup.na generation EGFRvIII CAR.

(152) FIG. 2B shows the inhibition of the TGF- signaling by expression of either the TGFR1 DN or TGFR2 DN (shown by FIG. 2A, and comprising the amino acid sequences of SEQ ID NOs 2 and 3, respectively). The data shown indicates that the TGFR2 DN chimeric cytokine receptor inhibits TGF- signaling induced by the TGF- ligand (up to 100 ng/ml), with higher efficacy than the TGFR1 DN. This is likely due to the higher affinity of TGFR2 binding to the TGF- ligand in comparison to the binding affinity of TGFR1 binding to the TGF- ligand (described in Groppe et al., 2008, Mol. Cell, 29(2):157-68). Consequentially, the designs of the following examples focus on the chimeric cytokine receptors having the binding domain of TGFR2.

Example 2: Designs and Testing of Inducible Chimeric Cytokine Receptors Using TGFR2

(153) A chimeric cytokine receptor was constructed, as briefly described when referring to FIG. 1, having a binding domain derived from TGFR2 (TGFR2 chimeric cytokine receptor). To investigate the utility of the TGFR2 chimeric cytokine receptor in the context of CAR-T cells, variants of TGFR2 extracellular domains (ECD) and variants of TPOR transmembrane (TM) domains were constructed. Fusions of each TGFR2 ECD variant, each TPOR TM domain variant, and the intracellular domains (ICD) of desired cytokine receptors were cloned into a lentiviral vector encoding a 2.sup.nd generation EGFRvIII-specific CAR (2173scFv; described in Sci Transl Med. 2015 Feb. 18; 7(275): 275ra22), and the activity of these receptor variants was tested. To permit stoichiometric co-expression of the chimeric cytokine receptor and the CAR, both genes were linked via a P2A peptide (chimeric cytokine receptor-CAR construct). To facilitate the detection of transduced cells, a v5 epitope tag (SEQ ID NO: 152) was inserted between the scFv and CD8 hinge domain.

(154) FIG. 3 shows a general schematic of the lentiviral vector used to co-express the TGFR2 chimeric cytokine receptor with the 2.sup.nd generation EGFRvIII CAR. One or more cytotails or recruiting domains may be joined in tandem to mimic signaling from one or more cytokines.

(155) FIGS. 4A-4C show the inhibition of TGF- signaling by the overexpression of chimeric cytokine receptors constructed using TGFR2. The lentiviral vectors used were constructed similarly as described in Example 1. FIG. 4A shows a schematic of the prototypic lentiviral vector used, bearing the IL7R(316-459) and the IL12Rb2(775-825) cytotail or recruiting domains to mimic IL7 and IL12 signaling in CAR-T-cells. A variety of truncations in the transmembrane domain of the TpoR cassette were designed (as shown in Table 3). The capacity of these truncations to regulate cytokine signaling was determined. FIG. 4B shows TGF- signaling activity determined by a luciferase reporter assay. All the tested chimeric cytokine receptors constructed using TGFR2 were shown to be able to inhibit TGF- signaling as they compete for binding via the extracellular domain of TGFR2 in these engineered chimeric receptors. FIG. 4C shows the activation of the chimeric cytokine receptors of FIG. 4A in the presence of TGF-. The activation of the chimeric cytokine receptor is measured by STAT reporter activity. Several variants were identified to have the ability to induce cytokine signaling by a TGF- ligand. The amino acid sequences of the transmembrane domains listed in the X-axes of FIGS. 4B-4C are SEQ ID NO: 29 to SEQ ID NO: 40 and SEQ ID NO: 50 to SEQ ID NO: 57, presented in Table 3.

(156) FIGS. 5A-5C show the inhibition of TGF- signaling by the overexpression of additional chimeric cytokine receptors constructed using TGFR2. The lentiviral vectors used were constructed similarly as described when referring to FIGS. 4A-4C, and Example 1. FIG. 5A shows a schematic of the prototypic lentiviral vector used, having truncations in the binding domain.

(157) Again, additional truncations (N-10, N-11, N-12, etc.) in the TM domain of TpoR cassette were designed (as shown in Table 3), and their capacity to regulate cytokine signaling was determined. FIG. 5B shows TGF- signaling activity determined by a luciferase reporter assay. Most of the chimeric cytokine receptors tested were shown to be able to inhibit TGF- signaling (other than the N-12, N-13, N-14 TM truncations, which show less extent of inhibition). FIG. 5C shows the activation of the chimeric cytokine receptors of FIG. 5A in the presence of TGF-. The activation of the chimeric cytokine receptors is measured by the STAT reporter activity. Several variants were identified to have the ability to induce cytokine signaling by a TGF- ligand. The amino acid sequences of the transmembrane domains listed in the X-axes of FIGS. 5B-5C are SEQ ID NOs: 29, 38, 53, SEQ ID NO: 40 to SEQ ID NO: 44, and SEQ ID NO: 61 to SEQ ID NO: 72, presented in Table 3.

Example 3: Modifications of the Chimeric Cytokine Receptor Binding Domain and Testing of the Constructed Chimeric Cytokine Receptors

(158) In the absence of TGFR2, TGFR1 interacts with the TGF- ligand with very low affinity. Once the ECD of TGFR2 binds to the TGF- ligand, the binary complex has an extended interface to efficiently recruit TGFR1 to form the ternary complex. The engineered TGFR2 chimeric cytokine receptor can also engage endogenous TGFR1, which may sterically intervene the intended signaling though the cytokine receptor ICDs. To abrogate interaction between the TGFR2 chimeric cytokine receptors and TGFR1, several variants for the TGFR1 cassette were designed, and modifications that can enhance cytokine signaling while inhibiting the TGF- signaling were identified.

(159) FIGS. 6A-6C show the inhibition of TGF- signaling by the expression of chimeric cytokine receptors constructed with TGFR2 having modifications. FIG. 6A shows a schematic of the modification introduced into the TGFR2 cassette. The lentiviral vectors used were constructed similarly as described in Example 1. To abolish the engagement of TGFR1, a truncation (N25) was introduced into the TGFR2 binding domain based on the previous constructs described when referring to FIGS. 6A-6C (TGFR2N25), and the inhibition of TGF- signaling was tested by a TGF- reporter assay. FIG. 6B shows that the TGFR2N25 chimeric cytokine receptors still retained the ability to inhibit TGF- signaling. FIG. 6C shows the activation of the chimeric cytokine receptors of FIG. 6A, evaluated by the STAT reporter activity. The amino acid sequences of the transmembrane domains listed in the X-axes of FIGS. 6B-6C are SEQ ID NOs: 29, 38, 39, 40, and 53, with a binding domain sequence of SEQ ID NO: 4 or SEQ ID NO: 3, presented in Tables 1 and 3.

(160) It was determined that the truncation in the TGFR2 binding domain enhances the cytokine signaling by 5-10 fold, even in the absence of a TGF- ligand. Interestingly, the N25 truncation was able to enhance the signaling synergistically with the TpoR TM truncations (e.g. N-7, N-8, N-9 and N+4). This combinatorial use of the TGFR2 binding domain and TpoR TM truncation mutants represents a novel approach for simultaneously inhibiting immunosuppressive TGF- signaling while transmitting immune-potentiating cytokine signaling.

Example 4: Design and Testing of the Constitutively Active Chimeric Cytokine Receptor

(161) FIG. 7 shows a schematic of the constitutively active chimeric cytokine receptor. To enable constitutively active signaling of the cytokine intracellular domains, double mutations that inherently dimerize the TPOR transmembrane domain and activate the JAK-STAT pathway were introduced in the TPOR transmembrane domain. As shown as an exemplary construct in FIG. 7, the binding domain comprises the extracellular portion of TGFR2; exemplary transmembrane domains may comprise the SEQ ID NOs 29, 40, 53 or 60.

(162) FIGS. 8A-8C show the design and tested function of the constitutively active chimeric cytokine receptors. The lentiviral vectors used were constructed similarly as described in Example 1. A double mutant (S505N, W515K) was introduced into the TPOR cassette to enforce the dimerization and activation of the receptors, in combination with variants that had shown the most promising functionality (e.g. TGFR2N25, N-9 and N+4 truncations in the TPOR cassette). FIG. 8A shows a schematic of the modification introduced into the TGFR2 cassette. FIG. 8B shows the inhibition of TGF- signaling by the expression of the chimeric cytokine receptors of FIG. 8A. FIG. 8C shows the activation of cytokine signaling via the chimeric cytokine receptors of FIG. 8A, measured by the STAT5 reporter activity in 293 cells. Compared to the parental designs (TGFR2_TpoR, TGFR2_TpoR_N-9, and TGFR2_TpoR_N+4), receptors with the S505N and W515K mutations display substantial cytokine signaling (e.g. TGFR2_TpoR.S505.W515K, TGFR2_TpoR_N-9.S505N.W515K). The sequences of the transmembrane domains listed in the X-axes of FIGS. 8B-8C comprise SEQ ID NOs: 40, 53, 59, and 60 with a binding domain sequence of SEQ ID NO: 4 or SEQ ID NO: 3, presented in Tables 1 and 3.

Example 5 Testing of Additional Chimeric Cytokine Receptors

(163) FIG. 10A shows additional design of inducible TGF--driven chimeric cytokine receptors. Constructs with further truncations in the transmembrane domain to decrease the flexibility between the ECD and intracellular signaling domain were made. FIG. 10B shows the inhibition of endogenous TGF- signaling as determined by luciferase assay by the overexpression of TGF--driven chimeric cytokine receptors shown in FIG. 10A in 293 cells in the presence of different concentrations of TGF-. Some of the constructs also carry the N25 deletion in the ECD domain (TGF-R2N25). All TGF--driven chimeric cytokine receptors in FIG. 10B inhibited the endogenous TGF- signaling, although clones with the N25 deletion showed slightly decreased inhibition of the TGF- signaling. The data in FIG. 10C show the activation of chimeric cytokine receptors in the presence of TGF- at various concentrations. Chimeric receptors with the deletion in the transmembrane domain and N25 deletion induced STAT5 signaling in the presence of TGF-.

(164) We next tested the constitutive chimeric receptors in CAR T cells. All constructs tested in FIGS. 11-16 contain the S505N and W515K substitutions in the TPOR/MPLR transmembrane domain. FIG. 11A shows schematics of the lentiviral vectors used to co-express in CAR T cells the TGF-R2 chimeric cytokine receptors with the EGFRvIII-specific CAR (2173scFv). All chimeric cytokine receptors carry dimerization mutations in the transmembrane domain of TPOR/MPLR (S505N, W515K, see SEQ ID NO:60), and one or more cytokine receptor recruiting domains joined in tandem to mimic signaling from one or more cytokines. IL2YY refers to IL2Rb (393-433, 518-551), and IL7IL12 refers to IL7R(316-459) and IL12Rb2(775-825) joined in tandem. As controls, CAR T cells were also produced, expressing a dominant negative truncation of TGF-R2 (TGF-R2.DN), constitutive chimeric cytokine receptor without the TGF-R2 ECD (IL7IL12, IL2YY) or a BFP protein. The method to produced CAR T cells were as described in Sommer C, et al. Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma. Mol Ther. 2019. doi:10.1016/j.ymthe.2019.04.001 and Sommer C, et al. Allogeneic FLT3 CAR T Cells with an Off-Switch Exhibit Potent Activity against AML and Can Be Depleted to Expedite Bone Marrow Recovery. Mol Ther. 2020. doi:10.1016/j.ymthe.2020.06.022. In brief, primary T cells from a healthy donor were transduced at MOI of 5, with lentiviruses expressing the CAR and each of the TGFR2 chimeric cytokine receptors or controls. FIG. 11B shows the percentage of CAR+ T cells at day 7, 9 and 14 during CAR T cell production. CAR T cells with a constitutive chimeric cytokine receptor as indicated (TGF-R2.IL7IL12, TGF-R2.IL2YY, IL7IL12, or IL2YY) show higher proliferation and enrichment as compared to BFP alone over the production period. As the result, more EGFRvIII CAR+ T cells were obtained over time as compared to CAR T expressing BFP alone without a chimeric cytokine receptor (FIG. 11C).

(165) FIGS. 11D and 11E show results of assessing STAT 5 phosphorylation in the CAR T cells co-expressing either the various chimeric cytokine receptors or controls. The antibody used for detecting phosphorylated STAT5 was from BD Biosciences (BDB612599). CAR T cells with constitutive chimeric cytokine receptor with an TGF-R2 ECD, i.e., TGF-R2.IL7IL12 or TGF-R2.IL2YY exhibited higher level of STAT5 phosphorylation, even in the absence of TGF, as compared to IL2YY and IL7IL12, i.e., constitutive chimeric cytokine receptors without a TGF-R2 ECD, indicating stronger cytokine signaling with a TGF-R2 ECD domain. The data suggest that the TGF-R2 ECD improved the intercellular recruiting domain signaling in CAR T cells.

(166) The data in FIGS. 11F and 11G show that the chimeric cytokine receptors regulated the differentiation of CAR T cells at Day 14 of CAR T production. CD62L and CD45RO staining was conducted using the antibodies from BioLegned (#304822) and BioLegand (#304234), respectively. Notably, CAR T cells expressing the TGF-R2.IL7IL12 chimeric cytokine receptor largely differentiated into central memory T cells (CD62L.sup.hiCD45RO.sup.hi)a result likely due to strong IL12Rb signaling, while CAR T cells expressing the TGFR2.IL2YY or IL2YY chimeric cytokine receptor exhibited an enriched population of stem cell-like (stem) memory T cell (CD62L.sup.hiCD45RO.sup.low), a desirable T cell phenotype that has been associated with better clinical outcome.

(167) Next, we compared the expression of TGF-R2 chimeric cytokine receptor to the expression of endogenous TGF-R2 by measuring total surface ECD by flow cytometry using an anti-human TGF-R2 polyclonal antibody (R&D Systems, FAB2411A100). The results in FIG. 11H show an MFI of the ECD staining at about 1400-2300 resulting from the endogenous TGF-R2 in the CAR T cells expressing the IL7IL12 or IL2YY chimeric cytokine receptor and CAR T cells expressing BFP. CAR T cells expressing a TGF-R2 chimeric cytokine receptor (TGF-R2.IL7IL12 and TGF-R2.IL2YY) showed a 2-3 folds excessive MFI value, indicating a 2-3 folds higher levels of the TGF-R2 ECD staining over the levels from endogenous TGF-R2 receptor. FIG. 11I shows the level of SMAD phosphorylation within CAR T cells expressing different chimeric cytokine receptors or controls when exposed to various concentrations of TGF. The antibody used for detecting phosphorylated SMAD was from BD Biosciences (BDB562586). The results show that CAR T cells expressing the TGF-R2.IL7IL12 and TGF-R2.IL2YY chimeric cytokine receptors exhibited decreased SMAD phosphorylation as compared to the CAR T cells expressing the IL7IL12 and IL2YY chimeric cytokine receptors without the TGF-R2 ectodomain, respectively.

(168) We next evaluated anti-tumor activities of the EGFRvIII CAR T cells expressing different chimeric cytokine receptors or controls against the target cells U87-EGFRvIII cells. In brief, CAR T cells were incubated with 10,000 target cells at E: T ratio of 1:2 in 200 ul of RPMI medium with 10% of FBS, and TGF- at various concentrations of 0, 5, and 20 ng/ml. After one week of co-culture with target cells, the CAR T cells in 100 ul supernatant were transferred into new target cells (10,000) with the same TGF concentrations as the previous week. The cytotoxicity of the CAR T cells in the second week without added TGF- was assessed and the results are shown in FIG. 12A. In the absence of exogenous TGF, CAR T cells expressing TGF-R2 chimeric cytokine receptors (TGF-R2.IL7IL12 and TGF-R2.IL2YY) showed the most persistent cytotoxicity, with most of the target cells killed by the CAR T cells. CAR T cells expressing chimeric cytokine receptors without the TGF-R2 ECD (IL7IL12 and IL2YY) also exhibited considerable cytotoxicity and inhibited the growth of the U87 cells till the second week. In comparison, CAR T cells with BFP or TGF-R2.DN lost the activity and failed to inhibit the growth of the U87 cells (FIG. 12A). The data indicate that TGF-R2 chimeric cytokine receptors enable more persistent cytotoxicity against the target cells. In the presence of TGF, the activity of CAR T cells without expressing a chimeric cytokine receptor with a TGFR2 ECD was inhibited to various levels by TGF-, likely the effect of signal transduction via the endogenous TGF- receptors (FIGS. 12B-12C). In contrast, CAR T cells expressing TGF-R2 chimeric cytokine receptors were resistant to TGF- inhibition and were able to maintain strong cytotoxicity in conditions up to 20 ng/ml of TGF- (FIGS. 12B, 12C).

(169) We next evaluated further modified constitutive TGF-R2 chimeric cytokine receptor in CAR T cells. As shown above constitutive TGFR2.IL7IL12 chimeric cytokine receptor having the S505N/W515K substitutions in the TPOR/MPLR transmembrane domain and the IL7Ra/IL12Rb recruiting domains (e.g., SEQ ID NO:163) increased STAT5 phosphorylation and led to substantial differentiation of central memory T cells. As the IL12 cytokine signaling has been implicated in the differentiation of memory T cells, we designed the TGF-R2.IL7 chimeric cytokine receptor that eliminates the IL12 signaling. In addition, we introduced two mutations in the TpoR JAK-binding domain, K553R and K573R, (designated as RR, e.g., SEQ ID NOS:165 and 170), to decrease ubiquitin-induced receptor degradation. See Saur S J, Sangkhae V, Geddis A E, Kaushansky K, Hitchcock IS. Ubiquitination and degradation of the thrombopoietin receptor c-Mpl. Blood. 2010. doi:10.1182/blood-2009-06-227033. CAR T cells expressing the chimeric cytokine receptor were produced and evaluated for STAT5 phosphorylation and T cell differentiation. Similar as before, these further modified TGF-R2 chimeric cytokine receptors showed higher levels of STAT5 signaling as determined by STAT5 phosphorylation than the chimeric cytokine receptors without the TGF-R2 ECD domain (both the IL7IL12 and IL7 chimeric cytokine receptor constructs contain the S505N/W515K substitutions) (FIG. 13A). In the assessment of T cell differentiation, CAR T cells expressing chimeric cytokine receptors without the IL12R recruiting domain (TGF-R2.IL7, TGF-R2.IL7_RR, and IL7) showed an increased proportion of stem memory T cell than their counterparts with the IL12R recruiting domain (FIG. 13B). These data demonstrate that by selecting different cytokine receptor motifs, we can modulate the TGF-R2 chimeric cytokine receptors signaling and T cell differentiation.

(170) To evaluate how the TGF-R2 chimeric cytokine receptors affect T cell functions, CAR T cells were evaluated in long-term killing assay. In brief, CAR T cells expressing different chimeric cytokine receptor were mixed with 10,000 U87-EGFRvIII cancer cells at an E:T ratio of 1:1, in 200 ul RPMI medium with 10% FBS, with or without 5 ng/ml of TGF. Every two or three days, 100 ul of the supernatant with CAR T cells were transferred onto 10,000 fresh target cells to the final volume of 200 ul RPMI medium with 10% FBS and 5 ng/ml of TGF, and the survival of old target cells were quantified. The long-term cytotoxicity of CAR T cells with different TGF-R2 chimeric cytokine receptors are summarized in FIGS. 14A-B. In the absence of exogenous TGF, TGF-R2 chimeric cytokine receptors with various recruiting domains, for example, TGF-R2.IL2YY, TGF-R2.IL7, or TGF-R2.IL2YYY(IL2Rb(339-379,393-433,518-551)) all conferred more potent and durable cytotoxicity than CAR T cells expressing chimeric cytokine receptors without the TGF-R2 ECD, confirming the previous observations that the TGF-R2 ECD domain enhanced the chimeric cytokine receptor signaling (FIG. 14A). In the presence of 5 ng/ml TGF, CAR T cells expressing the TGF-R2 chimeric cytokine receptor maintained more potent and persistent cytotoxicity than CAR T cells with or without expressing a chimeric cytokine receptor without a TGF-R2 ECD (FIG. 14B). The chimeric cytokine receptors tested all contain the S505N/W515K substitutions, and the TGFR2.IL2YYY and IL2YYY constructs have the additional H499L substitution in the TOPR/MPLR transmembrane domain.

(171) To further assess the inhibition on TGF signaling by a TGF-R2 chimeric cytokine receptor and its influence on the functionality of CAR T cells, we analyzed the TGF-R2.IL2YY_RR chimeric cytokine receptor (SEQ ID NO: 166), which carries the dimerization mutations in the TM region (S505N, W515K) and the degradation-resistant mutations (K553R and K573R) in the JAK-binding domain. We designed two additional variants bearing mutations in the TGF-R2 ECD (D32A.E119A and D32A.E119A.I53A) that abolished the receptor's ability to bind the TGF ligand. CAR T cells expressing the designated chimeric cytokine receptors were produced and evaluated for cytokine signaling (pSTAT5), TGF signaling (pSMAD), and persistency of cytotoxicity against U87-EGFRvIII target cells. FIG. 15A shows the analysis of STAT5 signaling in the CAR T cells, in which all the TGF-R2 chimeric cytokine receptors led to strong STAT5 phosphorylation in CAR T cells, comparing to the T cells expressing only the CAR. When the CAR T cells were exposed to 5 ng/ml of TGF ligand, various levels of SMAD phosphorylation were observed. Comparing to TGF-R2 chimeric cytokine receptor with the loss-of-binding mutants, TGF-R2.IL2YY_RR with the wildtype TGF binding domain exhibited a decreased level of SMAD phosphorylation, indicating that the endogenous TGF signaling was successfully inhibited by the TGF-R2 chimeric cytokine receptor with a wildtype, functional ligand binding domain (FIG. 15B).

(172) The long-term cytotoxicity of CAR T cells expressing different TGF-R2 chimeric cytokine receptor against cancer cells in the presence of 5 ng/ml TGF was shown in FIG. 15C. Comparing to the control CAR T cells, which quickly lost the activity to kill target cells at day 8, CAR T cells with TGF-R2 chimeric cytokine receptor conferred more durable activity. TGF-R2 chimeric cytokine receptors with impaired ability to bind to TGF (D32A.E119A and D32A.E119A.I53A) also showed a faster decline in the cytotoxicity assay than CAR T cells expressing the TGF-R2.IL2YY_RR chimeric cytokine receptor with a wildtype TGF binding ECD. These data demonstrate that both the cytokine signaling and the ability to inhibit endogenous TGF signaling are important for the long-term activity of CAR T cells.

(173) Results in FIGS. 16A-B show that the degradation-resistant mutations, K553R and K573R, can further improve the functionality of the constitutive TGF-R2 chimeric cytokine receptors. In this experiment, CAR T cells expressing TGF-R2 chimeric cytokine receptors with or without the degradation-resistant mutations (designated as RR) were evaluated for the strength of the cytokine signaling as well as the long-term cytotoxicity assay against U87-EGFRvIII in the medium with 5 ng/ml of TGF ligand. The TGF-R2 chimeric cytokine receptor with the K533R and K573R substitutions consistently display a stronger STAT5 phosphorylation (FIG. 16A) and a more durable capability to kill the target cells (FIG. 16B).